

L Number	Hits	Search Text	DB	Time stamp
1	439	(544/358).CCLS.	USPAT; US-PGPUB; EPO; JPO	2003/06/14 11:11
2	303	(544/359).CCLS.	USPAT; US-PGPUB; EPO; JPO	2003/06/14 11:12
3	540	(514/252.12).CCLS.	USPAT; US-PGPUB; EPO; JPO	2003/06/14 11:12
4	423	(514/252.13).CCLS.	USPAT; US-PGPUB; EPO; JPO	2003/06/14 11:12

V. Balasubramanian

Welcome to STN International! Enter x:x

LOGINID:sssptal611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	Jun 03	New e-mail delivery for search results now available
NEWS	4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS	6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS	7	Sep 03	JAPIO has been reloaded and enhanced
NEWS	8	Sep 16	Experimental properties added to the REGISTRY file
NEWS	9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS	10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS	11	Oct 24	BEILSTEIN adds new search fields
NEWS	12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS	13	Nov 18	DKILIT has been renamed APOLLIT
NEWS	14	Nov 25	More calculated properties added to REGISTRY
NEWS	15	Dec 04	CSA files on STN
NEWS	16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS	17	Dec 17	TOXCENTER enhanced with additional content
NEWS	18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS	19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS	20	Feb 13	CANCERLIT is no longer being updated
NEWS	21	Feb 24	METADEX enhancements
NEWS	22	Feb 24	PCTGEN now available on STN
NEWS	23	Feb 24	TEMA now available on STN
NEWS	24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS	25	Feb 26	PCTFULL now contains images
NEWS	26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS	27	Mar 20	EVENTLINE will be removed from STN
NEWS	28	Mar 24	PATDPAFULL now available on STN
NEWS	29	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS	30	Apr 11	Display formats in DGENE enhanced
NEWS	31	Apr 14	MEDLINE Reload
NEWS	32	Apr 17	Polymer searching in REGISTRY enhanced
NEWS	33	Jun 13	Indexing from 1947 to 1956 added to records in CA/CAPLUS
NEWS	34	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS	35	Apr 28	RDISCLOSURE now available on STN
NEWS	36	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS	37	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS	38	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS	39	May 16	CHEMREACT will be removed from STN
NEWS	40	May 19	Simultaneous left and right truncation added to WSCA

V. Balasubramanian

NEWS 41 May 19 RAPRA enhanced with new search field, simultaneous left and  
right truncation  
NEWS 42 Jun 06 Simultaneous left and right truncation added to CBNB  
NEWS 43 Jun 06 PASCAL enhanced with additional data  
  
NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT  
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),  
AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 11:06:36 ON 14 JUN 2003

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 11:06:46 ON 14 JUN 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 13 JUN 2003 HIGHEST RN 530739-23-2

DICTIONARY FILE UPDATES: 13 JUN 2003 HIGHEST RN 530739-23-2

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP  
PROPERTIES for more information. See STNote 27, Searching Properties  
in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

10/039,898

V. Balasubramanian

=>

Uploading C:\STNEXP4\QUERIES\10039898SP.str

L1 STRUCTURE UPLOADED




=> que L1

L2 QUE L1

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 [C1], [C2]

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 11:07:10 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 251 TO ITERATE

100.0% PROCESSED 251 ITERATIONS  
SEARCH TIME: 00.00.01

18 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 4070 TO 5970  
PROJECTED ANSWERS: 106 TO 614

L3 18 SEA SSS SAM L1

=> d scan

L3 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS

10/039,898

IN 2-Piperazinecarboxamide, N-hydroxy-4-[(4-methoxyphenyl)sulfonyl]-1-(1-methylethyl)-6-oxo-, (R)- (9CI)

MF C15 H21 N3 O6 S

COc1ccc(cc1)S(=O)(=O)N2CC(=O)N(C)C(R)C2C(=O)NO

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):17

**\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\***

[illegible]


V. Balasubramanian

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN 1H-Imidazole-1-carboxylic acid, 2-[3-[[1-(cyclohexylmethyl)-2-hydroxy-2-(tetrahydro-4-methyl-2-furanyl)ethyl]amino]-2-[4-[(4-methyl-1-piperazinyl)sulfonyl]-2-oxo-3-(phenylmethyl)-1-piperazinyl]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI)

MF C41 H63 N7 O8 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN 3,8-Diazabicyclo[3.2.1]octan-2-one, 3-[4-(3,4-dimethoxyphenyl)-1-(3-phenylpropyl)butyl]-8-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, (1S,5R)- (9CI)

MF C38 H46 N2 O8

Absolute stereochemistry.



V. Balasubramanian


\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-[[[[[4-(1-methylethyl)-3-oxo-1-piperazinyl]carbonyl]amino]phenylacetyl]amino]-7-oxo-, monosodium salt, [2S-[2.alpha.,5.alpha.,6.beta.(S\*)]]- (9CI)

MF C24 H31 N5 O6 S . Na

Absolute stereochemistry.




● Na

L3 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN 1-Piperazineacetamide, .alpha.-butyl-N-[1-(cyclohexylmethyl)-4-[[[2-(dimethylamino)ethyl]amino]carbonyl]-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, [3R-[1[S\*(1S\*,2S\*,4S\*)],3R\*]]- (9CI)

MF C42 H71 N7 O5

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN Carbamic acid, [2-[2-[2-(acetyloxy)ethyl]-4-[2-(methylamino)-1-(2-

V. Balasubramanian

naphthalenylmethyl)-2-oxoethyl]-3-oxo-1-piperazinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI)  
MF C36 H43 F N4 O7




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN 1-Piperazineacetamide, 4-(aminoacetyl)-N-[2-[[2-[4-[1-[[[2-[(2,5-dioxo-1-pyrrolidinyl)oxy]-2-oxoethyl]amino]carbonyl]-3-methylbutyl]-2-(2-methylpropyl)-3-oxo-1-piperazinyl]-2-oxoethyl]amino]-2-oxoethyl]-.alpha.,3-bis(2-methylpropyl)-2-oxo-, monohydrochloride, [2S-[1[R\*(R\*)],2R\*,4(R\*)]]-(9CI)  
SQL 8  
MF C40 H65 N9 O11 . Cl H

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*


Absolute stereochemistry.

PAGE 1-A




● HCl

10/039,898



L3 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN 1-Piperazineacetic acid, 3-methyl-4-[(2-nitrophenyl)sulfonyl]-2-oxo-  
.alpha.-(phenylmethyl)-, (.alpha.S,3S)- (9CI)  
MF C20 H21 N3 O7 S


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN 1-Piperazinecarbonyl chloride, 4-(1-methylethyl)-3-oxo- (9CI)  
MF C8 H13 Cl N2 O2


V. Balasubramanian



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN 1-Piperazineacetic acid, 4-(2,4-dinitrobenzoyl)-.alpha.-[3-[[[(2,4-dinitrobenzoyl)amino][[(4-methylphenyl)sulfonyl]amino]methylene]amino]propyl]-3-(1-hydroxyethyl)-2-oxo-, ethyl ester, [3S-[1(R\*),3R\*(S\*)]]- (9CI)  
MF C35 H37 N9 O16 S

Absolute stereochemistry.  
Double bond geometry unknown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN 1-Piperazineacetic acid, 4-benzoyl-.alpha.-(2-methylpropyl)-2-oxo-5-(phenylmethyl)-, (.alpha.S,5R)- (9CI)  
MF C24 H28 N2 O4

Absolute stereochemistry. †

†




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Glycine, N-[2-[4-[[[2-[4-[[[1,1-dimethylethoxy)carbonyl]amino]acetyl]-3-(2-methylpropyl)-2-oxo-1-piperazinyl]-4-methyl-1-oxopentyl]amino]acetyl]amino]acetyl]-3-(2-methylpropyl)-2-oxo-1-piperazinyl]-4-methyl-1-oxopentyl]-, methyl ester, [3S-[1(R\*),3R\*,4[R\*(R\*)]]]- (9CI)  
 SQL 8  
 MF C42 H72 N8 O11

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

PAGE 1-A



PAGE 1-B




L3 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-.alpha.,3-bis[(4-

V. Balasubramanian

hydroxyphenyl)methyl]-2-oxo-, ethyl ester, (.alpha.S,3S)- (9CI)  
MF C27 H34 N2 O7


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN 1-Piperazineacetic acid, 4-[3-(1H-imidazol-4-yl)-1-oxopropyl]-2-oxo-  
.alpha.,3-bis(phenylmethyl)-, ethyl ester, (.alpha.S,3S)- (9CI)  
MF C28 H32 N4 O4

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
IN 1,3-Piperazinediacetic acid, 4-[[[4-[(aminoiminomethyl)amino]benzoyl]amino]  
[acetyl]-.alpha.1-methyl-2-oxo-, monohydrochloride, [S-(R\*,R\*)]- (9CI)  
MF C19 H23 N5 O7 . Cl H

Absolute stereochemistry.


V. Balasubramanian



● HCl

L3 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN 1-Piperazinecarboxylic acid, 4-[(1R)-2-(acetyloxy)-1-[7-methyl-6-  
 [(methylsulfonyl)oxy]-1,3-benzodioxol-4-yl]ethyl]-2-[[2-iodo-4-methoxy-5-  
 methyl-3-(phenylmethoxy)phenyl]methyl]-5-methyl-3,6-dioxo-,  
 1,1-dimethylethyl ester, (2S)- (9CI)  
 MF C39 H45 I N2 O13 S

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 18 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN 1-Piperazineacetic acid, 4-[[[2-[4-[[[(1,1-dimethylethoxy)carbonyl]methylamino]acetyl]-3-methyl-2-oxo-1-piperazinyl]-1-oxopropyl]methylamino]acetyl]-  
 .alpha.,3-dimethyl-2-oxo-, methyl ester, [3S-[1(R\*),3R\*,4[2R\*(3R\*)]]]-  
 (9CI)  
 SQL 6  
 MF C28 H46 N6 O9

10/039,898

V. Balasubramanian


Absolute stereochemistry.



RN 474094-77-4 CAPLUS

CN 1-Piperazineacetamide, 3-[2-(acetyloxy)ethyl]-4-(N-acetyl-L-tyrosyl-4-fluorophenylalanyl)-N-methyl-.alpha.-(2-naphthalenylmethyl)-2-oxo- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



III. ANSWER 6 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 2002:777909 CAPLUS

DN 137:295253

TI Method for preparing monocyclic N-acyl aminolactam compounds and their combinatorial libraries

IN Cheng, Jie Fei; Chen, Mi; Nadzan, Alex

PA Chugai Seiyaku Kabushiki Kaisha, Japan

SO PCT Int. Appl., 30 pp.

CODEN: PIXXD2


DT Patent

LA English

10/039,898


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002079172	A1	20021010	WO 2001-US51579	20011210
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2000-255092P	P	20001212		
OS	MARPAT 137:295253				
IT	<b>467469-31-4P 467469-32-5P 467469-33-6P</b> <b>467469-34-7P 467469-35-8P 467469-36-9P</b> RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation) (prepn. of monocyclic N-acyl aminolactam compds. by solid-phase four-component reaction)				
RN	467469-31-4 CAPLUS				
CN	Hexanoic acid, 6-[[2-[5-[(butylamino)carbonyl]-3-methyl-2-oxo-4-(1-oxo-3-phenylpropyl)-1-piperazinyl]-1-oxo-4-phenylbutyl]amino]- (9CI) (CA INDEX NAME)				



RN 467469-32-5 CAPLUS

CN Hexanoic acid, 6-[[2-[5-[(butylamino)carbonyl]-3-methyl-4-(3-nitrobenzoyl)-2-oxo-1-piperazinyl]-1-oxo-4-phenylbutyl]amino]- (9CI) (CA INDEX NAME)




RN 467469-33-6 CAPLUS

CN Hexanoic acid, 6-[[2-[5-[[1,1-dimethylethyl]amino]carbonyl]-3-(1-methylethyl)-4-(3-nitrobenzoyl)-2-oxo-1-piperazinyl]-3-methyl-1-


V. Balasubramanian

oxobutyl]amino]- (9CI) (CA INDEX NAME)




RN 467469-34-7 CAPLUS

CN Benzoic acid, 4-[[4-[1-[[5-carboxypentyl]amino]carbonyl]-2-methylpropyl]-6-[[1,1-dimethylethyl]amino]carbonyl]-2-(1-methylethyl)-3-oxo-1-piperazinyl]carbonyl]-, 1-methyl ester (9CI) (CA INDEX NAME)




RN 467469-35-8 CAPLUS

CN Hexanoic acid, 6-[[cyclohexyl[4-(3-nitrobenzoyl)-2-oxo-5-[[1-(phenylmethyl)amino]carbonyl]-1-piperazinyl]acetyl]amino]- (9CI) (CA INDEX NAME)



RN 467469-36-9 CAPLUS

CN Hexanoic acid, 6-[[cyclohexyl[2-oxo-4-(1-oxo-3-phenylpropyl)-5-[[1-(phenylmethyl)amino]carbonyl]-1-piperazinyl]acetyl]amino]- (9CI) (CA INDEX NAME)




RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 82 CAPLUS COPYRIGHT 2003 ACS  
AN 2002:362728 CAPLUS  
DN 137:109413  
TI Total Synthesis of Ecteinasidin 743  
AU Endo, Atsushi; Yanagisawa, Arata; Abe, Masanao; Tohma, Shigemitsu; Kan, Toshiyuki; Fukuyama, Tohru  
CS Graduate School of Pharmaceutical Sciences, The University of Tokyo, CREST, The Japan Science and Technology Cooperation (JST), Bunkyo-ku, Tokyo, 113-0033, Japan  
SO Journal of the American Chemical Society (2002), 124(23), 6552-6554  
CODEN: JACSAT; ISSN: 0002-7863  
PB American Chemical Society  
DT Journal  
LA English  
OS CASREACT 137:109413  
IT **442663-32-3P 442663-33-4P 442663-34-5P**  
**442663-50-5P 442663-51-6P 442663-52-7P**  
**442663-53-8P 442663-54-9P 442663-55-0P**  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(total synthesis of ecteinasidin 743)  
RN 442663-32-3 CAPLUS  
CN 1,5-Imino-3-benzazocine-11-carboxylic acid, 3-[(1R)-2-(acetyloxy)-1-[7-methyl-6-[(methylsulfonyl)oxy]-1,3-benzodioxol-4-yl]ethyl]-1,2,3,4,5,6-hexahydro-9-methoxy-8-methyl-2-methylene-4-oxo-10-(phenylmethoxy)-, 1,1-dimethylethyl ester, (1R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


V. Balasubramanian



RN 442663-33-4 CAPLUS

CN 1,5-Imino-3-benzazocine-11-carboxylic acid, 3-[(1R)-2-(acetyloxy)-1-[6-(acetyloxy)-7-methyl-1,3-benzodioxol-4-yl]ethyl]-1,2,3,4,5,6-hexahydro-2-(hydroxymethyl)-2,9-dimethoxy-8-methyl-4-oxo-10-(phenylmethoxy)-, 2,2,2-trichloroethyl ester, (1R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 442663-34-5 CAPLUS

CN 1,5-Imino-3-benzazocine-11-carboxylic acid, 3-[(1R)-2-(acetyloxy)-1-[6-(acetyloxy)-7-methyl-1,3-benzodioxol-4-yl]ethyl]-1,2,3,4,5,6-hexahydro-2-(hydroxymethyl)-9-methoxy-8-methyl-4-oxo-10-(phenylmethoxy)-, 2,2,2-trichloroethyl ester, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


V. Balasubramanian



RN 442663-50-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(1R)-2-(acetyloxy)-1-[7-methyl-6-[(methylsulfonyl)oxy]-1,3-benzodioxol-4-yl]ethyl]-2-[[2-iodo-4-methoxy-5-methyl-3-(phenylmethoxy)phenyl]methyl]-5-methyl-3,6-dioxo-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 442663-51-6 CAPLUS

CN 1,5-Imino-3-benzazocine-11-carboxylic acid, 3-[(1R)-2-(acetyloxy)-1-[6-(acetyloxy)-7-methyl-1,3-benzodioxol-4-yl]ethyl]-1,2,3,4,5,6-hexahydro-9-methoxy-8-methyl-2-methylene-4-oxo-10-(phenylmethoxy)-, 1,1-dimethylethyl ester, (1R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


V. Balasubramanian



RN 442663-52-7 CAPLUS

CN 1,5-Imino-3-benzazocine-11-carboxylic acid, 3-[(1R)-2-(acetyloxy)-1-[6-(acetyloxy)-7-methyl-1,3-benzodioxol-4-yl]ethyl]-1,2,3,4,5,6-hexahydro-9-methoxy-8-methyl-2-methylene-4-oxo-10-(phenylmethoxy)-, 2,2,2-trichloroethyl ester, (1R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 442663-53-8 CAPLUS

CN 1,5-Imino-3-benzazocine-11-carboxylic acid, 3-[(1R)-2-(acetyloxy)-1-[6-(acetyloxy)-7-methyl-1,3-benzodioxol-4-yl]ethyl]-2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-1,2,3,4,5,6-hexahydro-9-methoxy-8-methyl-4-oxo-10-(phenylmethoxy)-, 2,2,2-trichloroethyl ester, (1R,2R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


V. Balasubramanian



RN 442663-54-9 CAPLUS

CN 1,5-Imino-3-benzazocine-11-carboxylic acid, 2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-1,2,3,4,5,6-hexahydro-3-[(1R)-2-hydroxy-1-(6-hydroxy-7-methyl-1,3-benzodioxol-4-yl)ethyl]-9-methoxy-8-methyl-4-oxo-10-(phenylmethoxy)-, 2,2,2-trichloroethyl ester, (1R,2R,5S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 442663-55-0 CAPLUS

CN 1,5-Imino-3-benzazocine-11-carboxylic acid, 2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-1,2,3,4,5,6-hexahydro-3-[(1R)-2-hydroxy-1-[7-methyl-6-(phenylmethoxy)-1,3-benzodioxol-4-yl]ethyl]-9-methoxy-8-methyl-4-oxo-10-(phenylmethoxy)-, 2,2,2-trichloroethyl ester, (1R,2R,5S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 2002:286697 CAPLUS

DN 136:309938

TI Preparation of new piperazinone derivatives by cyclization of  
N,N'-bis(dicarboxyalkyl)ethylenediamine derivatives

IN Nogami, Hiroyuki; Anzai, Ryuichi; Yoshioka, Akira

PA Mitsubishi Rayon Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 14 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2002114766	A2	20020416	JP 2000-304904	20001004
PRAI	JP 2000-304904		20001004		
OS	CASREACT 136:309938; MARPAT 136:309938				
IT	<b>410077-31-5P</b>				


RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of new piperazinone derivs. by cyclization of  
N,N'-bis(dicarboxyalkyl)ethylenediamine derivs. in presence of  
.alpha.-hydroxy carboxylic acid)

RN 410077-31-5 CAPLUS

CN Pentanedioic acid, 2-[(3R)-3-(2-carboxyethyl)-2-oxo-4-(1-oxododecyl)-1-piperazinyl]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

V. Balasubramanian



L5 ANSWER 9 OF 82 CAPLUS COPYRIGHT 2003 ACS  
AN 2002:197486 CAPLUS  
DN 137:155164  
TI Synthesis of diastereomerically pure 1,4,5-substituted-2-oxopiperazines on solid-phase  
AU Khan, Nawaz M.; Cano, Montserrat; Balasubramanian, Shankar  
CS Department of Chemistry, University of Cambridge, Cambridge, CB2 1EW, UK  
SO Tetrahedron Letters (2002), 43(13), 2439-2443  
CODEN: TELEAY; ISSN: 0040-4039  
PB Elsevier Science Ltd.  
DT Journal  
LA English  
OS CASREACT 137:155164  
IT **445273-93-8P 445273-94-9P 445273-96-1P**  
**445273-98-3P 445274-02-2P 445274-04-4P**  
**445274-06-6P**  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of as peptidomimetics using solid-phase synthesis techniques)  
RN 445273-93-8 CAPLUS  
CN 1-Piperazineacetic acid, 4-[(4-methylphenyl)sulfonyl]-.alpha.-(2-methylpropyl)-2-oxo-5-(phenylmethyl)-, (.alpha.S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 445273-94-9 CAPLUS  
CN 1-Piperazineacetic acid, 5-methyl-4-[(4-methylphenyl)sulfonyl]-.alpha.-(2-methylpropyl)-2-oxo-, (.alpha.S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 445273-96-1 CAPLUS

CN 1-Piperazineacetic acid, .alpha.,5-dimethyl-4-[(4-methylphenyl)sulfonyl]-2-oxo-, (.alpha.S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 445273-98-3 CAPLUS

CN 1-Piperazineacetic acid, 4-acetyl-.alpha.-(2-methylpropyl)-2-oxo-5-(phenylmethyl)-, (.alpha.S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 445274-02-2 CAPLUS

CN 1-Piperazineacetic acid, .alpha.-(2-methylpropyl)-4-[(4-nitrophenyl)sulfonyl]-2-oxo-5-(phenylmethyl)-, (.alpha.S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 445274-04-4 CAPLUS

CN 1-Piperazineacetic acid, 4-benzoyl-.alpha.-(2-methylpropyl)-2-oxo-5-(phenylmethyl)-, (.alpha.S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 445274-06-6 CAPLUS

CN 1-Piperazineacetic acid, 4-[(2S)-2-amino-1-oxopropyl]-.alpha.-(2-methylpropyl)-2-oxo-5-(phenylmethyl)-, (.alpha.S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 2002:136921 CAPLUS

DN 137:93725


TI Synthesis and structure-Activity relationships of M2-Selective muscarinic receptor ligands in the 1-[4-(4-Arylsulfonyl)-phenylmethyl]-4-(4-

10/039,898

V. Balasubramanian

piperidiny1)-piperazine family  
AU McCombie, Stuart W.; Lin, Sue-Ing; Tagat, Jayaram R.; Nazareno, Dennis;  
Vice, Susan; Ford, Jennifer; Asberom, Theodros; Leone, Daria; Kozlowski,  
Joseph A.; Zhou, Guowei; Ruperto, Vilma B.; Duffy, Ruth A.; Lachowicz,  
Jean E.  
CS Department of Chemistry, Schering-Plough Research Institute, Kenilworth,  
NJ, 07033, USA  
SO Bioorganic & Medicinal Chemistry Letters (2002), 12(5), 795-798  
CODEN: BMCLE8; ISSN: 0960-894X  
PB Elsevier Science Ltd.  
DT Journal  
LA English  
OS CASREACT 137:93725  
IT **441772-09-4P**  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(prepn. and structure-activity relationships of M2-selective muscarinic  
receptor ligands in the [[(arylsulfonyl)phenyl]methyl](piperidiny1)pipe  
razine family)  
RN 441772-09-4 CAPLUS  
CN 1-Piperazinecarboxylic acid, 4-[(1S)-1-[4-(1,3-benzodioxol-5-  
ylsulfonyl)phenyl]ethyl]-3-methyl-2,5-dioxo-, 1,1-dimethylethyl ester,  
(3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 82 CAPLUS COPYRIGHT 2003 ACS  
AN 2002:106262 CAPLUS  
DN 136:321186  
TI Insights into the Selective Inhibition of Candida albicans Secreted  
Aspartyl Protease: A Docking Analysis Study  
AU Pranav Kumar, S. K.; Kulkarni, Vithal M.  
CS Department of Chemical Technology, Pharmaceutical Division, University of  
Mumbai, Mumbai, 400 019, India  
SO Bioorganic & Medicinal Chemistry (2002), 10(4), 1153-1170  
CODEN: BMECEP; ISSN: 0968-0896  
PB Elsevier Science Ltd.  
DT Journal  
LA English  
IT **142928-23-2 143731-22-0 414896-67-6**  
**414896-68-7 414896-69-8 414896-70-1**  
**414896-71-2 414896-72-3**  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(mol. modeling study reveals hydrogen bonding hydrophobic interactions)


V. Balasubramanian

and binding energies play role in binding of inhibitors to *Candida albicans* aspartyl protease)

RN 142928-23-2 CAPLUS

CN 1-Piperazineacetamide, .alpha.-butyl-N-[(1S,2S,4R)-4-[(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, monohydrochloride, (.alpha.S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 143731-22-0 CAPLUS

CN 1-Piperazineacetamide, .alpha.-butyl-N-[(1S,2S,4R)-4-[(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, (.alpha.S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 414896-67-6 CAPLUS

CN 1-Piperazineacetamide, .alpha.-butyl-N-[(1S,2S,4R)-4-[(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, (.alpha.R,3R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 414896-68-7 CAPLUS

CN 1-Piperazineacetamide, .alpha.-butyl-N-[(1S,2S,4R)-4-[(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, (.alpha.S,3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 414896-69-8 CAPLUS

CN 1-Piperazineacetamide, .alpha.-butyl-N-[(1S,2S,4R)-4-[(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)sulfonyl]-2-oxo-3-(phenylmethyl)-, (.alpha.S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 414896-70-1 CAPLUS

CN 1-Piperazineacetamide, .alpha.-butyl-N-[(1S,2S,4R)-1-(cyclohexylmethyl)-2-hydroxy-5-methyl-4-[[[3-(4-morpholinyl)propyl]amino]carbonyl]hexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, (.alpha.S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






RN 414896-71-2 CAPLUS

CN 1-Piperazineacetamide, .alpha.-butyl-N-[(1S,2S,4R)-1-(cyclohexylmethyl)-4-  
[[[2-(dimethylamino)ethyl]amino]carbonyl]-2-hydroxy-5-methylhexyl]-4-[(4-  
methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, (.alpha.S,3R)-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 414896-72-3 CAPLUS

CN 1-Piperazineacetamide, .alpha.-butyl-N-[(1S,2S,4R)-1-(cyclohexylmethyl)-4-  
[[[3-(dimethylamino)propyl]amino]carbonyl]-2-hydroxy-5-methylhexyl]-4-[(4-  
methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, (.alpha.S,3R)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 12 OF 82 CAPLUS COPYRIGHT 2003 ACS  
AN 2001:545724 CAPLUS  
DN 135:147398  
TI Peptidomimetic modulators of cell adhesion  
IN Gour, Barbara J.; Blaschuk, Orest W.; Ali, Anmar; Ni, Feng; Chen, Zhigang;  
Michaud, Stephanie Denise; Wang, Shoameng; Hu, Zengjian  
PA Adherex Technologies, Inc., Can.  
SO PCT Int. Appl., 416 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001053331	A2	20010726	WO 2001-US2508	20010124
	WO 2001053331	A3	20020711		
	WO 2001053331	C2	20021031		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRAI US 2000-491078 A 20000124

OS MARPAT 135:147398

IT 351857-32-4 351857-33-5 351857-34-6


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(peptidomimetic modulators of cell adhesion)

RN 351857-32-4 CAPLUS

CN 1-Piperazineacetamide, 4-[(2S)-2-(acetylamino)-3-(1H-imidazol-4-yl)-1-oxopropyl]-3-methyl-.alpha.-(1-methylethyl)-2-oxo-, (.alpha.S,3S)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 351857-33-5 CAPLUS

V. Balasubramanian

CN 1-Piperazineacetamide, 4-[(2S)-2-(acetylamino)-3-(1H-imidazol-4-yl)-1-oxopropyl]-.alpha.-[(4-hydroxyphenyl)methyl]-3-methyl-2-oxo-, (.alpha.S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 351857-34-6 CAPLUS

CN L-Tyrosinamide, N-acetyl-L-histidyl-(.alpha.S,3S)-3-methyl-.alpha.-(1-methylethyl)-2-oxo-1-piperazineacetyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 13 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 2001:435076 CAPLUS

DN 135:46205

TI Preparation of neurotrophic bicyclic diamides with peptidylprolyl isomerase (PPIase or rotamase) inhibitory activity

IN: Dubowchik, Gene Michael; Provencal, David Paul

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 91 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001042245	A1	20010614	WO 2000-US32395	20001128

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

10/039,898

V. Balasubramanian

CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,  
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,  
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,  
ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1999-169600P P 19991208

OS MARPAT 135:46205

IT 344461-77-4P 344461-81-0P 344461-92-3P

344462-01-7P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(stereoselective prepn. and biol. activity of bicyclic diamides as neuroprotective agents and peptidylprolyl isomerase (PPIase or rotamase) inhibitors)

RN 344461-77-4 CAPLUS

CN 3,8-Diazabicyclo[3.2.1]octan-2-one, 8-[oxo(3,4,5-trimethoxyphenyl)acetyl]-3-[3-phenyl-1-(2-phenylethyl)propyl]-, (1S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 344461-81-0 CAPLUS

CN 3,8-Diazabicyclo[3.2.1]octan-2-one, 3-[4-(3,4-dimethoxyphenyl)-1-(3-phenylpropyl)butyl]-8-[oxo(3,4,5-trimethoxyphenyl)acetyl]-, (1S,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

V. Balasubramanian



RN 344461-92-3 CAPLUS


CN 3,9-Diazabicyclo[3.3.1]nonan-2-one, 3-[4-(3,4-dimethoxyphenyl)-1-(3-phenylpropyl)butyl]-9-[oxo(3,4,5-trimethoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)



RN 344462-01-7 CAPLUS

CN 3,8-Diazabicyclo[3.2.1]octan-2-one, 8-[difluoro(3,4,5-trimethoxyphenyl)acetyl]-3-[3-phenyl-1-(2-phenylethyl)propyl]-, (1S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10/039,898

V. Balasubramanian


IT **344462-62-0P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(stereoselective prepn. and biol. activity of bicyclic diamides as neuroprotective agents and peptidylprolyl isomerase (PPIase or rotamase) inhibitors)

RN 344462-62-0 CAPLUS

CN 3,9-Diazabicyclo[3.3.1]nonane-9-carboxylic acid, 3-[4-(3,4-dimethoxyphenyl)-1-(3-phenylpropyl)butyl]-2-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 14 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 2001:59590 CAPLUS

DN 134:237814

TI New analogues of bradykinin containing a conformationally restricted dipeptide fragment in their molecules

AU Derdowska, I.; Prahl, A.; Neubert, K.; Hartrodt, B.; Kania, A.; Dobrowolski, D.; Melhem, S.; Trzeciak, H. I.; Wierzba, T.; Lamnek, B.

CS Faculty of Chemistry, University of Gdansk, Gdansk, 80-952, Pol.

SO Journal of Peptide Research (2001), 57(1), 11-18

CODEN: JPERFA; ISSN: 1397-002X

PB Munksgaard International Publishers Ltd.

DT Journal

LA English

OS CASREACT 134:237814

IT **193091-08-6P 193091-09-7P 330184-10-6P**

**330184-14-0P 330184-19-5P 330184-23-1P**

**330184-27-5P 330184-31-1P**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. and structure-activity relationship of conformationally restricted bradykinin analogs)


RN 193091-08-6 CAPLUS

CN L-Arginine, D-arginyl-L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-L-phenylalanyl-L-seryl-(.alpha.S,3S)-2-oxo-.alpha.,3-bis(phenylmethyl)-1-piperazineacetyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).





PAGE 1-B





CN L-Arginine, N2-(tricyclo[3.3.1.1<sup>3,7</sup>]dec-1-ylacetyl)-D-arginyl-L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-L-phenylalanyl-L-seryl-(.alpha.S,3S)-2-oxo-.alpha.,3-bis(phenylmethyl)-1-piperazineacetyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 330184-10-6 CAPLUS  
 CN L-Arginine, D-arginyl-L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolyl-glycyl-3-(2-thienyl)-L-alanyl-L-seryl-(.alpha.S,3S)-2-oxo-.alpha.-3-bis(phenylmethyl)-1-piperazineacetyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 330184-14-0 CAPLUS

CN L-Arginine, N2-(tricyclo[3.3.1.1<sup>3,7</sup>]dec-1-ylacetyl)-D-arginyl-L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolyl-glycyl-3-(2-thienyl)-L-alanyl-L-seryl-( $\alpha$ ,S,3S)-2-oxo- $\alpha$ ,3-bis(phenylmethyl)-1-piperazineacetyl- (9CI)  
(CA INDEX NAME)



Absolute stereochemistry.



RN 330184-19-5 CAPLUS

CN L-Arginine, D-arginyl-L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-L-phenylalanyl-(.alpha.S,3S)-2-oxo-.alpha.,3-bis(phenylmethyl)-1-piperazineacetyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 330184-23-1 CAPLUS

CN L-Arginine, N2-(tricyclo[3.3.1.1<sup>3,7</sup>]dec-1-ylacetyl)-D-arginyl-L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolyl-glycyl-L-phenylalanyl-(.alpha.S,3S)-2-oxo-.alpha.,3-bis(phenylmethyl)-1-piperazineacetyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330184-27-5 , CAPLUS  
 CN L-Arginine, D-arginyl-L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolyl-glycyl-3-(2-thienyl)-L-alanyl-(.alpha.S,3S)-2-oxo-.alpha.,3-bis(phenylmethyl)-1-piperazineacetyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry.

NC(=N)NCC[C@H](S)C(=O)N[C@@H](Cc1ccccc1)C(=O)S[C@@H](Cc2ccccc2)N3CC[C@H](C(=O)N[C@@H](Cc4ccccc4)C(=O)S[C@@H](Cc5ccccc5)C(=O)NCC(=O)N)C(=O)N3C(=O)S[C@@H](Cc6ccccc6)C(=O)N3CC[C@H](C(=O)N[C@@H](Cc7ccccc7)C(=O)S[C@@H](Cc8ccccc8)C(=O)NCC(=O)N)C(=O)N3C(=O)S[C@@H](Cc9ccccc9)C(=O)N3

The chemical structure shows a thiazolidine ring (a five-membered ring with one sulfur atom 'S' and one nitrogen atom 'N'). The nitrogen atom is part of a thioamide group,  $\text{N}=\text{C}(=\text{S})\text{NH}-$ , which is linked to a  $(\text{CH}_2)_3$  chain. This chain is further connected to a guanidino group,  $\text{N}=\text{C}(\text{NH}_2)\text{NH}-$ . Another  $(\text{CH}_2)_3$  chain is attached to the nitrogen of this guanidino group, which is also connected to another guanidino group,  $\text{N}=\text{C}(\text{NH}_2)\text{NH}_2$ . The thiazolidine ring also has a methyl group on the carbon adjacent to the nitrogen, a hydroxyl group ( $\text{OH}$ ) on the carbon adjacent to the sulfur, and a substituent 'R' on the carbon between the sulfur and the nitrogen. The thioamide group is also linked to a carbonyl group ( $\text{C}=\text{O}$ ), which is further linked to another thiazolidine ring. This second thiazolidine ring has a sulfur atom 'S', a nitrogen atom 'N', and a substituent 'R' on the carbon between the sulfur and the nitrogen. The carbonyl group is also linked to a thioamide group,  $\text{N}=\text{C}(=\text{S})\text{NH}-$ , which is linked to a  $(\text{CH}_2)_3$  chain. This chain is further connected to a guanidino group,  $\text{N}=\text{C}(\text{NH}_2)\text{NH}-$ . Another  $(\text{CH}_2)_3$  chain is attached to the nitrogen of this guanidino group, which is also connected to another guanidino group,  $\text{N}=\text{C}(\text{NH}_2)\text{NH}_2$ .

CN L-Arginine, N2-(tricyclo[3.3.1.1<sup>3,7</sup>]dec-1-ylacetyl)-D-arginyl-L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-(.alpha.S,3S)-2-oxo-.alpha.,3-bis(phenylmethyl)-1-piperazineacetyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 193091-13-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of a conformationally restricted PhePhe fragment)

RN 193091-13-3 CAPLUS

CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-2-oxo-.alpha.,3-bis(phenylmethyl)-, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 15 OF 82 CAPLUS COPYRIGHT 2003 ACS  
AN 2001:31476 CAPLUS  
DN 134:95515  
TI Cyclized amino acid derivatives for the treatment of neurological diseases  
IN Lauffer, David; Ledford, Brian  
PA Vertex Pharmaceuticals Incorporated, USA  
SO PCT Int. Appl., 55 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001002372	A1	20010111	WO 2000-US18577	20000706
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1196395	A1	20020417	EP 2000-945224	20000706
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2003503482	T2	20030128	JP 2001-507811	20000706
PRAI	US 1999-142404P	P	19990706		
	WO 2000-US18577	W	20000706		
OS	MARPAT 134:95515				
IT	318948-03-7 318948-10-6 318948-17-3 318948-24-2 318948-31-1 318948-38-8				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(cyclized amino acid derivs. for treatment of neurol. diseases)				
RN	318948-03-7 CAPLUS				
CN	Piperazinone, 4-[oxo(3,4,5-trimethoxyphenyl)acetyl]-1-[4-phenyl-1-(3-phenylpropyl)butyl]- (PCI) (CA INDEX NAME)				

V. Balasubramanian




RN 318948-10-6 CAPLUS

CN Piperazinone, 4-[oxo(3,4,5-trimethoxyphenyl)acetyl]-3-phenyl-1-[4-phenyl-1-(3-phenylpropyl)butyl]- (9CI) (CA INDEX NAME)




RN 318948-17-3 CAPLUS

CN Piperazinone, 4-[oxo(3,4,5-trimethoxyphenyl)acetyl]-1-[3-phenyl-1-(2-phenylethyl)propyl]- (9CI) (CA INDEX NAME)



RN 318948-24-2 CAPLUS


CN Piperazinone, 4-[oxo(3,4,5-trimethoxyphenyl)acetyl]-3-phenyl-1-[3-phenyl-1-(2-phenylethyl)propyl]- (9CI) (CA INDEX NAME)




RN 318948-31-1 CAPLUS

CN Piperazinone, 1-(diphenylmethyl)-4-[oxo(3,4,5-trimethoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)

V. Balasubramanian





RN 318948-38-8 CAPLUS  
CN Piperazinone, 1-(diphenylmethyl)-4-[oxo(3,4,5-trimethoxyphenyl)acetyl]-3-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 16 OF 82 CAPLUS COPYRIGHT 2003 ACS  
AN 2000:591213 CAPLUS  
DN 133:261650  
TI New bradykinin analogs in contraction of rat uterus  
AU Trzeciak, H. I.; Kozik, W.; Melhem, S.; Kania, A.; Dobrowolski, D.; Prahl, A.; Derdowska, I.; Lammek, B.  
CS Department of Pharmacology, Silesian Medical University, Katowice, 40-752, Pol.  
SO Peptides (New York) (2000), 21(6), 829-834  
CODEN: PPTDD5; ISSN: 0196-9781  
PB Elsevier Science Inc.  
DT Journal  
LA English  
IT **193091-08-6 297175-25-8**  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)  
(new bradykinin analogs in contraction of rat uterus)  
RN 193091-08-6 CAPLUS  
CN L-Arginine, D-arginyl-L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolyl-glycyl-L-phenylalanyl-L-seryl-(.alpha.S,3S)-2-oxo-.alpha.,3-bis(phenylmethyl)-1-piperazineacetyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).




RN 297175-25-8 CAPLUS

CN L-Arginine, N2-(phenylacetyl)-D-arginyl-L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-L-phenylalanyl-L-seryl-(.alpha.S,3S)-2-oxo-.alpha.,3-bis(phenylmethyl)-1-piperazineacetyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 17 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 2000:296186 CAPLUS

DN 133:105336

TI Synthesis of a novel thyrotropin releasing hormone (TRH) analog  
incorporating a piperazin-2-one ring

AU Bhatt, Ulhas; Just, George

CS Department of Chemistry, McGill University, Montreal, QC, H3A 2K6, Can.

SO Helvetica Chimica Acta (2000), 83(4), 722-727

CODEN: HCACAV; ISSN: 0018-019X

PB Verlag Helvetica Chimica Acta

DT Journal

LA English

IT **282529-03-7P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); SPN (Synthetic preparation); BIOL (Biological  
study); PREP (Preparation)


(synthesis of a piperazinone-contg. peptidomimetic analog of TSH  
releasing hormone)

RN 282529-03-7 CAPLUS

CN 1-Piperazineacetamide, 3-(1H-imidazol-4-ylmethyl)-.alpha.-(1-methylethyl)-  
2-oxo-4-[[ (2S)-5-oxo-2-pyrrolidinyl]carbonyl]-, (.alpha.S,3S)- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.

V. Balasubramanian



IT 282529-08-2P 282529-12-8P 282529-13-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis of a piperazine-one-contg. peptidomimetic analog of TSH releasing hormone)

RN 282529-08-2 CAPLUS

CN 1-Piperazineacetic acid, .alpha.-(1-methylethyl)-4-[(4-nitrophenyl)sulfonyl]-2-oxo-3-[[1-(triphenylmethyl)-1H-imidazol-4-yl)methyl]-, methyl ester, (.alpha.S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282529-12-8 CAPLUS

CN 1-Piperazineacetic acid, .alpha.-(1-methylethyl)-2-oxo-4-[[ (2S)-5-oxo-2-pyrrolidinyl]carbonyl]-3-[[1-(triphenylmethyl)-1H-imidazol-4-yl)methyl]-, methyl ester, (.alpha.S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282529-13-9 CAPLUS

CN 1-Piperazineacetamide, .alpha.-(1-methylethyl)-2-oxo-4-[[ (2S)-5-oxo-2-pyrrolidinyl]carbonyl]-3-[[1-(triphenylmethyl)-1H-imidazol-4-yl]methyl]-, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 18 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 2000:242935 CAPLUS

DN 133:98608

TI Preparations and Characterizations of Novel N,N'-Ethylene-Bridged-(S)-Histidyl-(S)-Tyrosine Derivatives and Their Copper(II) Complexes as Models of Galactose Oxidase

AU Yamato, Kazuhiro; Inada, Takanori; Doe, Matsumi; Ichimura, Akio; Takui, Takeji; Kojima, Yoshitane; Kikunaga, Toshimitsu; Nakamura, Shin; Yanagihara, Naohisa; Onaka, Tomoko; Yano, Shigenobu

CS Dep. Chem., Grad. Sch. Sci., Osaka City University, Sumiyoshi-ku, Osaka, 558-8585, Japan

SO Bulletin of the Chemical Society of Japan (2000), 73(4), 903-912  
CODEN: BCSJA8; ISSN: 0009-2673

PB Chemical Society of Japan

DT Journal

V. Balasubramanian

LA English


IT **280558-83-0P**

RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. and electrochem. oxidn. and reactant for prepn. of copper N,N'-ethylene-bridged-hystidyltyrosine deriv. complex galactose oxidase model)

RN 280558-83-0 CAPLUS

CN 1-Piperazineacetic acid, 4-[[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]-.alpha.-[(4-hydroxyphenyl)methyl]-3-(1H-imidazol-4-ylmethyl)-2-oxo-, ethyl ester, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT **280558-85-2P 280558-87-4P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. and reactant for prepn. of copper N,N'-ethylene-bridged-hystidyltyrosine deriv. complex galactose oxidase model)

RN 280558-85-2 CAPLUS

CN 1-Piperazineacetic acid, 4-acetyl-.alpha.-[(4-hydroxyphenyl)methyl]-3-(1H-imidazol-4-ylmethyl)-2-oxo-, ethyl ester, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 280558-87-4 CAPLUS

CN Carbamic acid, [2-[(2S)-4-[(1S)-2-amino-1-[(4-hydroxyphenyl)methyl]-2-oxoethyl]-2-(1H-imidazol-4-ylmethyl)-3-oxo-1-piperazinyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

V. Balasubramanian

Absolute stereochemistry. Rotation (+).




IT 280558-89-6P

RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn., acid dissozn. consts. and reactant for prepn. of copper N,N'-ethylene-bridged-hystidyltyrosine deriv. complex galactose oxidase model)

RN 280558-89-6 CAPLUS

CN 1-Piperazineacetamide, 4-acetyl-.alpha.-[(4-hydroxyphenyl)methyl]-3-(1H-imidazol-4-ylmethyl)-2-oxo-, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 19 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 2000:188697 CAPLUS

DN 133:4959

TI Conformationally constrained substance P analogs: The total synthesis of a constrained peptidomimetic for the Phe7-Phe8 region

AU Tong, Yunsong; Fobian, Yvette M.; Wu, Meiye; Boyd, Norman D.; Moeller, Kevin D.

CS The Department of Chemistry, Washington University, St. Louis, MO, 63130, USA

10/039,898

V. Balasubramanian

SO Journal of Organic Chemistry (2000), 65(8), 2484-2493

CODEN: JOCEAH; ISSN: 0022-3263

PB American Chemical Society

DT Journal

LA English

IT 212612-56-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)


(synthesis of substance P analogs contg. conformationally constrained Phe-Phe peptidomimetic)

RN 212612-56-1 CAPLUS


CN L-Methioninamide, L-arginyl-L-prolyl-L-lysyl-L-prolyl-L-glutaminy-L-glutaminy-(.alpha.S,3S)-2-oxo-.alpha.,3-bis(phenylmethyl)-1-piperazineacetylglycyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



V. Balasubramanian

IT 193091-13-3P 270257-61-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis of substance P analogs contg. conformationally constrained Phe-Phe peptidomimetic)

RN 193091-13-3 CAPLUS

CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-2-oxo-.alpha.,3-bis(phenylmethyl)-, (.alpha.S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 270257-61-9 CAPLUS

CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-5-hydroxy-2-oxo-.alpha.,3-bis(phenylmethyl)-, methyl ester, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 20 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 2000:117072 CAPLUS

DN 132:166522

TI Preparation of depsipeptide derivatives bearing piperazinone rings as enhancers of apolipoprotein E production

IN Yanai, Makoto; Suzuki, Masashi; Oshida, Norio; Kawamura, Koji; Hiramoto, Shigeru; Yasuda, Orie; Kinoshita, Nobuhiro; Shingai, Akiko; Takasu, Masako

PA Nisshin Flour Milling Co., Ltd., Japan

SO PCT Int. Appl., 47 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.

KIND DATE

APPLICATION NO. DATE

10/039,898

V. Balasubramanian

PI	WO 2000008047	A1	20000217	WO 1999-JP4205	19990804
	W: JP, US				
	RW: DE, FR, GB, IT				
	EP 1028126	A1	20000816	EP 1999-935054	19990804
	R: DE, FR, GB, IT				
	US 6288038	B1	20010911	US 2000-509132	20000403
PRAI	JP 1998-220398	A	19980804		
	WO 1999-JP4205	W	19990804		

OS MARPAT 132:166522

IT 259087-00-8P 259087-08-6P 259087-24-6P  
259087-25-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn. of depsipeptide derivs. bearing piperazinone rings as enhancers of apolipoprotein E prodn. for remedies for nerve injury, dementia, and hyperlipidemia)

RN 259087-00-8 CAPLUS

CN 1-Piperazinepropanoic acid, .beta.-[[[(2E)-5-[[[(1R)-1-(carboxymethyl)dodecyl]oxy]-5-oxo-2-pentenyl]amino]carbonyl]-4-[(9H-fluoren-9-ylmethoxy)carbonyl]-2-oxo-, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 259087-08-6 CAPLUS

CN 1-Piperazinepropanoic acid, .beta.-[[[(1R)-1-[[[(1R,2R)-1-[[[(1R)-1-(carboxymethyl)dodecyl]oxy]carbonyl]-2-methylbutyl]amino]methyl]-3-methylbutyl]amino]carbonyl]-4-[(9H-fluoren-9-ylmethoxy)carbonyl]-2-oxo-, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 259087-24-6 CAPLUS

CN 1-Piperazinepropanoic acid, .beta.-[[[(1R)-5-[[[(1R)-1-(carboxymethyl)dodecyl]oxy]-1-(2-methylpropyl)-2,5-dioxopentyl]amino]carbonyl]-4-[(9H-fluoren-9-ylmethoxy)carbonyl]-2-oxo-, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 259087-25-7 CAPLUS

CN 1-Piperazinepropanoic acid, .beta.-[[[(1R)-1-[[[(1R,2R)-1-[[[(1R)-1-(carboxymethyl)dodecyl]oxy]carbonyl]-2-methylbutyl]amino]methyl]-3-methylbutyl]amino]carbonyl]-4-[(9H-fluoren-9-ylmethoxy)carbonyl]-2-oxo-, (.beta.S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

10/039,898

V. Balasubramanian


CRN 259087-08-6  
CMF C49 H72 N4 O10

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2



IT 259086-94-7P 259086-98-1P 259086-99-2P

259087-06-4P 259087-07-5P 259087-23-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(prepn. of depsipeptide derivs. bearing piperazinone rings as enhancers of apolipoprotein E prodn. for remedies for nerve injury, dementia, and hyperlipidemia)

RN 259086-94-7 CAPLUS

CN Butanedioic acid, [4-[(9H-fluoren-9-ylmethoxy)carbonyl]-2-oxo-1-piperazinyl]-, 4-(1,1-dimethylethyl) ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

V. Balasubramanian





RN 259086-98-1 CAPLUS

CN 1-Piperazinepropanoic acid, 4-[(9H-fluoren-9-ylmethoxy)carbonyl]-2-oxo-  
 .beta.-[[[(2E)-5-oxo-5-[[[(1R)-1-[2-oxo-2-(2-oxo-2-  
 phenylethoxy)ethyl]dodecyl]oxy]-2-pentenyl]amino]carbonyl]-,  
 1,1-dimethylethyl ester, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.


PAGE 1-A





RN 259086-99-2 CAPLUS  
 CN 1-Piperazinepropanoic acid, .beta.-[[[(2E)-5-[[[(1R)-1-(carboxymethyl)dodecyl]oxy]-5-oxo-2-pentenyl]amino]carbonyl]-4-[(9H-fluoren-9-ylmethoxy)carbonyl]-2-oxo-, .alpha.-(1,1-dimethylethyl) ester, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.




RN 259087-06-4 CAPLUS ‡  
 CN 1-Piperazinepropanoic acid, 4-[(9H-fluoren-9-ylmethoxy)carbonyl]-.beta.-[(3R,6R,9R)-6-[(1R)-1-methylpropyl]-3-(2-methylpropyl)-1,7,11-trioxo-13-phenyl-5-[(phenylmethoxy)carbonyl]-9-undecyl-8,12-dioxo-2,5-diazatridec-1-yl]-2-oxo-, 1,1-dimethylethyl ester, (.beta.S)- (9CI) (CA INDEX NAME)


V. Balasubramanian

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 259087-07-5 CAPLUS

CN 1-Piperazinepropanoic acid, .beta.-[[[(1R)-1-[[[(1R,2R)-1-[[[(1R)-1-(carboxymethyl)dodecyl]oxy]carbonyl]-2-methylbutyl]amino]methyl]-3-methylbutyl]amino]carbonyl]-4-[(9H-fluoren-9-ylmethoxy)carbonyl]-2-oxo-, .alpha.-(1,1-dimethylethyl) ester, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 259087-23-5 CAPLUS

CN 1-Piperazinepropanoic acid, .beta.-[[[(1R)-5-[[ (1R)-1-[2-(1,1-dimethylethoxy)-2-oxoethyl]dodecyl]oxy]-1-(2-methylpropyl)-2,5-dioxopentyl]amino]carbonyl]-4-[(9H-fluoren-9-ylmethoxy) carbonyl]-2-oxo-, 1,1-dimethylethyl ester, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 21 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 2000:68456 CAPLUS

DN 132:107945

TI Preparation of 9-trimethoxyphenyloxalyl-2-oxo-3,9-diaza[3.3.1]nonanes and

10/039,898

V. Balasubramanian

analogs as FKBP rotamase inhibitors

IN Katoh, Susumu; Kawakami, Hiroshi; Tada, Hiroki; Linton, Maria Angelica;  
Kalish, Vincent; Tatlock, John Howard; Villafranca, J. Ernest

PA Agouron Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 130 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000004020	A1	20000127	WO 1999-US15965	19990715
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2337377	AA	20000127	CA 1999-2337377	19990715
	AU 9949963	A1	20000207	AU 1999-49963	19990715
	AU 756912	B2	20030123		
	EP 1098897	A1	20010516	EP 1999-934043	19990715
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9912423	A	20010605	BR 1999-12423	19990715
	SI 20638	C	20020228	SI 1999-20067	19990715
	EE 200100032	A	20020617	EE 2001-32	19990715
	JP 2002520413	T2	20020709	JP 2000-560126	19990715
	NZ 509211	A	20021025	NZ 1999-509211	19990715
	NO 2001000191	A	20010316	NO 2001-191	20010112
	LT 4850	B	20011025	LT 2001-12	20010215
	BG 105268	A	20011130	BG 2001-105268	20010216
	LV 12665	B	20011120	LV 2001-23	20010313
PRAI	US 1998-93299P	P	19980717		
	US 1999-132884P	P	19990506		
	WO 1999-US15965	W	19990715		
OS	MARPAT 132:107945				
IT	255909-53-6P 255909-66-1P 255909-67-2P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(prepn. of 9-trimethoxyphenyloxalyl-2-oxo-3,9-diaza[3.3.1]nonanes and analogs as FKBP rotamase inhibitors)				
RN	255909-53-6 CAPLUS				
CN	3,9-Diazabicyclo[3.3.1]nonan-2-one, 3-[(1R,2R)-1-methyl-2-phenyl-2-(phenylmethoxy)ethyl]-9-[oxo(3;4,5-trimethoxyphenyl)acetyl]-, rel- (9CI)				
	(CA INDEX NAME)				


Relative stereochemistry.

V. Balasubramanian




RN 255909-66-1 CAPLUS

CN 3,9-Diazabicyclo[3.3.1]nonan-2-one, 3-[1-(hydroxymethyl)-2-(phenylmethoxy)ethyl]-9-[oxo(3,4,5-trimethoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)



RN 255909-67-2 CAPLUS

CN 3,9-Diazabicyclo[3.3.1]nonan-2-one, 3-[1-[(acetyloxy)methyl]-2-(phenylmethoxy)ethyl]-9-[oxo(3,4,5-trimethoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE.FORMAT

L5 ANSWER 22 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 2000:15184 CAPLUS

DN 132:64256

TI Preparation of non-peptidyl inhibitors of VLA-4 dependent cell binding  
useful in treating inflammatory, autoimmune and respiratory diseases

IN Duplantier, Allen Jacob; Milici, Anthony John; Chupak, Louis Stanley

PA Pfizer Products Inc., USA

SO PCT Int. Appl., 120 pp.

10/039,898

V. Balasubramanian

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000000477	A1	20000106	WO 1999-IB973	19990531
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2336625	AA	20000106	CA 1999-2336625	19990531
	AU 9938416	A1	20000117	AU 1999-38416	19990531
	AU 758939	B2	20030403		
	BR 9911701	A	20010320	BR 1999-11701	19990531
	EP 1091943	A1	20010418	EP 1999-921046	19990531
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO			
	JP 2002519344	T2	20020702	JP 2000-557238	19990531
	NZ 508033	A	20021220	NZ 1999-508033	19990531
	ZA 9903777	A	20001204	ZA 1999-3777	19990604
	US 6306887	B1	20011023	US 1999-338832	19990623
	US 6355662	B1	20020312	US 1999-403846	19991026
	NO 2000006600	A	20010221	NO 2000-6600	20001222
	BG 105190	A	20011231	BG 2001-105190	20010126
PRAI	US 1998-91180P	P	19980630		
	WO 1999-IB973	W	19990531		
	US 1999-338832	A3	19990623		
OS	MARPAT 132:64256				
IT	<b>253346-18-8P 253346-22-4P</b>				
	RL:	BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)			
		(prepn. of non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune and respiratory diseases)			
RN	253346-18-8	CAPLUS			
CN	1-Piperazinepropanoic acid, .beta.-methyl-4-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-3-(2-methylpropyl)-2-oxo-, (3S)- (9CI) (CA INDEX NAME)				


Absolute stereochemistry.



V. Balasubramanian

RN 253346-22-4 CAPLUS

CN 1-Piperazinepropanoic acid, .beta.-1,3-benzodioxol-5-yl-4-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-3-(2-methylpropyl)-2-oxo-(9CI) (CA INDEX NAME)



IT 253348-65-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of non-peptidyl inhibitors of VLA-4 dependent cell binding  
useful in treating inflammatory, autoimmune and respiratory diseases)

RN 253348-65-1 CAPLUS

CN 1-Piperazinepropanoic acid, .beta.-methyl-4-[[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]acetyl]-3-(2-methylpropyl)-2-oxo-, methyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2        THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 23 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 1999:511143 CAPLUS

DN 131:170361

TI Preparation of sulfonamides as inhibitors of activated blood coagulation factor X

IN Tawada, Hiroyuki; Itoh, Fumio; Banno, Hiroshi; Terashita, Zenichi

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 187 pp. \*

CODEN: PIXXD2


DT Patent

LA Japanese

FAN.CNT 1


## V. Balasubramanian

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9940075	A1	19990812	WO 1999-JP470	19990204
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2317017	AA	19990812	CA 1999-2317017	19990204
	AU 9922988	A1	19990823	AU 1999-22988	19990204
	JP 2000204081	A2	20000725	JP 1999-27053	19990204
	EP 1054005	A1	20001122	EP 1999-902829	19990204
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	US 6403595	B1	20020611	US 2000-601660	20000803
	US 2002193382	A1	20021219	US 2002-128809	20020424
PRAI	JP 1998-24833	A	19980205		
	JP 1998-317205	A	19981109		
	WO 1999-JP470	W	19990204		
	US 2000-601660	A3	20000803		
OS	MARPAT 131:170361				
IT	<b>239071-71-7P 239071-72-8P 239071-98-8P 239072-70-9P</b>				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(prepn. of sulfonamides as inhibitors of activated blood coagulation factor X)				
RN	239071-71-7	CAPLUS			
CN	1-Piperazineacetoneitrile, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-.alpha.-[1-(4-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)				




RN 239071-72-8 CAPLUS  
 CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[1-[4-(1H-imidazol-1-yl)phenyl]ethyl]- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 239071-98-8 CAPLUS

CN 1-Piperazinepropanoic acid, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-.beta.-[1-(4-pyridinyl)-4-piperidinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 239072-70-9 CAPLUS

CN 1-Piperazineacetic acid, .alpha.-[4-(aminoiminomethyl)phenyl]-4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT 239073-30-4P 239073-31-5P 239073-33-7P

239073-60-0P 239073-62-2P 239074-07-8P

239074-08-9P 239074-09-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(prepn. of sulfonamides as inhibitors of activated blood coagulation factor X)

RN 239073-30-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-1-piperazinyl]cyanomethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


V. Balasubramanian

NAME)



RN 239073-31-5 CAPLUS


CN 1-Piperazineacetone nitrile, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-.alpha.-4-piperidinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 239073-33-7 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[1-[4-(1H-imidazol-1-yl)phenyl]ethyl]-3-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



V. Balasubramanian


RN 239073-60-0 CAPLUS

CN 1-Piperazinepropanoic acid, 4-[(1,1-dimethylethoxy)carbonyl]-2-oxo-.beta.-[1-[(phenylmethoxy)carbonyl]-4-piperidinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 239073-62-2 CAPLUS

CN 1-Piperazinepropanoic acid, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-.beta.-[1-[(phenylmethoxy)carbonyl]-4-piperidinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 239074-07-8 CAPLUS


CN 1-Piperazineacetic acid, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-.alpha.-(4-cyanophenyl)-2-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 239074-08-9 CAPLUS


± CN 1-Piperazineacetic acid, .alpha.-(4-bromophenyl)-4-[(1,1-dimethylethoxy)carbonyl]-2-oxo-, methyl ester (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 239074-09-0 CAPLUS

CN 1-Piperazineacetic acid, .alpha.-(4-cyanophenyl)-4-[(1,1-dimethylethoxy)carbonyl]-2-oxo-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 24 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 1999:434172 CAPLUS

DN 131:81017

TI N-tert-butoxycarbonyl-N,N'-ethylene-bridged (S)-tyrosyl-(S)-tyrosine methyl ester

AU Yamato, Kazuhiro; Miyake, Hiroyuki; Hirotsu, Ken; Kojima, Yoshitane

CS Department of Chemistry, Graduate School of Science, Osaka City University, Osaka, 558-585, Japan

SO Acta Crystallographica, Section C: Crystal Structure Communications (1999), C55(6), 1023-1025

CODEN: ACSCEE; ISSN: 0108-2701

PB Munksgaard International Publishers Ltd.

DT Journal

LA English

IT **229024-26-4**

RL: PRP (Properties)


(crystal structure of)

RN 229024-26-4 CAPLUS

CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-.alpha.,3-bis[(4-hydroxyphenyl)methyl]-2-oxo-, methyl ester, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


X



RN 226890-57-9 CAPLUS

CN 1-Piperazineacetamide, 4-(3-amino-3-methyl-1-oxobutyl)-N-methyl-N-[(1R)-2-(methyldamino)-2-oxo-1-(phenylmethyl)ethyl]-.alpha.-(2-naphthalenylmethyl)-2-oxo-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 226890-50-2P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(synthesis and biol. activity of piperazinone-contg. peptidomimetics as constrained analogs of the growth hormone secretagogue NN-703)

RN 226890-50-2 CAPLUS

CN D-Phenylalaninamide, 2-methylalanyl-(.alpha.R)-.alpha.-(2-naphthalenylmethyl)-2-oxo-1-piperazineacetyl-N,N.alpha.-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 26 OF 82 CAPLUS COPYRIGHT 2003 ACS  
AN 1998:742814 CAPLUS  
DN 130:81880  
TI Selective BH<sub>3</sub>-reduction of amide carbonyl groups of lithium salts of  
N-tert-butoxycarbonyl-(S)-O-benzyltyrosyl-(S)-proline and  
N,N'-ethylene-bridged dipeptides  
AU Adachi, Kenichi; Tsuru, Eiji; Banjyo, Eri; Doe, Matsumi; Shibata, Kozo;  
Yamashita, Tetsushi  
CS Department Chemistry, Faculty Science, Osaka City University, Osaka, 558,  
Japan  
SO Synthesis (1998), (11), 1623-1626  
CODEN: SYNTBF; ISSN: 0039-7881  
PB Georg Thieme Verlag  
DT Journal  
LA English  
OS CASREACT 130:81880  
IT 172801-42-2 217977-54-3 217977-55-4  
217977-56-5  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(selective borane-redn. of amide carbonyl groups of dipeptide lithium  
salts)  
RN 172801-42-2 CAPLUS  
CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-.alpha.,3-bis[2-  
(methylthio)ethyl]-2-oxo-, ethyl ester, (.alpha.S,3S)- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 217977-54-3 CAPLUS

CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-.alpha.,3-bis[(4-hydroxyphenyl)methyl]-2-oxo-, ethyl ester, (.alpha.S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 217977-55-4 CAPLUS

CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-2-oxo-.alpha.,3-bis(phenylmethyl)-, ethyl ester, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 217977-56-5 CAPLUS

CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-.alpha.,3-bis(2-methylpropyl)-2-oxo-, ethyl ester, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

10/039,898

V. Balasubramanian

Absolute stereochemistry.




IT 217977-57-6P 217977-58-7P 218160-81-7P  
218162-88-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(selective borane-redn. of amide carbonyl groups of dipeptide lithium  
salts)

RN 217977-57-6 CAPLUS

CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-2-oxo-.alpha.,3-  
bis[[4-(phenylmethoxy)phenyl]methyl]-, lithium salt, (.alpha.S,3S)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




● Li

RN 217977-58-7 CAPLUS

CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-.alpha.,3-bis[2-  
(methylthio)ethyl]-2-oxo-, lithium salt, (.alpha.S,3S)- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.

V. Balasubramanian




● Li

RN 218160-81-7 CAPLUS

CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-2-oxo-.alpha.,3-bis(phenylmethyl)-, lithium salt, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● Li

RN 218162-88-0 CAPLUS

CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-.alpha.,3-bis(2-methylpropyl)-2-oxo-, lithium salt, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● Li


10/039,898

V. Balasubramanian

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 27 OF 82 CAPLUS COPYRIGHT 2003 ACS  
AN 1998:689985 CAPLUS  
DN 130:81803  
TI Efficient synthesis of substituted oxopiperazines from amino acids  
AU Mohamed, Nazim; Bhatt, Ulhas; Just, George  
CS Dep. of Chemistry, McGill University, Montreal, QC, H3A 2K6, Can.  
SO Tetrahedron Letters (1998), 39(45), 8213-8216  
CODEN: TELEAY; ISSN: 0040-4039  
PB Elsevier Science Ltd.  
DT Journal  
LA English  
IT 218785-69-4P 218785-70-7P 218785-71-8P  
218785-72-9P 218785-73-0P 218785-74-1P  
218785-78-5DP, resin-bound 218785-81-0DP, resin-bound  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(efficient synthesis of substituted oxopiperazines from amino acids as  
peptide mimics by cyclocondensation of N-(nitrobenzenesulfonyl)diptid  
es with ethylene dibromide or bromoethanol)  
RN 218785-69-4 CAPLUS  
CN 1-Piperazineacetic acid, .alpha.-(2-methylpropyl)-4-[(4-  
nitrophenyl)sulfonyl]-2-oxo-, methyl ester, (.alpha.S)- (9CI) (CA INDEX  
NAME)


Absolute stereochemistry.



RN 218785-70-7 CAPLUS  
CN 1-Piperazineacetic acid, 3-methyl-4-[(4-nitrophenyl)sulfonyl]-2-oxo-  
.alpha.-(phenylmethyl)-, methyl ester, (.alpha.S,3S)- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 218785-71-8 CAPLUS

CN 1-Piperazineacetic acid, 3-(1-methylethyl)-.alpha.-(2-methylpropyl)-4-[(4-nitrophenyl)sulfonyl]-2-oxo-, methyl ester, (.alpha.S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 218785-72-9 CAPLUS

CN 1-Piperazineacetic acid, 3-methyl-4-[(2-nitrophenyl)sulfonyl]-2-oxo-.alpha.-(phenylmethyl)-, methyl ester, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 218785-73-0 CAPLUS

CN 1-Piperazineacetic acid, 3-(1-methylethyl)-4-[(2-nitrophenyl)sulfonyl]-2-oxo-.alpha.-(phenylmethyl)-, methyl ester, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 218785-74-1 CAPLUS

CN 1H-Indole-3-propanoic acid, .alpha.-[(3S)-4-[(2-nitrophenyl)sulfonyl]-2-oxo-3-(phenylmethyl)-1-piperazinyl]-, methyl ester, (.alpha.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 218785-78-5 CAPLUS

CN 1-Piperazineacetic acid, 3-methyl-4-[(2-nitrophenyl)sulfonyl]-2-oxo-.alpha.-(phenylmethyl)-, (.alpha.S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 218785-81-0 CAPLUS

CN 1-Piperazineacetic acid, 4-[(2S)-2-[[[1,1-dimethylethoxy]carbonyl]amino]-1-oxopropyl]-3-methyl-2-oxo-.alpha.-(phenylmethyl)-, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 218785-54-7P

RL: SPN (Synthetic preparation); PREP (Preparation)

(efficient synthesis of substituted oxopiperazines from amino acids as peptide mimics by cyclocondensation of N-(nitrobenzenesulfonyl) dipeptides with ethylene dibromide or bromoethanol)

RN 218785-54-7 CAPLUS


CN 1-Piperazineacetic acid, 4-[(2S)-2-amino-1-oxopropyl]-3-methyl-2-oxo-.alpha.-(phenylmethyl)-, (.alpha.S,3S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 218785-53-6

CMF C17 H23 N3 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 28 OF 82 CAPLUS COPYRIGHT 2003 ACS

V. Balasubramanian

AN 1998:556399 CAPLUS  
DN 129:312485  
TI Structure of secreted aspartic proteinases from Candida: implications for the design of antifungal agents  
AU Abad-Zapatero, Cele; Goldman, Robert; Muchmore, Steven W.; Hutchins, Charles; Oie, Tetsuro; Stewart, Kent; Cutfield, Sue M.; Cutfield, John F.; Foundling, Stephen I.; Ray, Thomas L.  
CS Laboratory of Protein Crystallography, Abbott Laboratories, Abbott Park, IL, 60064, USA  
SO Advances in Experimental Medicine and Biology (1998), 436(Aspartic Proteinases), 297-313  
CODEN: AEMBAP; ISSN: 0065-2598  
PB Plenum Publishing Corp.  
DT Journal; General Review  
LA English  
IT **142928-23-2**, A-70450  
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)  
(inhibitor binding conformation; structure of secreted aspartic proteinases from Candida and implications for the design of antifungal agents)  
RN 142928-23-2 CAPLUS  
CN 1-Piperazineacetamide, .alpha.-butyl-N-[(1S,2S,4R)-4-[(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, monohydrochloride, (.alpha.S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 29 OF 82 CAPLUS COPYRIGHT 2003 ACS  
AN 1998:482693 CAPLUS  
DN 129:216902  
TI Conformational probes for elucidating the nature of substance P<sub>2</sub> binding to the NK1 receptor: initial efforts to map the Phe7-Phe8 region  
AU Tong, Yunsong; Fobian, Yvette M.; Wu, Meiye; Boyd, Norman D.; Moeller, Kevin D.  
CS The Department of Chemistry, Washington University, St. Louis, MO, 63130,


10/039,898

V. Balasubramanian


USA  
SO Bioorganic & Medicinal Chemistry Letters (1998), 8(13), 1679-1682  
CODEN: BMCLE8; ISSN: 0960-894X  
PB Elsevier Science Ltd.  
DT Journal  
LA English  
IT **212612-56-1P**  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(prepn. of piperazinone-based conformational probes for studying the binding of substance P to NK1 receptor)  
RN 212612-56-1 CAPLUS  
CN L-Methioninamide, L-arginyl-L-prolyl-L-lysyl-L-prolyl-L-glutaminy-L-glutaminy-(.alpha.S,3S)-2-oxo-.alpha.,3-bis(phenylmethyl)-1-piperazineacetylglucyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



V. Balasubramanian

IT 193091-13-3P 212612-64-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of piperazinone-based conformational probes for studying the binding of substance P to NK1 receptor)

RN 193091-13-3 CAPLUS

CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-2-oxo-.alpha.,3-bis(phenylmethyl)-, (.alpha.S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 212612-64-1 CAPLUS

CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-2-oxo-.alpha.,3-bis(phenylmethyl)-, methyl ester, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 30 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 1998:403019 CAPLUS

DN 129:136488

TI New fMLF-OMe analogs containing constrained mimics of phenylalanine residue

AU Torrini, Ines; Mastropietro, Gaia; Pagani Zecchini, Giampiero; Paglialunga Paradisi, Mario; Lucente, Gino; Spisani, Susanna

CS Dipartimento Studi Farmaceutici, Univ. La Sapienza, Rome, I-00185, Italy

SO Archiv der Pharmazie (Weinheim, Germany) (1998), 331(5), 170-176

† CODEN: ARPMAS; ISSN: 0365-6233

PB Wiley-VCH Verlag GmbH

DT Journal

LA English

IT 210473-08-8P

V. Balasubramanian


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. and biol. activity of formyl peptide analogs contg. constrained mimics of phenylalanine residue)

RN 210473-08-8 CAPLUS

CN 1-Piperazineacetic acid, 4-(N-formyl-L-methionyl-L-leucyl)-2-oxo-.alpha.,3-bis(phenylmethyl)-, methyl ester, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 210473-24-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and biol. activity of formyl peptide analogs contg. constrained mimics of phenylalanine residue)

RN 210473-24-8 CAPLUS

CN 1-Piperazineacetic acid, 4-[N-[(1,1-dimethylethoxy)carbonyl]-L-methionyl-L-leucyl]-2-oxo-.alpha.,3-bis(phenylmethyl)-, methyl ester, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 31 OF 82 CAPLUS COPYRIGHT 2003 ACS


AN 1998:270546 CAPLUS

DN 129:16374

TI The use of heterocycles for the conformational restriction of biologically active peptoids

AU Horwell, David C.; Lewthwaite, Russell A.; Pritchard, Martyn C.; Ratcliffe, Giles S.; Rubin, J. Ronald

CS Parke-Davis Neurosci. Research Centre, Cambridge Univ. Forvie Site, Cambridge, CB2 2QB, UK



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 25 OF 82 CAPLUS COPYRIGHT 2003 ACS  
AN 1999:292485 CAPLUS  
DN 131:32160  
TI Synthesis of piperazinones and their application in constrained mimetics  
of the growth hormone secretagogue NN-703  
AU Hansen, Thomas K.; Schlienger, Nathalie; Hansen, Birgit S.; Andersen,  
Peter H.; Bryce, Martin R.  
CS Medicinal Chemistry Research, Novo Nordisk A/S, Malov, 2760, Den.  
SO Tetrahedron Letters (1999), 40(18), 3651-3654  
CODEN: TELEAY; ISSN: 0040-4039  
PB Elsevier Science Ltd.  
DT Journal  
LA English  
IT **226890-56-8P 226890-57-9P**  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); PNU (Preparation, unclassified); BIOL (Biological  
study); PREP (Preparation)  
(synthesis and biol. activity of piperazinone-contg. peptidomimetics as  
constrained analogs of the growth hormone secretagogue NN-703)  
RN 226890-56-8 CAPLUS  
CN 1H-Indole-3-propanoic acid, .alpha.-[(3R)-4-[(2E)-5-amino-5-methyl-1-oxo-2-  
hexenyl]-3-(1H-indol-3-ylmethyl)-2-oxo-1-piperazinyl]-6,7-dihydro-, methyl  
ester, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

V. Balasubramanian

SO Tetrahedron (1998), 54(18), 4591-4606

CODEN: TETRAB; ISSN: 0040-4020

PB Elsevier Science Ltd.

DT Journal

LA English

IT 207690-72-0


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(use of heterocycles for conformational restriction of biol. active peptoids)

RN 207690-72-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(1S)-1-(hydroxymethyl)-2-phenylethyl]-2-(1H-indol-3-ylmethyl)-3-oxo-, tricyclo[3.3.1.1<sup>3,7</sup>]dec-1-yl ester, (2R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 207690-54-8P 207690-62-8P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(use of heterocycles for conformational restriction of biol. active peptoids)

RN 207690-54-8 CAPLUS

CN 1-Piperazinecarboxylic acid, 3-oxo-4-[(1S)-1-phenylethyl]-2-(phenylmethyl)-, (1R)-2-methyl-1-phenylpropyl ester, (2R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 207690-62-8 CAPLUS

CN 1-Piperazinecarboxylic acid, 2-(1H-indol-3-ylmethyl)-3-oxo-4-[(1S)-1-

V. Balasubramanian

phenylethyl]-, 2-benzofuranylmethyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT 207690-55-9P 207690-71-9P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(use of heterocycles for conformational restriction of biol. active peptoids)

RN 207690-55-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 3-oxo-4-[(1S)-1-phenylethyl]-2-(phenylmethyl)-, (1S)-2-methyl-1-phenylpropyl ester, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 207690-71-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 2-(1H-indol-3-ylmethyl)-3-oxo-4-[(1S)-1-(phenylmethyl)-2-[[tris(1-methylethyl)silyl]oxy]ethyl]-, tricyclo[3.3.1.1<sup>3,7</sup>]dec-1-yl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 32 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 1998:163571 CAPLUS

DN 128:204899

TI Heterocyclic metalloprotease inhibitors

IN Pikul, Stanislaw; McDow-Dunham, Kelly Lynn; De, Biswanath; Taiwo, Yetunde Olabisi; Almstead, Neil Gregory; Bradley, Rimma Sandler; Natchus, Michael George; Cupps, Thomas Lee

PA Procter & Gamble Company, USA

SO PCT Int. Appl., 53 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9808823	A1	19980305	WO 1997-US14553	19970822
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9741530	A1	19980319	AU 1997-41530	19970822
	AU 734834	B2	20010621		
	EP 923561	A1	19990623	EP 1997-939443	19970822
	EP 923561	B1	20021023		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI			
	CN 1228772	A	19990915	CN 1997-197544	19970822
	BR 9712085	A	20001024	BR 1997-12085	19970822
	NZ 334254	A	20001124	NZ 1997-334254	19970822
	JP 2000516953	T2	20001219	JP 1998-511713	19970822
	JP 3347331	B2	20021120		
	AT 226573	E	20021115	AT 1997-939443	19970822
	US 6121258	A	20000919	US 1997-918957	19970826
	ZA 9707696	A	19980223	ZA 1997-7696	19970827
	NO 9900759	A	19990427	NO 1999-759	19990218

V. Balasubramanian

US 6399598 B1 20020604 US 2000-516726 20000301  
PRAI US 1996-24846P P 19960828  
WO 1997-US14553 W 19970822  
US 1997-918957 A3 19970826  
OS MARPAT 128:204899  
IT **203938-93-6P**  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of heterocyclic metalloprotease inhibitors and their pharmaceutical comps.)  
RN 203938-93-6 CAPLUS  
CN 2-Piperazinecarboxamide, N-hydroxy-4-[(4-methoxyphenyl)sulfonyl]-1-(1-methylethyl)-6-oxo-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 33 OF 82 CAPLUS COPYRIGHT 2003 ACS  
AN 1998:93877 CAPLUS  
DN 128:226371  
TI Biologically active analogs of arginine vasopressin containing conformationally restricted dipeptide fragments  
AU Lammek, Bernard; Czaja, Malgorzata; Derdowska, Izabela; Lempicka, Elzbieta; Sikora, Piotr; Szkrobka, Witold; Trzeciak, Henryk I.  
CS Faculty of Chemistry, University of Gdansk, Gdansk, 80-952, Pol.  
SO Journal of Peptide Research (1998), 51(2), 149-154  
CODEN: JPERFA; ISSN: 1397-002X  
PB Munksgaard International Publishers Ltd.  
DT Journal  
LA English  
IT **193091-13-3P 204758-26-9P 204758-27-0P**  
**204758-28-1P 204758-40-7P**  
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(biol. active analogs of arginine vasopressin contg. conformationally restricted dipeptide fragments)  
RN 193091-13-3 CAPLUS  
CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-2-oxo-.alpha.,3-bis(phenylmethyl)-, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


V. Balasubramanian




RN 204758-26-9 CAPLUS  
 CN Glycinamide, S-(phenylmethyl)-L-cysteinyl-(.alpha.S,3S)-2-oxo-.alpha.,3-bis(phenylmethyl)-1-piperazineacetyl-L-glutaminy-L-asparaginy-L-S-(phenylmethyl)-L-cysteinyl-L-prolyl-N5-[imino[[4-methylphenyl)sulfonyl]amino]methyl]-L-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 204758-27-0 CAPLUS  
 CN Glycinamide, N2-[(2S)-1-oxo-2-[(3S)-2-oxo-4-[1-oxo-3-[(phenylmethyl)thio]propyl]-3-(phenylmethyl)-1-piperazinyl]-3-


10/039,898

V. Balasubramanian


phenylpropyl]-L-glutaminy]-L-asparaginy]-S-(phenylmethyl)-L-cysteinyl-L-prolyl-N5-[imino[[4-methylphenyl)sulfonyl]amino]methyl]-L-ornithyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 1-B



RN 204758-28-1 CAPLUS  
CN Glycinamide, N-[(2S)-1-oxo-2-[(3S)-2-oxo-3-(phenylmethyl)-4-[[1-(phenylmethyl)thio]cyclohexyl]acetyl]-1-piperazinyl]-3-phenylpropyl]-L-glutaminy]-L-asparaginy]-S-(phenylmethyl)-L-cysteinyl-L-prolyl-N5-[imino[[4-methylphenyl)sulfonyl]amino]methyl]-L-ornithyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 204758-40-7 CAPLUS

CN Glycinamide, N-[(2S)-1-oxo-2-[(3S)-2-oxo-3-(phenylmethyl)-4-[[1-[(phenylmethyl)thio]cyclohexyl]acetyl]-1-piperazinyl]-3-phenylpropyl]-L-valyl-L-asparaginyl-S-(phenylmethyl)-L-cysteinyl-L-prolyl-N5-[imino[[4-methylphenyl)sulfonyl]amino]methyl]-L-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 34 OF 82 CAPLUS COPYRIGHT 2003 ACS  
AN 1998:93872 CAPLUS  
DN 128:192910  
TI Synthesis and conformational analysis of two 2-oxopiperazine-containing tetrapeptide analogs  
AU Pohlmann, Adriana; Guillaume, Dominique; Quirion, Jean-Charles; Husson, Henri-Philippe  
CS Laboratoire de Chimie Therapeutique, Faculte des Sciences Pharmaceutiques et Biologiques, Paris, Fr. <sup>1</sup>  
SO Journal of Peptide Research (1998), 51(2), 116-120  
CODEN: JPERFA; ISSN: 1397-002X  
PB Munksgaard International Publishers Ltd.  
DT Journal

V. Balasubramanian

LA English

IT **186821-29-4**


RL: PRP (Properties)

(synthesis and conformational anal. of oxopiperazine-contg.  
tetrapeptide analogs)

RN 186821-29-4 CAPLUS

CN 1-Piperazineacetic acid, .alpha.-(2-methylpropyl)-2-oxo-4-[1-oxo-2-  
[[ (phenylmethoxy) carbonyl] amino]propyl]-, methyl ester, [S-(R\*,R\*)]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **186821-31-8**


RL: PRP (Properties); RCT (Reactant); RACT (Reactant or reagent)

(synthesis and conformational anal. of oxopiperazine-contg.  
tetrapeptide analogs)

RN 186821-31-8 CAPLUS

CN 1-Piperazineacetic acid, 3-methyl-.alpha.-(2-methylpropyl)-2-oxo-4-[1-oxo-  
2-[[ (phenylmethoxy) carbonyl] amino]propyl]-, methyl ester,  
[3S-[1(R\*),3R\*,4(R\*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **203575-40-0P 203575-41-1P**

RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP  
(Preparation); RACT (Reactant or reagent)


(synthesis and conformational anal. of oxopiperazine-contg.  
tetrapeptide analogs)

RN 203575-40-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-[[[1-(methoxycarbonyl)-3-  
methylbutyl] amino] carbonyl]-3-methylbutyl]-3-oxo-, 1,1-dimethylethyl  
ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


V. Balasubramanian



RN 203575-41-1 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-[[[1-(methoxycarbonyl)-3-methylbutyl]amino]carbonyl]-3-methylbutyl]-2-methyl-3-oxo-, 1,1-dimethylethyl ester, [2S-[2R\*,4[R\*(R\*)]]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 203575-42-2P 203575-43-3P


RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)  
(synthesis and conformational anal. of oxopiperazine-contg.  
tetrapeptide analogs)

RN 203575-42-2 CAPLUS

CN L-Leucine, N-[(phenylmethoxy)carbonyl]-L-alanyl-(.alpha.S)-.alpha.-(2-methylpropyl)-2-oxo-1-piperazineacetyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


V. Balasubramanian



RN 203575-43-3 CAPLUS

CN L-Leucine, N-[(phenylmethoxy)carbonyl]-L-alanyl-(.alpha.S,3S)-3-methyl-.alpha.-(2-methylpropyl)-2-oxo-1-piperazineacetyl-, methyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT 186821-11-4 203575-44-4

RL: RCT (Reactant); RACT (Reactant or reagent)  
(synthesis and conformational anal. of oxopiperazine-contg.  
tetrapeptide analogs)

RN 186821-11-4 CAPLUS

CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-.alpha.-(2-methylpropyl)-2-oxo-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 203575-44-4 CAPLUS

10/039,898

V. Balasubramanian

CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-3-methyl-.alpha.-(2-methylpropyl)-2-oxo-, methyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 35 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 1998:87706 CAPLUS

DN 128:154388

TI Preparation of peptide analogs with growth hormone releasing properties

IN Peschke, Bernd; Ankersen, Michael; Hansen, Thomas Kruse; Thogersen, Henning

PA Novo Nordisk A/S, Den.; Peschke, Bernd; Ankersen, Michael; Hansen, Thomas Kruse; Thogersen, Henning

SO PCT Int. Appl., 178 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9803473	A1	19980129	WO 1997-DK314	19970717
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9734346	A1	19980210	AU 1997-34346	19970717
	EP 923539	A1	19990623	EP 1997-930368	19970717
	EP 923539	B1	20020605		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
	US 5922770	A	19990713	US 1997-896550	19970717
	JP 2000515517	T2	20001121	JP 1998-506465	19970717
	EP 1184370	A2	20020306	EP 2001-123155	19970717
	EP 1184370	A3	20020327		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
	AT 218537	E	20020615	AT 1997-930368	19970717
	US 6127354	A	20001003	US 1999-270862	19990317
	US 6274584	B1	20010814	US 2000-619227	20000719

V. Balasubramanian

PRAI DK 1996-803 A 19960722  
EP 1997-930368 A3 19970717  
US 1997-896550 A3 19970717  
WO 1997-DK314 W 19970717  
US 1999-270862 A3 19990317

OS MARPAT 128:154388

IT **202810-14-8P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn. of peptide analogs with growth hormone releasing properties)

RN 202810-14-8 CAPLUS

CN 1-Piperazineacetamide, 4-(5-amino-5-methyl-1-oxo-2-hexenyl)-N-methyl-5-(2-naphthalenylmethyl)-2-oxo-.alpha.-(phenylmethyl)-, [R-[R\*,R\*-(E)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



IT **202810-94-4P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(prepn. of peptide analogs with growth hormone releasing properties)

RN 202810-94-4 CAPLUS

CN Carbamic acid, [1,1-dimethyl-5-[4-[2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl]-2-(2-naphthalenylmethyl)-5-oxo-1-piperazinyl]-5-oxo-3-pentenyl]-, 1,1-dimethylethyl ester, [R-[R\*,R\*-(E)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 36 OF 82 CAPLUS COPYRIGHT 2003 ACS  
AN 1998:66709 CAPLUS  
DN 128:149206  
TI Novel Non-Peptide Fibrinogen Receptor Antagonists. 1. Synthesis and Glycoprotein IIb-IIIa Antagonistic Activities of 1,3,4-Trisubstituted 2-Oxopiperazine Derivatives Incorporating Side-Chain Functions of the RGDF Peptide  
AU Sugihara, Hirosada; Fukushima, Hideto; Miyawaki, Toshio; Imai, Yumi; Terashita, Zen-ichi; Kawamura, Masaki; Fujisawa, Yukio; Kita, Shunbun  
CS Pharmaceutical Research Division, Takeda Chemical Industries Ltd., Osaka, 532, Japan  
SO Journal of Medicinal Chemistry (1998), 41(4), 489-502  
CODEN: JMCMAR; ISSN: 0022-2623  
PB American Chemical Society  
DT Journal  
LA English  
IT 148126-81-2P 148126-89-0P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(prepn. and glycoprotein IIb-IIIa antagonistic activities of trisubstituted oxopiperazine derivs. incorporating RGDF side chain functions)  
RN 148126-81-2 CAPLUS  
CN 1,3-Piperazinediacetic acid, 4-[[[4-(aminoiminomethyl)benzoyl]amino]acetyl]-2-oxo-.alpha.1-(phenylmethyl)-, monohydrochloride, [S-(R\*,R\*)]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




● HCl

RN 148126-89-0 CAPLUS

CN 1,3-Piperazinediacetic acid, 4-[[[4-[(aminoiminomethyl)amino]benzoyl]amino]acetyl]-.alpha.1-methyl-2-oxo-, monohydrochloride, [S-(R\*,R\*)]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



● HCl

L5 ANSWER 37 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 1998:5383 CAPLUS

DN 128:102361

TI Synthesis and opiate activity of pseudo-tetrapeptides containing chiral piperazin-2-one and piperazine derivatives

AU Yamashita, Tetsushi; Tsuru, Eiji; Banjyo, Eri; Doe, Matsumi; Shibata, Kozo; Yasuda, Masahide; Gamba, Munekazu

CS Department of Chemistry, Faculty of Science, Osaka City University, Osaka, 558, Japan

SO Chemical & Pharmaceutical Bulletin (1997), 45(12), 1940-1944  
CODEN: CPBTAL; ISSN: 0009-2363

PB Pharmaceutical Society of Japan

DT Journal

LA English

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(synthesis and opiate activity of pseudotetrapeptides contg. chiral piperazinone and piperazine derivs.)

CN Glycine, L-tyrosyl-(.alpha.S,3S)-3-methyl-2-oxo-.alpha.-(phenylmethyl)-1-piperazineacetyl-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

CCOC(=O)CN(C(=O)S[C@H](Cc1ccccc1)N2CCN(C(=O)S[C@@H](Cc3ccc(O)cc3)C(=O)N2)C(=O)N3C(=O)SC(C)C3=O

CN Glycine, D-tyrosyl-(.alpha.R,3R)-3-methyl-2-oxo-.alpha.-(phenylmethyl)-1-piperazineacetyl-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(synthesis and opiate activity of pseudotetrapeptides contg. chiral  
piperazinone and piperazine derivs.)

V. Balasubramanian

RN 201293-41-6 CAPLUS

CN 1-Piperazineacetic acid, 3-methyl-2-oxo-4-[(phenylmethoxy)carbonyl]-  
.alpha.-(phenylmethyl)-, ethyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 201293-42-7 CAPLUS

CN 1-Piperazineacetic acid, 3-methyl-2-oxo-4-[(phenylmethoxy)carbonyl]-  
.alpha.-(phenylmethyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 201293-45-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[(2-ethoxy-2-oxoethyl)amino]-2-oxo-1-(phenylmethyl)ethyl]-2-methyl-3-oxo-, phenylmethyl ester, [S-(R\*,R\*)]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 201293-47-2 CAPLUS

CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl-(.alpha.S,3S)-3-methyl-  
2-oxo-.alpha.-(phenylmethyl)-1-piperazineacetyl-, ethyl ester (9CI) (CA  
INDEX NAME)

10/039,898

V. Balasubramanian


Absolute stereochemistry.



RN 201293-50-7 CAPLUS

CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-.alpha.,3-bis[(4-hydroxyphenyl)methyl]-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 201293-51-8 CAPLUS


CN Glycine, N-[(2S)-2-[(3S)-4-[(1,1-dimethylethoxy)carbonyl]-3-[(4-hydroxyphenyl)methyl]-2-oxo-1-piperazinyl]-3-(4-hydroxyphenyl)-1-oxopropyl]-L-phenylalanyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

V. Balasubramanian



RN 201414-33-7 CAPLUS  
 CN 1-Piperazineacetic acid, 3-methyl-2-oxo-4-[(phenylmethoxy)carbonyl]-  
 .alpha.-(phenylmethyl)-, lithium salt, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry. Rotation (+).



● Li

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 38 OF 82 CAPLUS COPYRIGHT 2003 ACS  
 AN 1997:425268 CAPLUS  
 DN 127:34247  
 TI Preparation of bicyclic heteroaryl-alkylene-(homo)piperazinones and  
 -thiones as selective agonists of 5-HT1-like receptors  
 IN Chambers, Mark Stuart; Hobbs, Sarah Christine; Street, Leslie Joseph  
 PA Merck Sharp & Dohme Limited, UK; Chambers, Mark Stuart; Hobbs, Sarah  
 SO Christine; Street, Leslie Joseph  
 PCT Int. Appl., 69 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9716446	A1	19970509	WO 1996-GB2624	19961028

10/039,898

V. Balasubramanian

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG  
 AU 9673190 A1 19970522 AU 1996-73190 19961028  
 US 5998415 A 19991207 US 1998-65020 19980417  
 PRAI GB 1995-22473 19951102  
 GB 1995-23907 19951122  
 WO 1996-GB2624 19961028  
 OS MARPAT 127:34247  
 IT **190953-84-5P**  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (prepn. of bicyclic heteroaryl-alkylene-(homo)piperazinones and -thiones as selective agonists of 5-HT1-like receptors)  
 RN 190953-84-5 CAPLUS  
 CN 1-Piperazinecarboxylic acid, 3-oxo-4-(1-phenylethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




L5 ANSWER 39 OF 82 CAPLUS COPYRIGHT 2003 ACS  
 AN 1997:421503 CAPLUS  
 DN 127:136058  
 TI Antagonists of bradykinin modified with conformationally restricted dipeptide fragment  
 AU Prahl, A.; Wierzba, T.; Winklewski, P.; Musial, P.; Juzwa, W.; Lammek, B.  
 CS Department Chemistry, University Gdansk, Gdansk, 80-952, Pol.  
 SO Polish Journal of Chemistry (1997), 71(7), 929-935  
 CODEN: PJCHDQ; ISSN: 0137-5083  
 PB Polish Chemical Society  
 DT Journal  
 LA English  
 IT **193091-08-6P 193091-09-7P 193091-10-0P 193091-11-1P**  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (prepn. and structure-activity of conformationally restricted bradykinin antagonists)  
 RN 193091-08-6 CAPLUS  
 CN L-Arginine, D-arginyl-L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-L-phenylalanyl-L-seryl-(.alpha.S,3S)-2-oxo-.alpha.,3-bis(phenylmethyl)-1-piperazineacetyl- (9CI) (CA INDEX NAME)


V. Balasubramanian

Absolute stereochemistry. Rotation (-).

PAGE 1-A





PAGE 1-B



RN 193091-09-7 CAPLUS



CN L-Arginine, N2-(tricyclo[3.3.1.1<sup>3,7</sup>]dec-1-ylacetyl)-D-arginyl-L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolyl-glycyl-L-phenylalanyl-L-seryl-(.alpha.S,3S)-2-oxo-.alpha.,3-bis(phenylmethyl)-1-piperazineacetyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 193091-10-0 CAPLUS  
 CN L-Arginine, D-arginyl-L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolyl-glycyl-3-(2-thienyl)-L-alanyl-(.alpha.S,3S)-2-oxo-.alpha.,3-bis(phenylmethyl)-1-piperazineacetyl-3-(2-thienyl)-L-alanyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry. Rotation (-).



RN 193091-11-1 CAPLUS

CN L-Arginine, N2-(tricyclo[3.3.1.1<sup>3,7</sup>]dec-1-ylacetyl)-D-arginyl-L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolyl-glycyl-3-(2-thienyl)-L-alanyl-(.alpha.S,3S)-2-oxo-.alpha.,3-bis(phenylmethyl)-1-piperazineacetyl-3-(2-thienyl)-L-alanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 193091-13-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and structure-activity of conformationally restricted bradykinin antagonists)

RN 193091-13-3 CAPLUS

CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-2-oxo-.alpha.,3-bis(phenylmethyl)-, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

V. Balasubramanian



L5 ANSWER 41 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 1997:88714 CAPLUS

DN 126:157788

TI Efficient Synthesis of Conformationally Constrained Peptidomimetics  
Containing 2-Oxopiperazines

AU Pohlmann, Adriana; Schanen, Vincent; Guillaume, Dominique; Quirion,  
Jean-Charles; Husson, Henri-Philippe

CS Laboratoire de Chimie Therapeutique Faculte des Sciences Pharmaceutiques  
et Biologiques, Universite Rene Descartes, Paris, 75270, Fr.

SO Journal of Organic Chemistry (1997), 62(4), 1016-1022

CODEN: JOCEAH; ISSN: 0022-3263

PB American Chemical Society

DT Journal

LA English

OS CASREACT 126:157788

IT 174585-12-7P 186820-89-3P 186820-92-8P

186820-93-9P 186820-95-1P 186820-96-2P

186820-97-3P 186820-99-5P 186821-01-2P

186821-11-4P 186821-12-5P 186821-13-6P

186821-17-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(efficient prepn. of conformationally constrained oxopiperazine-contg.  
peptide mimics)

RN 174585-12-7 CAPLUS

CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-.alpha.,3-bis(2-  
methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 186820-89-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-(hydroxymethyl)-3-methylbutyl]-3-oxo-,  
1,1-dimethylethyl ester, (S)- (9CI) (CA INDEX NAME)

10/039,898

V. Balasubramanian

Absolute stereochemistry. Rotation (-).



L5 ANSWER 40 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 1997:348294 CAPLUS

DN 127:66135

TI Derivatized oxopiperazine rings from amino acids

AU Bhatt, Ulhas; Mohamed, Nazim; Just, George; Roberts, Edward

CS Dep. Chem., McGill Univ., Montreal, QC, H3A 2K6, Can.

SO Tetrahedron Letters (1997), 38(21), 3679-3682

CODEN: TELEAY; ISSN: 0040-4039

PB Elsevier

DT Journal

LA English

OS CASREACT 127:66135

IT 191337-32-3P 191337-35-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(derivatized oxopiperazine rings from amino acids)

RN 191337-32-3 CAPLUS

CN 1-Piperazineacetic acid, 5-hydroxy-.alpha.-(1-methylethyl)-2-oxo-4-[(phenylmethoxy)carbonyl]-3-(phenylmethyl)-, methyl ester, [1(S),3S]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 191337-35-6 CAPLUS

CN 1,3-Piperazinediacetic acid, 5-hydroxy-2-oxo-4-[(phenylmethoxy)carbonyl]-.alpha.1-(phenylmethyl)-, .alpha.1-methyl .alpha.3-(phenylmethyl) ester, [1(S),3S]-[partial]- (9CI) (CA INDEX,NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 186820-96-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-(hydroxymethyl)-3-methylbutyl]-3-oxo-2-(phenylmethyl)-, 1,1-dimethylethyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 186820-97-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-(hydroxymethyl)-3-methylbutyl]-2-(2-methylpropyl)-3-oxo-, 1,1-dimethylethyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 186820-99-5 CAPLUS

CN 1-Piperazinecarboxylic acid, 2-[(2-bromophenyl)methyl]-4-[1-(hydroxymethyl)-3-methylbutyl]-3-oxo-, 1,1-dimethylethyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

V. Balasubramanian


Absolute stereochemistry. Rotation (-).



RN 186820-92-8 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-3-methylbutyl]-3-oxo-, 1,1-dimethylethyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 186820-93-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(1,1-dimethylethoxy)carbonyl]-.alpha.-(2-methylpropyl)-2-oxo-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 186820-95-1 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-(hydroxymethyl)-3-methylbutyl]-2-methyl-3-oxo-, 1,1-dimethylethyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


V. Balasubramanian



RN 186821-01-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-(hydroxymethyl)-3-methylbutyl]-3-oxo-2-(2-propenyl)-, 1,1-dimethylethyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 186821-11-4 CAPLUS

CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-.alpha.-(2-methylpropyl)-2-oxo-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 186821-12-5 CAPLUS

CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-3-methyl-.alpha.-(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


V. Balasubramanian



RN 186821-13-6 CAPLUS

CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-.alpha.-(2-methylpropyl)-2-oxo-3-(phenylmethyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 186821-17-0 CAPLUS

CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-.alpha.-(2-methylpropyl)-2-oxo-3-(2-propenyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 186821-04-5P 186821-05-6P 186821-07-8P

186821-09-0P 186821-16-9P 186821-29-4P

186821-31-8P 186821-33-0P 186821-35-2P

RL: SPN (Synthetic preparation); PREP (Preparation)

(efficient prepn. of conformationally constrained oxopiperazine-contg. peptide mimics)


RN 186821-04-5 CAPLUS

CN 2-Piperazineacetic acid, 1-[(1,1-dimethylethoxy)carbonyl]-4-[1-(hydroxymethyl)-3-methylbutyl]-3-oxo-, 1,1-dimethylethyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/039,898


V. Balasubramanian



RN 186821-05-6 CAPLUS

CN 2-Piperazineacetic acid, 1-[(1,1-dimethylethoxy)carbonyl]-4-[1-(hydroxymethyl)-3-methylbutyl]-3-oxo-, ethyl ester, [S-(R\*,R\*)]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 186821-07-8 CAPLUS

CN 1-Piperazinecarboxylic acid, 2-[2-(acetyloxy)ethyl]-4-[1-(hydroxymethyl)-3-methylbutyl]-3-oxo-, 1,1-dimethylethyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 186821-09-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 2-(2-hydroxyethyl)-4-[1-(hydroxymethyl)-3-methylbutyl]-3-oxo-, 1,1-dimethylethyl ester, [4(S)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 177980-76-6 CAPLUS

CN Glycine, N-[2-[4-[[[(1,1-dimethylethoxy)carbonyl]methylamino]acetyl]-3-(2-methylpropyl)-2-oxo-1-piperazinyl]-4-methyl-1-oxopentyl]-, ethyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 177980-77-7 CAPLUS

CN Glycine, N-[N-[2-[4-[[[(1,1-dimethylethoxy)carbonyl]methylamino]acetyl]-3-(2-methylpropyl)-2-oxo-1-piperazinyl]-4-methyl-1-oxopentyl]glycyl]-N-methyl-, ethyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 177980-78-8 CAPLUS

CN Carbamic acid, [2-[4-[1-[[[2-[[2-[(2,5-dioxo-1-pyrrolidinyl)oxy]-2-oxoethyl]methylamino]-2-oxoethyl]amino]carbonyl]-3-methylbutyl]-2-(2-

V. Balasubramanian

methylpropyl)-3-oxo-1-piperazinyl]-2-oxoethyl]methyl-, 1,1-dimethylethyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 44 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 1996:295914 CAPLUS

DN 125:47488

TI Synthesis and structure of chiral dinuclear copper(II) complex of novel structurally reinforced hexaazamacrocyclic ligand

AU Seki, Yoshio; Miyake, Hiroyuki; Kojima, Yoshitane; Doi, Mayumi; Yano, Shigenobu

CS Dep. Chem., Osaka City Univ., Osaka, 558, Japan

SO Molecular Crystals and Liquid Crystals Science and Technology, Section A:

Molecular Crystals and Liquid Crystals (1996), 276, 79-84

CODEN: MCLCE9; ISSN: 1058-725X

PB Gordon & Breach

DT Journal

LA English

IT 174585-12-7


RL: RCT (Reactant); RACT (Reactant or reagent)

(for prepn. of tricyclohexaazamacrocyclic deriv. and its reduced tetraisobutylhexaazatricyclodocosane)

RN 174585-12-7 CAPLUS

CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-.alpha.,3-bis(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




L5 ANSWER 45 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 1996:210303 CAPLUS

DN 124:311048

TI Structure of a secreted aspartic protease from Candida albicans complexed


V. Balasubramanian



RN 186821-16-9 CAPLUS

CN 1-Piperazineacetic acid, 3-[(2-bromophenyl)methyl]-4-[(1,1-dimethylethoxy)carbonyl]-.alpha.-(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 186821-29-4 CAPLUS

CN 1-Piperazineacetic acid, .alpha.-(2-methylpropyl)-2-oxo-4-[1-oxo-2-[[ (phenylmethoxy)carbonyl]amino]propyl]-, methyl ester, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 186821-31-8 CAPLUS

CN 1-Piperazineacetic acid, 3-methyl-.alpha.-(2-methylpropyl)-2-oxo-4-[1-oxo-2-[[ (phenylmethoxy)carbonyl]amino]propyl]-, methyl ester, [3S-[1(R\*),3R\*,4(R\*)]]-(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

V. Balasubramanian

with a potent inhibitor: implications for the design of antifungal agents

AU Abad-Zapatero, Cele; Goldman, Robert; Muchmore, Steven W.; Hutchins, Charles; Stewart, Kent; Navaza, Jorge; Payne, Candia D.; Ray, Thomas L.

CS Laboratory Protein Crystallography, Abbott Laboratories, Abbott Park, IL, 60064-3500, USA

SO Protein Science (1996), 5(4), 640-52  
CODEN: PRCIEI; ISSN: 0961-8368

PB Cambridge University Press

DT Journal

LA English


IT 142928-23-2 176047-03-3 176047-04-4  
176047-05-5 176200-46-7 176200-47-8  
176200-48-9 176200-49-0

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
(structure of secreted aspartic protease from Candida albicans complexed with potent inhibitor and implications for design of antifungal agents)

RN 142928-23-2 CAPLUS

CN 1-Piperazineacetamide, .alpha.-butyl-N-[(1S,2S,4R)-4-[(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, monohydrochloride, (.alpha.S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 176047-03-3 CAPLUS

CN 1-Piperazineacetamide, .alpha.-butyl-N-[4-[(butylamino)methyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, [3R-[1[S\*(1S\*,2S\*,4S\*)],3R\*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 176047-04-4 CAPLUS

CN 1-Piperazineacetamide, .alpha.-butyl-N-[1-(cyclohexylmethyl)-4-[[[2-(dimethylamino)ethyl]amino]carbonyl]-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, [3R-[1[S\*(1S\*,2S\*,4S\*)],3R\*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 176047-05-5 CAPLUS

CN 1-Piperazineacetamide, .alpha.-butyl-N-[1-(cyclohexylmethyl)-4-[[[3-(dimethylamino)propyl]amino]carbonyl]-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, [3R-[1[S\*(1S\*,2S\*,4S\*)],3R\*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 176200-46-7 CAPLUS

10/039,898

V. Balasubramanian

CN 1-Piperazineacetamide, .alpha.-butyl-N-[4-[(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, [3R-[1[R\*(1S\*,2S\*,4S\*)],3R\*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 176200-47-8 CAPLUS

CN 1-Piperazineacetamide, .alpha.-butyl-N-[4-[(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, [3S-[1[R\*(1R\*,2R\*,4R\*)],3R\*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 176200-48-9 CAPLUS

CN 1-Piperazineacetamide, .alpha.-butyl-N-[4-[(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)sulfonyl]-2-oxo-3-(phenylmethyl)-, [3R-[1[S\*(1S\*,2S\*,4S\*)],3R\*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

V. Balasubramanian




RN 176200-49-0 CAPLUS


CN 1-Piperazineacetamide, .alpha.-butyl-N-[1-(cyclohexylmethyl)-2-hydroxy-5-methyl-4-[[[3-(4-morpholinyl)propyl]amino]carbonyl]hexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, [3R-[1[S\*(1S\*,2S\*,4S\*)],3R\*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L5 ANSWER 46 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 1996:98979 CAPLUS

DN 124:276741

TI Syntheses and structures of novel optically active dinuclear copper(II) complexes of structurally reinforced macrocyclic polyamines

AU Seki, Yoshio; Miyake, Hiroyuki; Kojima, Yoshitane

10/039,898

V. Balasubramanian

CS Dep. Chem., Osaka City Univ., Sumiyoshi, 558, Japan

SO Chemistry Letters (1996), (2), 153-4

CODEN: CMLTAG; ISSN: 0366-7022

PB Nippon Kagakkai

DT Journal

LA English

IT **174585-12-7**


RL: RCT (Reactant); RACT (Reactant or reagent)

(for prepn. of hexaazamacrocyclic)

RN 174585-12-7 CAPLUS

CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-.alpha.,3-bis(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L5 ANSWER 47 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 1995:984449 CAPLUS

DN 124:104652

TI Syntheses of silver(I) complexes with N,N'-ethylene-bridged-(S)-histidyl-(S)-histidine and -(S)-methionyl-(S)-methionine derivatives

AU Kojima, Yoshitane; Watanabe, Masaaki; Miyake, Hiroyuki

CS Fac. Sci., Osaka City Univ., Osaka, 558, Japan

SO Chemistry Letters (1995), (12), 1097-8

CODEN: CMLTAG; ISSN: 0366-7022

PB Nippon Kagakkai

DT Journal

LA English

IT **171731-29-6 172801-42-2**


RL: RCT (Reactant); RACT (Reactant or reagent)

(for prepn. of silver complexes)

RN 171731-29-6 CAPLUS

CN 1-Piperazineacetic acid, 4-formyl-.alpha.,3-bis(1H-imidazol-4-ylmethyl)-2-oxo-, methyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




V. Balasubramanian

RN 172801-42-2 CAPLUS

CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-.alpha.,3-bis[2-(methylthio)ethyl]-2-oxo-, ethyl ester, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 171731-29-6D, dimeric silver complexes 172801-42-2D,  
dimeric silver complexes

RL: FMU (Formation, unclassified); FORM (Formation, nonpreparative)  
(formation in dissocn. of monomeric silver complexes)

RN 171731-29-6 CAPLUS

CN 1-Piperazineacetic acid, 4-formyl-.alpha.,3-bis(1H-imidazol-4-ylmethyl)-2-oxo-, methyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 172801-42-2 CAPLUS


CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-.alpha.,3-bis[2-(methylthio)ethyl]-2-oxo-, ethyl ester, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 48 OF 82 CAPLUS COPYRIGHT 2003 ACS  
AN 1995:966510 CAPLUS  
DN 124:3950  
TI The crystal structure of a major secreted aspartic proteinase from *Candida albicans* in complexes with two inhibitors  
AU Cutfield, S. M.; Dodson, E. J.; Anderson, B. F.; Moody, P. C. E.;  
Marshall, C. J.; Sullivan, P. A.; Cutfield, J. F.  
CS Biochemistry Department, University Otago, Dunedin, N. Z.  
SO Structure (London) (1995), 3(11), 1261-71  
CODEN: STRUE6; ISSN: 0969-2126  
PB Current Biology  
DT Journal  
LA English  
IT **142928-23-2D**, A70450, complexes with secreted aspartic proteinase  
RL: PRP (Properties)  
(crystal structure of *Candida albicans* secreted aspartic proteinase  
SAP2 complexes with synthetic hexapeptide analog inhibitor and  
pepstatin A)  
RN 142928-23-2 CAPLUS  
CN 1-Piperazineacetamide, .alpha.-butyl-N-[(1S,2S,4R)-4-  
[(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-  
methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, monohydrochloride,  
(.alpha.S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

L5 ANSWER 49 OF 82 CAPLUS COPYRIGHT 2003 ACS  
AN 1995:794797 CAPLUS  
DN 124:30346  
TI Syntheses of novel structurally constrained (S)-histidyl-(S)-histidine  
derivatives and their copper(II) complexes  
AU Kojima, Yoshitane; Watanabe, Masaaki; Seki, Yoshio; Yamato, Kazuhiro;  
Miyake, Hiroyuki  
CS Fac. Sci., Osaka City univ., Osaka, 558, Japan  
SO Chemistry Letters (1995), (9), 797-8  
CODEN: CMLTAG; ISSN: 0366-7022  
PB Nippon Kagakkai  
DT Journal

V. Balasubramanian


LA English  
OS CASREACT 124:30346  
IT **171731-29-6P 171731-30-9P**  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(prepn. and properties of ethylene-bridged histidylhistidine copper(II)  
complexes)  
RN 171731-29-6 CAPLUS  
CN 1-Piperazineacetic acid, 4-formyl-.alpha.,3-bis(1H-imidazol-4-ylmethyl)-2-  
oxo-, methyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 171731-30-9 CAPLUS  
CN 1-Piperazineacetic acid, 4-[[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]-  
.alpha.,3-bis(1H-imidazol-4-ylmethyl)-2-oxo-, methyl ester, [S-(R\*,R\*)]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L5 ANSWER 50 OF 82 CAPLUS COPYRIGHT 2003 ACS  
AN 1995:427460 CAPLUS  
DN 123:83982  
TI Structure of cyclic hexa-pseudopeptide constructed from  
N,N'-ethylene-bridged-(S)-alanyl-(S)-alanine and glycine  
AU Kojima, Yoshitane; Yamashita, Tetsushi; Miyake, Hiroyuki  
CS Fac. Sci., Osaka City Univ., Osaka, 558, Japan  
SO Chemistry Letters (1995), (3), 201-2  
CODEN: CMLTAG; ISSN: 0366-7022  
PB Nippon Kagakkai  
DT Journal  
LA English  
IT **164857-03-8**


V. Balasubramanian

RL: RCT (Reactant); RACT (Reactant or reagent)  
(structure of cyclic hexapseudopeptide constructed from  
ethylene-bridged alanylalanine and glycine)

RN 164857-03-8 CAPLUS

CN Piperazinone, 4-(aminoacetyl)-1-[2-[(2,5-dioxo-1-pyrrolidinyl)oxy]-1-  
methyl-2-oxoethyl]-3-methyl-, monohydrochloride, [S-(R\*,R\*)]- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.



● HCl

L5 ANSWER 51 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 1995:384242 CAPLUS

DN 122:265988

TI Conformation constraints emerging in the N,N'-ethylene- and  
N,N'-propylene-bridged dipeptide units

AU Czaplewski, C.; Lammek, B.; Ciarkowski, J.

CS Fac. Chem., Univ. Gdansk, Gdansk, 80-952, Pol.

SO Polish Journal of Chemistry (1994), 68(12), 2589-98

CODEN: PJCHDQ; ISSN: 0137-5083

PB Polish Chemical Society

DT Journal

LA English

IT **162611-47-4**

RL: PRP (Properties)

(conformation of N,N'-ethylene- and N,N'-propylene-bridged dipeptides)


RN 162611-47-4 CAPLUS

CN 1-Piperazineacetamide, 4-acetyl-N-methyl-2-oxo-.alpha.,3-bis(phenylmethyl)-  
, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

2 Absolute stereochemistry.

2

2



L5 ANSWER 52 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 1994:681106 CAPLUS

DN 121:281106

TI Conformations of 24-membered ring pseudopeptides containing  
N,N'-ethylene-bridged dipeptides constructed from (S)-alanine, -leucine,  
-isoleucine, and -phenylalanine

AU Kojima, Yoshitane; Goto, Hisayo; Miyake, Hiroyuki; Yamashita, Tetsushi

CS Fac. Sci., Osaka City Univ., Osaka, 558, Japan

SO Polymer Journal (Tokyo, Japan) (1994), 26(3), 257-65

CODEN: POLJB8; ISSN: 0032-3896

DT Journal

LA English

IT 158861-92-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(prepn. and peptide coupling reactions of, in prepn. of  
ethylene-bridged cyclooctapeptide)

RN 158861-92-8 CAPLUS

CN 1-Piperazineacetic acid, 4-[[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]-  
.alpha.,3-bis(1-methylpropyl)-2-oxo-, [3S-[1[R\*(R\*)],3R\*(R\*)]]- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.



V. Balasubramanian

L5 ANSWER 53 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 1994:591121 CAPLUS

DN 121:191121

TI silver halide color photographic material

IN Saito, Naoki; Nakagawa, Hajime

PA Fuji Photo Film Co Ltd, Japan

SO Jpn. Kokai Tokkyo Koho, 48 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 05341461	A2	19931224	JP 1992-170039	19920605
PRAI	JP 1992-170039		19920605		


IT **157683-21-1**

RL: USES (Uses)

(yellow photog. coupler)

RN 157683-21-1 CAPLUS

CN Benzoic acid, 3-[[3-(5-bromo-2,3-dihydro-1H-indol-1-yl)-2-[4-[(dimethylamino)sulfonyl]-2,6-dioxo-1-piperazinyl]-1,3-dioxopropyl]amino]-4-(4-carboxyphenoxy)-5-chloro-, 1-dodecyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 54 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 1994:457461 CAPLUS

DN 121:57461

TI Asymmetric synthesis. XXXI. Synthesis of 2-substituted piperazines from chiral non-racemic lactams

AU Schanen, Vincent; Riche, Claude; Chiaroni, Angele; Quirion, Jean-Charles; Husson, Henri-Philippe

CS Fac. Sci. Pharm. Biol., Univ. R. Descartes, Paris, 75270/Q6, Fr.

SO Tetrahedron Letters (1994), 35(16), 2533-6

CODEN: TELEAY; ISSN: 0040-4039

DT Journal

LA English

V. Balasubramanian

OS CASREACT 121:57461


IT **156022-76-3P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(prepn. and benzylation of)

RN 156022-76-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-(2-hydroxy-1-phenylethyl)-2-methyl-3-oxo-,  
1,1-dimethylethyl ester, [R-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT **156022-75-2P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(prepn. and diastereoselective alkylation of)

RN 156022-75-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-(2-hydroxy-1-phenylethyl)-3-oxo-,  
1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **156022-79-6P 156022-80-9P**


RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)

RN 156022-79-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-(2-hydroxy-1-phenylethyl)-3-oxo-2-  
(phenylmethyl)-, 1,1-dimethylethyl ester, [R-(R\*,R\*)]- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 156022-80-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-(2-hydroxy-1-phenylethyl)-3-oxo-2-(2-propenyl)-, 1,1-dimethylethyl ester, [R-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 55 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 1994:211394 CAPLUS

DN 120:211394

TI Crystallization of inhibited aspartic proteinase from Candida albicans

AU Cutfield, Sue; Marshall, Craig; Moody, Peter; Sullivan, Patrick; Cutfield, John

CS Biochem. Dep., Univ. Otago, Dunedin, N. Z.

SO Journal of Molecular Biology (1993), 234(4), 1266-9

CODEN: JMOBAK; ISSN: 0022-2836

DT Journal

LA English

IT 142928-23-2, A70450

RL: BIOL (Biological study)


(aspartic proteinase of Candida albicans treated with, crystn. and structure of)

RN 142928-23-2 CAPLUS

CN 1-Piperazineacetamide, .alpha.-butyl-N-[(1S,2S,4R)-4-[(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, monohydrochloride, (.alpha.S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/039,898



● HCl

L5 ANSWER 56 OF 82 CAPLUS COPYRIGHT 2003 ACS  
 AN 1994:135148 CAPLUS  
 DN 120:135148  
 TI N,N'-ethylene-bridged dipeptide composed of different optically active  
 (.alpha.)-amino acids and production thereof  
 IN Kojima, Yoshitane; Yamashita, Tetsushi; Adachi, Hidenari  
 PA Sanyo Fine Co., Ltd., Japan  
 SO PCT Int. Appl., 44 pp.  
 CODEN: PIXXD2

DT Patent


LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9318013	A1	19930916	WO 1993-JP292	19930310
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	JP 3265378	B2	20020311	JP 1993-515534	19930310
PRAI	JP 1992-51241	A	19920310		
	WO 1993-JP292	W	19930310		
OS	CASREACT 120:135148; MARPAT 120:135148				
IT	<b>153052-92-7P 153052-93-8P 153052-94-9P</b> <b>153052-95-0P 153052-98-3P 153092-45-6P</b>				
	RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of, as intermediate for physiolog. active peptides, process for)				
RN	153052-92-7 CAPLUS				
CN	1-Piperazineacetic acid, 4-(2,4-dinitrobenzoyl)-3-[3-[[imino[(4-methylphenyl)sulfonyl]amino]methyl]amino]propyl]-2-oxo-.alpha.-[(phenylmethoxy)methyl]-, ethyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.


V. Balasubramanian



RN 153052-93-8 CAPLUS

CN 1-Piperazineacetic acid, 4-(2,4-dinitrobenzoyl)-.alpha.-[3-[[imino[(4-methylphenyl)sulfonyl]amino]methyl]amino]propyl]-2-oxo-3-[(phenylmethoxy)methyl]-, ethyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 153052-94-9 CAPLUS

CN 1-Piperazineacetic acid, 4-(2,4-dinitrobenzoyl)-.alpha.-(1-hydroxyethyl)-3-[3-[[imino[(4-methylphenyl)sulfonyl]amino]methyl]amino]propyl]-2-oxo-, ethyl ester, [3S-[1[R\*(S\*)]]]- (9CI) (CA INDEX NAME)


V. Balasubramanian



RN 153052-95-0 CAPLUS

CN 1-Piperazineacetic acid, 4-(2,4-dinitrobenzoyl)-3-methyl-2-oxo-.alpha.-(phenylmethyl)-, ethyl ester, [S-(R\*,S\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 153052-98-3 CAPLUS

CN 1-Piperazineacetic acid, 4-(2,4-dinitrobenzoyl)-.alpha.-methyl-2-oxo-3-[(phenylmethoxy)methyl]-, ethyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/039,898

V. Balasubramanian

RN 153092-45-6 CAPLUS

CN 1-Piperazineacetic acid, 4-(2,4-dinitrobenzoyl)-.alpha.-[3-[[[(2,4-dinitrobenzoyl)amino][[(4-methylphenyl)sulfonyl]amino]methylene]amino]propyl]-3-(1-hydroxyethyl)-2-oxo-, ethyl ester, [3S-[1(R\*),3R\*(S\*)]]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.



L5 ANSWER 57 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 1993:671678 CAPLUS

DN 119:271678

TI Preparations of N,N'-ethylene-bridged dipeptides (eXX) constructed from (S)-methionine, -tryptophan, -tyrosine and -N(.epsilon.)-benzyloxycarbonyllysine through acid-catalyzed cyclization

AU Yamashita, T.; Takenaka, H.; Kojima, Y.

CS Fac. Sci., Osaka City Univ., Osaka, Japan

SO Amino Acids (1993), 4(1-2), 187-92

CODEN: AACIE6; ISSN: 0939-4451

DT Journal

LA English

OS CASREACT 119:271678

IT **150763-75-0P 150763-76-1P 150763-78-3P**  
**150763-79-4P**


RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)

RN 150763-75-0 CAPLUS

CN 1-Piperazineacetic acid, 4-(3,5-dinitrobenzoyl)-.alpha.,3-bis[2-(methylthio)ethyl]-2-oxo-, ethyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 150763-76-1 CAPLUS

CN 1H-Indole-2-propanoic acid, .alpha.-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]-3-(1H-indol-2-ylmethyl)-2-oxo-1-piperazinyl]-, ethyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 150763-78-3 CAPLUS

CN 1-Piperazineacetic acid, 4-(3,5-dinitrobenzoyl)-2-oxo-.alpha.,3-bis[4-[(phenylmethoxy)carbonyl]amino]butyl]-, ethyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



V. Balasubramanian


RN 150763-79-4 CAPLUS  
CN 1-Piperazineacetic acid, 4-(3,5-dinitrobenzoyl)-.alpha.,3-bis[2-(methylthio)ethyl]-2-oxo-, methyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L5 ANSWER 58 OF 82 CAPLUS COPYRIGHT 2003 ACS  
AN 1993:650442 CAPLUS  
DN 119:250442  
TI Synthesis of Met- and Leu-enkephalin analogs containing chiral N,N'-ethylene-bridged phenylalanyl-methionine and -leucine  
AU Takenaka, Hiroshi; Miyake, Hiroyuki; Kojima, Yoshitane; Yasuda, Masahide; Gamba, Munekazu; Yamashita, Tetsushi  
CS Fac. Sci., Osaka City Univ., Osaka, 558, Japan  
SO Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1993), (8), 933-7  
CODEN: JCPRB4; ISSN: 0300-922X  
DT Journal  
LA English  
OS CASREACT 119:250442  
IT **151141-70-7P**  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. and deblocking of)  
RN 151141-70-7 CAPLUS  
CN L-Tyrosine, N-[N-[N-[2-[4-[(1,1-dimethylethoxy) carbonyl]-3-[2-(methylthio)ethyl]-2-oxo-1-piperazinyl]-1-oxo-3-phenylpropyl]glycyl]-D-alanyl]-, ethyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

PAGE 1-A






IT 151141-60-5P 151141-61-6P 151215-18-8P  
 151215-19-9P 151215-20-2P 151215-21-3P  
 151215-22-4P 151215-23-5P 151215-24-6P  
 151215-25-7P 151282-41-6P 151282-42-7P  
 151282-43-8P 151282-44-9P 151282-45-0P  
 151282-46-1P


RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. and opiate activity of)

RN 151141-60-5 CAPLUS

CN D-Alaninamide, N-[(1,1-dimethylethoxy)carbonyl]-O-(phenylmethyl)-L-tyrosyl-  
 N-[2-[4-[1-(ethoxycarbonyl)-3-(methylthio)propyl]-3-oxo-2-(phenylmethyl)-1-  
 piperazinyl]-2-oxoethyl]-, monohydrochloride, [S-(R\*,R\*)]- (9CI) (CA  
 INDEX NAME)



● HCl




RN 151141-61-6 CAPLUS

CN D-Alaninamide, N-[(1,1-dimethylethoxy)carbonyl]-O-(phenylmethyl)-L-tyrosyl-  
 N-[2-[4-[1-(ethoxycarbonyl)-3-methylbutyl]-3-oxo-2-(phenylmethyl)-1-  
 piperazinyl]-2-oxoethyl]-, monohydrochloride, [S-(R\*,R\*)]- (9CI) (CA

V. Balasubramanian

INDEX NAME)

PAGE 1-A



● HCl


PAGE 1-B

— Ph


RN 151215-18-8 CAPLUS

CN D-Alaninamide, N-[(1,1-dimethylethoxy)carbonyl]-O-(phenylmethyl)-L-tyrosyl-N-[2-[4-[1-(ethoxycarbonyl)-3-(methylthio)propyl]-3-oxo-2-(phenylmethyl)-1-piperazinyl]-2-oxoethyl]-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 151215-19-9 CAPLUS

CN D-Alaninamide, N-[(1,1-dimethylethoxy) carbonyl]-O-(phenylmethyl)-L-tyrosyl-N-[2-[4-[1-(ethoxycarbonyl)-3-(methylthio)propyl]-3-oxo-2-(phenylmethyl)-1-piperazinyl]-2-oxoethyl]-, [S-(R\*,S\*)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 151215-20-2 CAPLUS

CN D-Alaninamide, N-[(1,1-dimethylethoxy)carbonyl]-O-(phenylmethyl)-L-tyrosyl-N-[2-[4-[1-(ethoxycarbonyl)-3-(methylthio)propyl]-3-oxo-2-(phenylmethyl)-1-piperazinyl]-2-oxoethyl]-, [R-(R\*,S\*)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 151215-21-3 CAPLUS


CN D-Alaninamide, N-[(1,1-dimethylethoxy) carbonyl]-O-(phenylmethyl)-L-tyrosyl-N-[2-[4-[1-(ethoxycarbonyl)-3-(methylthio)propyl]-3-oxo-2-(phenylmethyl)-1-piperazinyl]-2-oxoethyl]-, [R-(R\*,R\*)]-(9CI) (CA INDEX NAME)

PAGE 1-A






RN 151215-22-4 CAPLUS  
 CN D-Alaninamide, N-[(1,1-dimethylethoxy)carbonyl]-O-(phenylmethyl)-L-tyrosyl-  
 N-[2-[4-[1-(ethoxycarbonyl)-3-methylbutyl]-3-oxo-2-(phenylmethyl)-1-  
 piperazinyl]-2-oxoethyl]-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)



RN 151215-23-5 CAPLUS  
 CN D-Alaninamide, N-[(1,1-dimethylethoxy)carbonyl]-O-(phenylmethyl)-L-tyrosyl-  
 N-[2-[4-[1-(ethoxycarbonyl)-3-methylbutyl]-3-oxo-2-(phenylmethyl)-1-  
 piperazinyl]-2-oxoethyl]-, [S-(R\*,S\*)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— Ph

RN 151215-24-6 CAPLUS

CN D-Alaninamide, N-[(1,1-dimethylethoxy) carbonyl]-O-(phenylmethyl)-L-tyrosyl-N-[2-[4-[1-(ethoxycarbonyl)-3-methylbutyl]-3-oxo-2-(phenylmethyl)-1-piperazinyl]-2-oxoethyl]-, [R-(R\*,S\*)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— Ph

RN 151215-25-7 CAPLUS  
 CN D-Alaninamide, N-[(1,1-dimethylethoxy)carbonyl]-O-(phenylmethyl)-L-tyrosyl-N-[2-[4-[1-(ethoxycarbonyl)-3-methylbutyl]-3-oxo-2-(phenylmethyl)-1-piperazinyl]-2-oxoethyl]-, [R-(R\*,R\*)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— Ph


RN 151282-41-6 CAPLUS  
 CN D-Alaninamide, N-[(1,1-dimethylethoxy)carbonyl]-O-(phenylmethyl)-L-tyrosyl-N-[2-[4-[1-(ethoxycarbonyl)-3-(methylthio)propyl]-3-oxo-2-(phenylmethyl)-1-piperazinyl]-2-oxoethyl]-, monohydrochloride, [S-(R\*,S\*)]- (9CI) (CA INDEX NAME)

PAGE 1-A




● HCl

PAGE 1-B




RN 151282-42-7 CAPLUS  
 CN D-Alaninamide, N-[(1,1-dimethylethoxy)carbonyl]-O-(phenylmethyl)-L-tyrosyl-N-[2-[4-[1-(ethoxycarbonyl)-3-(methylthio)propyl]-3-oxo-2-(phenylmethyl)-1-piperazinyl]-2-oxoethyl]-, monohydrochloride, [R-(R\*,S\*)]- (9CI) (CA INDEX NAME)

PAGE 1-A




● HCl




RN 151282-43-8 CAPLUS

CN D-Alaninamide, N-[(1,1-dimethylethoxy)carbonyl]-O-(phenylmethyl)-L-tyrosyl-N-[2-[4-[1-(ethoxycarbonyl)-3-(methylthio)propyl]-3-oxo-2-(phenylmethyl)-1-piperazinyl]-2-oxoethyl]-, monohydrochloride, [R-(R\*,R\*)]- (9CI) (CA INDEX NAME)




● HCl



RN 151282-44-9 CAPLUS

CN D-Alaninamide, N-[(1,1-dimethylethoxy)carbonyl]-O-(phenylmethyl)-L-tyrosyl-N-[2-[4-[1-(ethoxycarbonyl)-3-methylbutyl]-3-oxo-2-(phenylmethyl)-1-piperazinyl]-2-oxoethyl]-, monohydrochloride, [S-(R\*,S\*)]- (9CI) (CA INDEX NAME)

PAGE 1-A




● HCl

PAGE 1-B

— Ph

RN 151282-45-0 CAPLUS  
 CN D-Alaninamide, N-[(1,1-dimethylethoxy) carbonyl]-O-(phenylmethyl)-L-tyrosyl-N-[2-[4-[1-(ethoxycarbonyl)-3-methylbutyl]-3-oxo-2-(phenylmethyl)-1-piperazinyl]-2-oxoethyl]-, monohydrochloride, [R-(R\*,S\*)]- (9CI) (CA INDEX NAME)


PAGE 1-A



● HCl

— Ph

RN 151282-46-1 CAPLUS  
 CN D-Alaninamide, N-[(1,1-dimethylethoxy)carbonyl]-O-(phenylmethyl)-L-tyrosyl-  
 N-[2-[4-[1-(ethoxycarbonyl)-3-methylbutyl]-3-oxo-2-(phenylmethyl)-1-  
 piperazinyl]-2-oxoethyl]-, monohydrochloride, [R-(R\*,R\*)]- (9CI) (CA  
 INDEX NAME)




● HCl

— Ph

IT 151141-65-0P 151141-66-1P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (prepn. and peptide coupling of, with peptide ester)  
 RN 151141-65-0 CAPLUS  
 CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-3-[2-  
 (methylthio)ethyl]-2-oxo-.alpha.-(phenylmethyl)-, ethyl ester,  
 [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

V. Balasubramanian


Absolute stereochemistry.



RN 151141-66-1 CAPLUS

CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-3-(2-methylpropyl)-2-oxo-.alpha.-(phenylmethyl)-, ethyl ester, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 151141-48-9P 151141-49-0P 151141-50-3P  
151141-51-4P


RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)

RN 151141-48-9 CAPLUS

CN 1-Piperazineacetic acid, 4-(aminoacetyl)-.alpha.-[2-(methylthio)ethyl]-2-oxo-3-(phenylmethyl)-, ethyl ester, monohydrochloride, [S-(R\*,S\*)]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

V. Balasubramanian




● HCl

RN 151141-49-0 CAPLUS

CN 1-Piperazineacetic acid, 4-(aminoacetyl)-3-[2-(methylthio)ethyl]-2-oxo-.alpha.-(phenylmethyl)-, ethyl ester, monohydrochloride, [R-(R\*,S\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 151141-50-3 CAPLUS

CN 1-Piperazineacetic acid, 4-(aminoacetyl)-.alpha.-[2-(methylthio)ethyl]-2-oxo-3-(phenylmethyl)-, ethyl ester, monohydrochloride, [R-(R\*,S\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

2

2

10/039,898

V. Balasubramanian




● HCl

RN 151141-51-4 CAPLUS

CN 1-Piperazineacetic acid, 4-(aminoacetyl)-3-[2-(methylthio)ethyl]-2-oxo-.alpha.-(phenylmethyl)-, ethyl ester, monohydrochloride, [S-(R\*,S\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L5 ANSWER 59 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 1993:472626 CAPLUS

DN 119:72626

TI Preparation and formulation of 4-[(.alpha.-acylamino)acyl]-2-oxopiperazine-1-acetates and analogs as cell adhesion inhibitors

IN Sugihara, Hirosada; Terashita, Zenichi

PA Takeda Chemical Industries, Ltd., Japan

SO Eur. Pat. Appl., 49 pp.

CODEN: EPXXDW

DT Patent

LA English


10/039,898

V. Balasubramanian

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 529858	A1	19930303	EP 1992-307292	19920810
	EP 529858	B1	19971015		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	AU 9220908	A1	19930225	AU 1992-20908	19920807
	AU 646966	B2	19940310		
	US 5294713	A	19940315	US 1992-926171	19920807
	AT 159249	E	19971115	AT 1992-307292	19920810
	JP 06025285	A2	19940201	JP 1992-217778	19920817
	JP 2879280	B2	19990405		
	NO 9203253	A	19930224	NO 1992-3253	19920819
	HU 63154	A2	19930728	HU 1992-2686	19920819
	CA 2076619	AA	19930224	CA 1992-2076619	19920821
	CN 1069730	A	19930310	CN 1992-109703	19920822
	JP 09169742	A2	19970630	JP 1996-346409	19961226
	JP 3125212	B2	20010115		
PRAI	JP 1991-212397	A	19910823		
	JP 1992-123146	A	19920515		
	JP 1992-217778	A3	19920817		
OS	MARPAT 119:72626				
IT	<b>148126-81-2P 148126-89-0P</b>				
	RL: SPN (Synthetic preparation); PREP (Preparation)				
	(prepn. of, as cell adhesion inhibitor)				
RN	148126-81-2 CAPLUS				
CN	1,3-Piperazinediacetic acid, 4-[[[4-(aminoiminomethyl)benzoyl]amino]acetyl]-2-oxo-.alpha.1-(phenylmethyl)-, monohydrochloride, [S-(R*,R*)]- (9CI)				
	(CA INDEX NAME)				


Absolute stereochemistry. Rotation (+).



● HCl

RN 148126-89-0 CAPLUS  
CN 1,3-Piperazinediacetic acid, 4-[[[4-[(aminoiminomethyl)amino]benzoyl]amino]acetyl]-.alpha.1-methyl-2-oxo-, monohydrochloride, [S-(R\*,R\*)]- (9CI)  
(CA<sub>2</sub> INDEX NAME)

Absolute stereochemistry.



● HCl

L5 ANSWER 60 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 1993:409168 CAPLUS

DN 119:9168

TI Preparation of oxiranyl and oxetanyl renin inhibiting compounds

IN Rosenberg, Saul H.

PA Abbott Laboratories, USA

SO PCT Int. Appl., 168 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9222313	A1	19921223	WO 1992-US4423	19920526
	W: AU, CA, JP, KR				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
	US 5258362	A	19931102	US 1992-880250	19920513
	AU 9221593	A1	19930112	AU 1992-21593	19920526
PRAI	US 1991-713475		19910611		
	US 1992-880250		19920513		
	WO 1992-US4423		19920526		
OS	MARPAT 119:9168				
IT	<b>147933-38-8</b>				
	RL: RCT (Reactant); RACT (Reactant or reagent)				
	(peptide coupling reactions of, in prepn. of renin inhibitors)				
RN	147933-38-8	CAPLUS			
CN	1-Piperazineacetic acid, 4-[(4-methylphenyl)sulfonyl]-2-oxo-3-(phenylmethyl)-.alpha.-(4-thiazolylmethyl)- (9CI) (CA INDEX NAME)				




IT **147896-50-2P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(prepn. of, as renin inhibitor)

RN 147896-50-2 CAPLUS

CN L-Altritol, 4,6-anhydro-1-cyclohexyl-1,2,5-trideoxy-5-ethyl-2-[[2-[4-[(4-methylphenyl)sulfonyl]-2-oxo-3-(phenylmethyl)-1-piperazinyl]-1-oxo-3-(4-thiazolyl)propyl]amino]- (9CI) (CA INDEX NAME)



L5 ANSWER 61 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 1993:408830 CAPLUS

DN 119:8830

TI Compounds with renin-inhibiting properties, process for their preparation and their use

IN Heitsch, Holger; Henning, Rainer; Urbach, Hansjoerg; Ruppert, Dieter; Linz, Wolfgang

PA Hoechst A.-G., Germany

SO Eur. Pat. Appl., 18 pp.

CODEN: EPXXDW

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 519433	A1	19921223	EP 1992-110244	19920617
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, PT, SE				
	NO 9202426	A	19921222	NO 1992-2426	19920619
	CA 2071744	AA	19921222	CA 1992-2071744	19920619
	BR 9202325	A	19930119	BR 1992-2325	19920619
	ZA 9204522	A	19930224	ZA 1992-4522	19920619
	HU 61744	A2	19930301	HU 1992-2062	19920619
	JP 05186461	A2	19930727	JP 1992-160476	19920619
	CN 1068112	A	19930120	CN 1992-104887	19920620
PRAI	DE 1991-4120510		19910621		

OS CASREACT 119:8830; MARPAT 119:8830

IT **147937-63-1P 147937-64-2P 147937-67-5P**

**147937-68-6P 147937-69-7P 147961-52-2P**


RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of, as antihypertensive (renin inhibitor))

RN 147937-63-1 CAPLUS

V. Balasubramanian

CN 1-Piperazinecarboxylic acid, 4-[1-[[[1-(cyclohexylmethyl)-2,3-dihydroxy-5-(2-pyridinyl)pentyl]amino]carbonyl]pentyl]-3-oxo-2-(phenylmethyl)-, 1,1-dimethylethyl ester, [2R-[2R\*,4[S\*(1S\*,2R\*,3S\*)]]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 147937-64-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[[1-(cyclohexylmethyl)-2,3-dihydroxy-5-(2-pyridinyl)pentyl]amino]-1-(1H-imidazol-4-ylmethyl)-2-oxoethyl]-3-oxo-2-(phenylmethyl)-, 1,1-dimethylethyl ester, [2R-[2R\*,4[S\*(1S\*,2R\*,3S\*)]]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 147937-67-5 CAPLUS


CN 1-Piperazineacetamide, N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-(2-pyridinyl)pentyl]-4-[(4-methylphenyl)sulfonyl]-2-oxo-3-(phenylmethyl)-.alpha.-(4-thiazolylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 147937-68-6 CAPLUS

CN 1-Piperazineacetamide, N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-(2-pyridinyl)pentyl]-4-[(4-methyl-1-piperazinyl)sulfonyl]-2-oxo-3-(phenylmethyl)-.alpha.-(4-thiazolylmethyl)- (9CI) (CA INDEX NAME)



RN 147937-69-7 CAPLUS


CN 1-Piperazineacetamide, N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-(2-pyridinyl)pentyl]-.alpha.-(1H-imidazol-4-ylmethyl)-4-[(4-methyl-1-piperazinyl)sulfonyl]-2-oxo-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 147961-52-2 CAPLUS

CN 1-Piperazineacetamide, N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-(2-pyridinyl)pentyl]-4-(4-morpholinylcarbonyl)-2-oxo-3-(phenylmethyl)-.alpha.-(4-thiazolylmethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A





IT 131288-18-1 147937-73-3


RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant for N-[(benzyl)piperazinyl]alkanoyl] cyclohexyldihydroxy (pyridyl)hexylamine deriv. (antihypertensive))

RN 131288-18-1 CAPLUS

CN 1-Piperazineacetic acid, .alpha.-butyl-4-[(1,1-dimethylethoxy) carbonyl]-2-oxo-3-(phenylmethyl)-, [R-(R\*,S\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 147937-73-3 CAPLUS

CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy) carbonyl]-.alpha.-(1H-imidazol-4-ylmethyl)-2-oxo-3-(phenylmethyl)-, [R-(R\*,S\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 147933-38-8 147937-75-5 147937-76-6

RL: RCT (Reactant); RACT (Reactant or reagent)  
(reactant for N-[[[(benzyl)piperazinyl]alkanoyl]cyclohexyldihydroxy(pyridyl)hexylamine deriv. deriv. (antihypertensive))


RN 147933-38-8 CAPLUS

CN 1-Piperazineacetic acid, 4-[(4-methylphenyl)sulfonyl]-2-oxo-3-(phenylmethyl)-.alpha.-(4-thiazolylmethyl)- (9CI) (CA INDEX NAME)




RN 147937-75-5 CAPLUS

CN 1-Piperazineacetic acid, 4-(4-morpholinylcarbonyl)-2-oxo-3-(phenylmethyl)-.alpha.-(4-thiazolylmethyl)- (9CI) (CA INDEX NAME)



RN 147937-76-6 CAPLUS

CN 1-Piperazineacetic acid, 4-[(4-methyl-1-piperazinyl)sulfonyl]-2-oxo-3-(phenylmethyl)-.alpha.-(4-thiazolylmethyl)- (9CI) (CA INDEX NAME)




IT 147937-77-7

RL: RCT (Reactant); RACT (Reactant or reagent)  
(reactant for N-[[[(benzyl)piperidinyl]alkanoyl]cyclohexyldihydroxy(pyridyl)hexylamine deriv. (antihypertensive))

RN 147937-77-7 CAPLUS

CN 1-Piperazineacetic acid, .alpha.-[[1-[(1,1-dimethylethoxy)carbonyl]-1H-imidazol-4-yl]methyl]-4-[(4-methyl-1-piperazinyl)sulfonyl]-2-oxo-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 62 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 1992:571470 CAPLUS

DN 117:171470

TI Candida acid protease inhibiting compounds

IN Goldman, Robert C.; Baker, William R.; Jae, Hwan Soo; De, Biswanath; Zydowsky, Thomas M.; De Lara, Edwin

PA Abbott Laboratories, USA

SO U.S., 14 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5120718	A	19920609	US 1991-714820	19910613
PRAI	US 1991-714820		19910613		

OS MARPAT 117:171470

IT 143487-50-7P 143692-59-5P 143692-61-9P

143692-70-0P 143692-82-4P 143692-87-9P

143692-89-1P 143692-95-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and amidation of)


RN 143487-50-7 CAPLUS

CN 1-Piperazineacetic acid, .alpha.-butyl-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, [R-(R\*,S\*)]- (9CI) (CA

V. Balasubramanian

INDEX NAME)


Absolute stereochemistry.



RN 143692-59-5 CAPLUS

CN 1-Piperazineacetic acid, .alpha.-butyl-4-[(4-methylphenyl) sulfonyl]-2-oxo-5-(phenylmethyl)-, [R-(R\*,S\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 143692-61-9 CAPLUS

CN 1-Piperazineacetic acid, .alpha.-butyl-4-[(4-methylphenyl) sulfonyl]-2-oxo-3-(phenylmethyl)-, [R-(R\*,S\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 143692-70-0 CAPLUS

CN L-Norleucine, N-[2-[4-[(4-methylphenyl) sulfonyl]-2-oxo-5-(phenylmethyl)-1-piperazinyl]-1-oxohexyl]-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


V. Balasubramanian



RN 143692-82-4 CAPLUS

CN 1-Piperazineacetic acid, .alpha.-butyl-4-[(4-methyl-1-piperazinyl)sulfonyl]-2-oxo-3-(phenylmethyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 143692-87-9 CAPLUS

CN 1-Piperazineacetic acid, .alpha.-butyl-4-[[4-(methoxymethoxy)-1-piperazinyl]carbonyl]-2-oxo-3-(phenylmethyl)-, lithium salt, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Li

RN 143692-89-1 CAPLUS


CN 1-Piperazineacetic acid, .alpha.-butyl-4-[[4-(methoxymethoxy)-1-piperazinyl]carbonyl]-2-oxo-3-(phenylmethyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

10/039,898

V. Balasubramanian

INDEX NAME)


Absolute stereochemistry.



RN 143692-95-9 CAPLUS

CN 1-Piperazineacetic acid, .alpha.-butyl-4-[(4-methoxyphenyl) sulfonyl]-2-oxo-3-(phenylmethyl)-, [R-(R\*,S\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 143692-86-8P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and conversion of, to lithium salt)

RN 143692-86-8 CAPLUS

CN 1-Piperazineacetic acid, .alpha.-butyl-4-[[4-(methoxymethoxy)-1-piperazinyl]carbonyl]-2-oxo-3-(phenylmethyl)-, methyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 143692-76-6P

10/039,898

V. Balasubramanian


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and coupling of, with phenylalanine Me ester)

RN 143692-76-6 CAPLUS

CN 1-Piperazineacetic acid, .alpha.-butyl-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 131288-17-0P 143487-49-4P 143692-58-4P

143692-68-6P 143692-69-7P 143692-78-8P

143692-81-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and hydrolysis of)

RN 131288-17-0 CAPLUS

CN 1-Piperazineacetic acid, .alpha.-butyl-4-[(1,1-dimethylethoxy)carbonyl]-2-oxo-3-(phenylmethyl)-, methyl ester, [R-(R\*,S\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 143487-49-4 CAPLUS

CN 1-Piperazineacetic acid, .alpha.-butyl-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, methyl ester, [R-(R\*,S\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 143692-58-4 CAPLUS

CN 1-Piperazineacetic acid, .alpha.-butyl-4-[(4-methylphenyl)sulfonyl]-2-oxo-5-(phenylmethyl)-, methyl ester, [R-(R\*,S\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 143692-68-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-[[[1-(methoxycarbonyl)pentyl]amino]carbonyl]pentyl]-5-oxo-2-(phenylmethyl)-, 1,1-dimethylethyl ester, [2S-[2R\*,4[R\*(R\*)]]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 143692-69-7 CAPLUS

CN L-Norleucine, N-[2-[4-[(4-methylphenyl)sulfonyl]-2-oxo-5-(phenylmethyl)-1,1-dimethylethyl ester]-1,1-dimethylethyl ester]-L-Norleucine

10/039,898

V. Balasubramanian


piperazinyl]-1-oxohexyl]-, methyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)



RN 143692-78-8 CAPLUS

CN 1-Piperazineacetic acid, .alpha.-butyl-4-[[4-(methylamino)phenyl]sulfonyl]-2-oxo-3-(phenylmethyl)-, methyl ester, [R-(R\*,S\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 143692-81-3 CAPLUS

CN 1-Piperazineacetic acid, .alpha.-butyl-4-[(4-methyl-1-piperazinyl)sulfonyl]-2-oxo-3-(phenylmethyl)-, methyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 131288-18-1P

10/039,898


V. Balasubramanian

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(prepn. and reaction of, with phosgene in presence of methylpiperazine)

RN 131288-18-1 CAPLUS

CN 1-Piperazineacetic acid, .alpha.-butyl-4-[(1,1-dimethylethoxy)carbonyl]-2-  
oxo-3-(phenylmethyl)-, [R-(R\*,S\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 143788-47-0P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and toluenesulfonylation of)

RN 143788-47-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-[[[1-(methoxycarbonyl)pentyl]amino]carbo  
nyl]pentyl]-5-oxo-2-(phenylmethyl)-, 1,1-dimethylethyl ester,  
monohydrochloride, [2S-[2R\*,4[R\*(R\*)]]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 131287-78-0P 143692-55-1P 143692-60-8P

2 143692-62-0P 143692-63-1P 143692-71-1P 2

143692-75-5P 143692-79-9P 143692-80-2P

143692-83-5P 143692-88-0P 143692-90-4P

143692-92-6P 143692-94-8P 143715-51-9P

143731-22-0P 143731-24-2P 143731-25-3P

V. Balasubramanian


**143788-48-1P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of, as Candida acid protease inhibitor)

RN 131287-78-0 CAPLUS

CN 1-Piperazineacetamide, .alpha.-butyl-N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, [3R-[1[S\*(1S\*,2R\*,3S\*)],3R\*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 143692-55-1 CAPLUS

RN 143692-60-8 CAPLUS

CN 1-Piperazineacetamide, .alpha.-butyl-N-[4-[(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-methylphenyl)sulfonyl]-2-oxo-5-(phenylmethyl)-, [5R-[1[S\*(1S\*,2S\*,4R\*)],5R\*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 143692-62-0 CAPLUS

CN 1-Piperazineacetamide, .alpha.-butyl-N-[4-[(butylamino) carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-methylphenyl) sulfonyl]-2-oxo-3-(phenylmethyl)-, [3R-[1[S\*(1S\*,2S\*,4R\*)],3R\*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 143692-63-1 CAPLUS

10/039,898

CN 1-Piperazineacetamide, .alpha.-butyl-N-[4-[(butylamino) carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-methoxyphenyl) sulfonyl]-2-oxo-3-(phenylmethyl)-, [3R-[1[S\*(1S\*,2S\*,4R\*)],3R\*]]- (9CI) (CA INDEX NAME)

The chemical structure is a complex molecule with the following features:

- A **cyclohexyl** group is attached to a **CH<sub>2</sub>** group, which is further connected to a **CH** group. This **CH** group is bonded to a **CH** group that is part of a **5-membered ring** containing two **S** atoms and an **NH** group. This ring also has an **OH** group and an **R** substituent.
- The **CH** group of the 5-membered ring is bonded to a **CH** group that is part of a **6-membered ring** containing two **N** atoms and a **C=O** group. This ring also has an **R** substituent and a **Ph** group attached to one of the **N** atoms.
- The **CH** group of the 6-membered ring is bonded to a **CH** group that is part of a **5-membered ring** containing two **S** atoms and an **NH** group. This ring also has an **OH** group and an **R** substituent.
- The **CH** group of the 5-membered ring is bonded to a **CH** group that is part of a **5-membered ring** containing two **S** atoms and an **NH** group. This ring also has an **OH** group and an **R** substituent.
- The **CH** group of the 5-membered ring is bonded to a **CH** group that is part of a **5-membered ring** containing two **S** atoms and an **NH** group. This ring also has an **OH** group and an **R** substituent.
- The **CH** group of the 5-membered ring is bonded to a **CH** group that is part of a **5-membered ring** containing two **S** atoms and an **NH** group. This ring also has an **OH** group and an **R** substituent.

CN 1-Piperazineacetamide, .alpha.-butyl-N-[1-[[[4-(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]amino]carbonyl]pentyl]-4-[(4-methylphenyl)sulfonyl]-2-oxo-5-(phenylmethyl)-, [5S-[1[R\*[R\*(1R\*,2R\*,4S\*)]],5R\*]]- (9CI) (CA INDEX NAME)


Chemical structure of compound 10, showing a cyclohexane ring substituted with a hydroxyl group (OH), an isopropyl group (i-Pr), a butyl group (Bu-n), and a sulfonamide moiety (SO<sub>2</sub>Ph).

10/039,898

V. Balasubramanian

CN 1-Piperazineacetamide, N-[4-[(butylamino) carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-methylphenyl)sulfonyl]-2-oxo-3-(phenylmethyl)-.alpha.-4-thiazolyl-, [3R-[1[S\*(1S\*,2S\*,4R\*)],3R\*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 143692-79-9 CAPLUS

CN 1-Piperazineacetamide, .alpha.-butyl-N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-4-[[4-(methylamino)phenyl]sulfonyl]-2-oxo-3-(phenylmethyl)-, [3R-[1[S\*(1S\*,2R\*,3S\*)],3R\*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




2 RN 143692-80-2 CAPLUS

CN 1-Piperazineacetamide, .alpha.-butyl-N-[1-(cyclohexylmethyl)-2-hydroxy-5-methyl-4-[[[3-(4-morpholinyl)propyl]amino]carbonyl]hexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, [3S-[1[R\*(1R\*,2R\*,4S\*)],3R\*]]- (9CI) (CA INDEX NAME)


10/039,898

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 143692-83-5 CAPLUS  
CN 1-Piperazineacetamide, .alpha.-butyl-N-[4-[(butylamino) carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)sulfonyl]-2-oxo-3-(phenylmethyl)-, [3S-[1[R\*(1R\*,2R\*,4S\*)],3R\*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 143692-88-0 CAPLUS

CN 1-Piperazineacetamide, .alpha.-butyl-N-[1-(cyclohexylmethyl)-2-hydroxy-5-methyl-4-[[[3-(4-morpholinyl)propyl]amino]carbonyl]hexyl]-4-[(4-methyl-1-piperazinyl)sulfonyl]-2-oxo-3-(phenylmethyl)-, [3S-[1[R\*(1R\*,2R\*,4S\*)]],3R\*]]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 143692-90-4 CAPLUS

CN 1-Piperazineacetamide, .alpha.-butyl-N-[1-(cyclohexylmethyl)-2-hydroxy-5-methyl-4-[[[3-(4-morpholinyl)propyl]amino]carbonyl]hexyl]-4-[[4-(methoxymethoxy)-1-piperazinyl]carbonyl]-2-oxo-3-(phenylmethyl)-, [3S-[1[R\*(1R\*,2R\*,4S\*)]],3R\*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 143692-92-6 CAPLUS

CN 1-Piperazineacetamide, .alpha.-butyl-N-[1-(cyclohexylmethyl)-4-[[2-(dimethylamino)ethyl]amino]-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, [3R-[1[S\*(1S\*,2S\*,4R\*)],3R\*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




V. Balasubramanian

RN 143692-94-8 CAPLUS

CN 1-Piperazineacetamide, .alpha.-butyl-N-[1-(cyclohexylmethyl)-4-[[3-(dimethylamino)propyl]amino]-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, [3R-[1[S\*(1S\*,2S\*,4R\*)],3R\*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 143715-51-9 CAPLUS

CN 1-Piperazineacetamide, .alpha.-butyl-N-[4-[(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[[4-(methoxymethoxy)-1-piperazinyl]carbonyl]-2-oxo-3-(phenylmethyl)-, [3S-[1[R\*(1R\*,2R\*,4S\*)],3R\*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 143731-22-0 CAPLUS

CN 1-Piperazineacetamide, .alpha.-butyl-N-[(1S,2S,4R)-4-  
[(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-  
methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, (.alpha.S,3R)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 143731-24-2 CAPLUS

V. Balasubramanian

CN 1-Piperazineacetamide, .alpha.-butyl-N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, monohydrochloride, [3S-[1[R\*(1R\*,2S\*,3R\*)],3R\*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 143731-25-3 CAPLUS

CN 1-Piperazineacetamide, .alpha.-butyl-N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, monohydrochloride, [3R-[1[S\*(1S\*,2R\*,3S\*)],3R\*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 143788-48-1 CAPLUS

10/039,898

V. Balasubramanian

CN 1-Piperazineacetamide, .alpha.-butyl-N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, [3S-[1[R\*(1R\*,2S\*,3R\*)],3R\*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 143692-84-6

RL: RCT (Reactant); RACT (Reactant or reagent)  
(reaction of, with methoxymethoxypiperidine)

RN 143692-84-6 CAPLUS

CN 1-Piperazineacetic acid, .alpha.-butyl-4-(chlorocarbonyl)-2-oxo-3-(phenylmethyl)-, methyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 63 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 1992:506860 CAPLUS

DN 117:106860


TI Application of a fluorogenic substrate in the assay of proteolytic activity and in the discovery of a potent inhibitor of Candida albicans

10/039,898

V. Balasubramanian

aspartic proteinase  
AU Capobianco, John O.; Lerner, Claude G.; Goldman, Robert C.  
CS Dep. 47M, Abbott Lab., Abbott Park, IL, 60064-3500, USA  
SO Analytical Biochemistry (1992), 204(1), 96-102  
CODEN: ANBCA2; ISSN: 0003-2697  
DT Journal  
LA English  
IT 142928-23-2, A 70450  
RL: ANST (Analytical study)  
(aspartic proteinase of *Candida albicans* inhibition by)  
RN 142928-23-2 CAPLUS  
CN 1-Piperazineacetamide, .alpha.-butyl-N-[(1S,2S,4R)-4-  
[(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-  
methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, monohydrochloride,  
(.alpha.S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L5 ANSWER 64 OF 82 CAPLUS COPYRIGHT 2003 ACS  
AN 1992:59994 CAPLUS  
DN 116:59994  
TI Preparation of p-chlorophenylacetyl-containing peptides as tachykinin  
agonists and/or antagonists  
IN Weber, Wolf Dietrich; Hoelzemann, Guenter; Jonczyk, Alfred; Lues,  
Ingeborg; Bartoszyk, Gerd; Greiner, Hartmut  
PA Merck Patent G.m.b.H., Germany  
SO Eur. Pat. Appl., 15 pp.  
CODEN: EPXXDW  
DT Patent  
LA German  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 446706	A2	19910918	EP 1991-102903	19910228
	EP 446706	A3	19920930		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	DE 4007869	A1	19910919	DE 1990-4007869	19900313
	AU 9172760	A1	19910919	AU 1991-72760	19910308
	CA 2037990	AA	19910914	CA 1991-2037990	19910311

V. Balasubramanian

HU 56580	A2	19910930	HU 1991-802	19910312
ZA 9101849	A	19911224	ZA 1991-1849	19910313
JP 05078390	A2	19930330	JP 1991-154150	19910313
PRAI DE 1990-4007869		19900313		


OS MARPAT 116:59994

IT **138564-51-9 138564-52-0**

RL: RCT (Reactant); RACT (Reactant or reagent)  
(peptide coupling of, in prepn. of tachykinin agonists and/or antagonists)


RN 138564-51-9 CAPLUS

CN 1H-Indole-3-propanamide, .alpha.-amino-N-[1-[[4-[1-[[[2-amino-2-oxo-1-(phenylmethyl)ethyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]carbonyl]-2-methylbutyl]-, stereoisomer (9CI) (CA INDEX NAME)



RN 138564-52-0 CAPLUS

CN 1-Piperazineacetamide, N-[2-amino-2-oxo-1-(phenylmethyl)ethyl]-4-(2-amino-1-oxo-3-phenylpropyl)-.alpha.-(2-methylpropyl)-2-oxo-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



IT **138564-29-1P 138564-30-4P 138564-31-5P**  
**138564-32-6P 138564-33-7P 138564-34-8P**  
**138564-35-9P 138564-36-0P 138564-37-1P**  
**138564-38-2P 138564-39-3P 138564-40-6P**  
**138564-41-7P 138564-42-8P 138564-47-3P**  
**138564-48-4P 138564-49-5P 138564-50-8P**


V. Balasubramanian

138581-63-2P 138662-47-2P 138662-48-3P  
 138662-49-4P 138662-50-7P 138662-51-8P  
 138662-52-9P 138662-53-0P 138662-54-1P  
 138662-55-2P 138662-56-3P 138662-57-4P  
 138663-55-5P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of, as tachykinin agonist and/or antagonist)


RN 138564-29-1 CAPLUS

CN 1H-Indole-3-propanamide, N-[1-[[4-[1-[[[2-amino-2-oxo-1-(phenylmethyl)ethyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]carbonyl]-2-methylbutyl]-.alpha.-[[4-chlorophenyl]acetyl]amino]-, stereoisomer (9CI) (CA INDEX NAME)




RN 138564-30-4 CAPLUS

CN 1-Piperazineacetamide, N-[1-(aminocarbonyl)-3-(methylthio)propyl]-4-[N-[N-[(4-chlorophenyl)acetyl]-L-phenylalanyl]-L-valyl]-.alpha.-(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)




PAGE 1-A



RN 138564-31-5 CAPLUS

CN 1-Piperazineacetic acid, 4-[2-[[[2-[(4-chlorophenyl)acetyl]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-yl]carbonyl]amino]-1-oxo-3-phenylpropyl]-.alpha.-(2-methylpropyl)-2-oxo-, methyl ester, [3R-[3R\*[S\*(S\*)]]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 138564-32-6 CAPLUS


CN 1H-Indole-3-propanamide, N-[2-[4-[1-[[[1-(aminocarbonyl)-3-methylbutyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-.alpha.-[[[4-chlorophenyl]acetyl]amino]-, [.alpha.S-[N[R\*(R\*(R\*))]],.alpha.R\*]]- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 138564-33-7 CAPLUS


CN 1-Piperazineacetic acid, 4-[N-[N-[(4-chlorophenyl)acetyl]-D-tryptophyl]-L-phenylalanyl]-.alpha.-(2-methylpropyl)-2-oxo-, methyl ester, (S)- (9CI)  
(CA INDEX NAME)



RN 138564-34-8 CAPLUS


CN 1H-Indole-3-propanamide, N-[2-[4-[1-[[[1-(aminocarbonyl)-2-methylbutyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-.alpha.-[[4-chlorophenyl)acetyl]amino]-, [1S-[1R\*[R\*[R\*(S\*)]]],2R\*]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 138564-35-9 CAPLUS  
 CN 1H-Indole-3-propanamide, N-[2-[4-[1-[[[1-(aminocarbonyl)-3-(methylsulfonyl)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-.alpha.-[[[4-chlorophenyl]acetyl]amino]-, [.alpha.R-[N[S\*(S\*)]], .alpha.R\*]]- (9CI) (CA INDEX NAME)


PAGE 1-A



— Me


RN 138564-36-0 CAPLUS

CN 1H-Indole-3-propanamide, N-[2-[4-[1-[[[1-(aminocarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-.alpha.-[[ (4-chlorophenyl)acetyl]amino]-, [.alpha.R-[N[S\*(S\*(R\*))]],.alpha.R\*]]- (9CI) (CA INDEX NAME)




RN 138564-37-1 CAPLUS

CN 1H-Indole-3-propanamide, N-[2-[4-[1-[[[2-amino-2-oxo-1-(phenylmethyl)ethyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-.alpha.-[[ (4-chlorophenyl)acetyl]amino]-, [.alpha.R-[N[S\*(S\*(S\*))]],.alpha.R\*]]- (9CI) (CA INDEX NAME)




RN 138564-38-2 CAPLUS

CN L-Phenylalanine, N-[2-[4-[N-[N-[(4-chlorophenyl)acetyl]-D-tryptophyl]-L-phenylalanyl]-2-oxo-1-piperazinyl]-4-methyl-1-oxopentyl]-, methyl ester, (S)- (9CI) (CA INDEX NAME)




RN 138564-39-3 CAPLUS

CN 1H-Indole-3-propanamide, N-[2-[4-[1-[[[2-amino-2-oxo-1-(phenylmethyl)ethyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-1-[(4-hydroxyphenyl)methyl]-2-oxoethyl]-.alpha.-[[[4-chlorophenyl)acetyl]amino]-, [.alpha.R-[N[S\*(S\*)(S\*)]],.alpha.R\*]]- (9CI) (CA INDEX NAME)




RN 138564-40-6 CAPLUS

CN 1H-Indole-3-propanamide, N-[2-[4-[1-[[[1-(aminocarbonyl)-3-methylbutyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-.alpha.-[[4-chlorophenyl]acetyl]methylamino]-, [.alpha.S-[N[R\*(R\*)]],.alpha.R\*]]- (9CI) (CA INDEX NAME)




RN 138564-41-7 CAPLUS

CN 1-Piperazineacetic acid, 4-[N-[N-[(4-chlorophenyl)acetyl]-N-methyltryptophyl]-L-isoleucyl]-.alpha.-(2-methylpropyl)-2-oxo-, methyl ester, (S)- (9CI) (CA INDEX NAME)



RN 138564-42-8 CAPLUS


CN 1H-Indole-3-propanamide, N-[2-[4-[1-[[[2-amino-2-oxo-1-(phenylmethyl)ethyl]amino]carbonyl]-3-methylbutyl]-3-oxo-2-(phenylmethyl)-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-.alpha.-[[4-chlorophenyl]acetyl]amino]- (9CI) (CA INDEX NAME)



RN 138564-47-3 CAPLUS

CN 1-Piperazineacetic acid, 4-[N-[N-[(4-chlorophenyl)acetyl]-D-tryptophyl]-L-phenylalanyl]-.alpha.-(2-methylpropyl)-2-oxo-, (S)- (9CI) (CA INDEX NAME)


V. Balasubramanian



RN 138564-48-4 CAPLUS

CN 1-Piperazineacetic acid, 4-[2-[[[2-[(4-chlorophenyl)acetyl]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-yl]carbonyl]amino]-1-oxo-3-phenylpropyl]-.alpha.-(2-methylpropyl)-2-oxo-, [3R-[3R\*[S\*(S\*)]]]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 138564-49-5 CAPLUS

CN 1-Piperazineacetic acid, 4-[N-[N-[(4-chlorophenyl)acetyl]-N-methyl-D-phenylalanyl]-L-phenylalanyl]-.alpha.-(2-methylpropyl)-2-oxo-, (S)- (9CI)  
(CA INDEX NAME)


V. Balasubramanian




RN 138564-50-8 CAPLUS

CN 1-Piperazineacetamide, N-[1-(aminocarbonyl)-3-(methylsulfinyl)propyl]-4-[N-[N-[(4-chlorophenyl)acetyl]-L-phenylalanyl]-L-valyl]-.alpha.-(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 138581-63-2 CAPLUS

CN 1H-Pyrido[3,4-b]indole-3-carboxamide, N-[2-[4-[1-[[[2-amino-2-oxo-1-(phenylmethyl)ethyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-2-[(4-chlorophenyl)acetyl]-2,3,4,9-tetrahydro-, [3R-[3R\*[S\*[S\*(S\*)]]]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 138662-47-2 CAPLUS  
 CN 1H-Indole-3-propanamide, N-[2-[4-[1-[[[1-(aminocarbonyl)-3-methylbutyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-.alpha.-[[4-chlorophenyl]acetyl]amino]-, stereoisomer (9CI) (CA INDEX NAME)




RN 138662-48-3 CAPLUS  
 CN 1H-Indole-3-propanamide, N-[1-[[4-[1-[[[2-amino-2-oxo-1-(phenylmethyl)ethyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]carbonyl]-2-methylbutyl]-.alpha.-[[4-chlorophenyl]acetyl]amino]-, stereoisomer (9CI) (CA INDEX NAME)




RN 138662-49-4 CAPLUS

CN 1H-Indole-3-propanamide, N-[2-[4-[1-[[[1-(aminocarbonyl)-2-methylbutyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-.alpha.-[[ (4-chlorophenyl)acetyl]amino]-, stereoisomer (9CI) (CA INDEX NAME)




RN 138662-50-7 CAPLUS

CN 1H-Indole-3-propanamide, N-[2-[4-[1-[[[1-(aminocarbonyl)-3-methylbutyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-.alpha.-[[ (4-chlorophenyl)acetyl]amino]-, stereoisomer (9CI) (CA INDEX NAME)




RN 138662-51-8 CAPLUS

CN 1H-Indole-3-propanamide, N-[2-[4-[1-[[[1-(aminocarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-.alpha.-[[4-chlorophenyl]acetyl]amino]-, stereoisomer (9CI) (CA INDEX NAME)




RN 138662-52-9 CAPLUS

CN L-Phenylalanine, N-[2-[4-[N-[N-[(4-chlorophenyl)acetyl]-D-tryptophyl]-L-phenylalanyl]-2-oxo-1-piperazinyl]-4-methyl-1-oxopentyl]-, methyl ester, (R)- (9CI) (CA INDEX NAME)




RN 138662-53-0 CAPLUS

CN 1H-Indole-3-propanamide, N-[2-[4-[1-[[[2-amino-2-oxo-1-(phenylmethyl)ethyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-.alpha.-[[4-(4-chlorophenyl)acetyl]amino]-, stereoisomer (9CI) (CA INDEX NAME)




RN 138662-54-1 CAPLUS

CN 1H-Indole-3-propanamide, N-[2-[4-[1-[[[2-amino-2-oxo-1-(phenylmethyl)ethyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-1-[(4-hydroxyphenyl)methyl]-2-oxoethyl]-.alpha.-[[4-(4-chlorophenyl)acetyl]amino]-, stereoisomer (9CI) (CA INDEX NAME)




RN 138662-55-2 CAPLUS

CN 1H-Indole-3-propanamide, N-[2-[4-[1-[[[1-(aminocarbonyl)-3-methylbutyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-.alpha.-[[4-chlorophenyl]acetyl]methylamino]-, stereoisomer (9CI) (CA INDEX NAME)




RN 138662-56-3 CAPLUS

CN 1H-Indole-3-propanamide, N-[2-[4-[1-[[[1-(aminocarbonyl)-3-methylbutyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-.alpha.-[[4-chlorophenyl]acetyl]methylamino]-, stereoisomer (9CI) (CA INDEX NAME)



RN 138662-57-4 CAPLUS


CN 1H-Indole-3-propanamide, N-[2-[4-[1-[[[1-(aminocarbonyl)-3-methylbutyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-.alpha.-[[[4-chlorophenyl]acetyl]methylamino]-, stereoisomer (9CI) (CA INDEX NAME).



RN 138663-55-5 CAPLUS


CN 1H-Pyrido[3,4-b]indole-3-carboxamide, N-[2-[4-[1-[[[2-amino-2-oxo-1-(phenylmethyl)ethyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-2-[(4-chlorophenyl)acetyl]-2,3,4,9-tetrahydro-, [3R-[3R\*[R\*[S\*(S\*)]]]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 65 OF 82 CAPLUS COPYRIGHT 2003 ACS  
 AN 1991:536730 CAPLUS  
 DN 115:136730  
 TI Preparations, solution conformations and molecular structures of  
 N,N-ethylene-bridged dipeptides and their derivatives  
 AU Kojima, Yoshitane; Ikeda, Youko; Kumata, Etsuko; Maruo, Joji; Okamoto,  
 Akihiro; Hirotsu, ken; Shibata, Kozo; Ohsuka, Akio  
 CS Fac. Sci., Osaka City Univ., Osaka, 558, Japan  
 SO International Journal of Peptide & Protein Research (1991), 37(6), 468-75  
 CODEN: IJPPC3; ISSN: 0367-8377  
 DT Journal  
 LA English  
 IT **135928-49-3**  
 RL: PRP (Properties)  
 (crystal structure of and conformation of, by NMR and mol. mechanics  
 calcs.)  
 RN 135928-49-3 CAPLUS  
 CN 1-Piperazineacetic acid, 4-[[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]-2-  
 oxo-.alpha.,3-bis(phenylmethyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 135884-97-8P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and conformation of, by NMR and mol. mechanics calcns.)

RN 135884-97-8 CAPLUS

CN Glycine, N-[2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]-3-(1-methylethyl)-2-oxo-1-piperazinyl]-3-methyl-1-oxobutyl]-, [S-(R\*,R\*)]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 135884-99-0P


RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and crystal structure of)

RN 135884-99-0 CAPLUS

CN 1-Piperazineacetic acid, 4-[[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]-  
.alpha.,3-bis(1-methylethyl)-2-oxo-, hydrate (2:1), [S-(R\*,R\*)]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

V. Balasubramanian



● 1/2 H<sub>2</sub>O


IT 135884-96-7P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and mol. structure of)

RN 135884-96-7 CAPLUS

CN 1-Piperazineacetic acid, 4-[[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]-  
.alpha.,3-bis(1-methylethyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 66 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 1991:229392 CAPLUS

DN 114:229392

TI Preparation of peptides as renin inhibitors for treating vascular diseases

IN Kleinert, Hollis D.

PA Abbott Laboratories, USA

SO PCT Int. Appl., 189 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.

KIND

DATE

APPLICATION NO.


DATE

10/039,898

V. Balasubramanian

PI WO 9005531 A1 19900531 WO 1989-US5248 19891120  
W: JP, US  
RW: BE, CH, DE, ES, FR, GB, IT, NL, SE  
CA 2003382 AA 19900521 CA 1989-2003382 19891120  
EP 444156 A1 19910904 EP 1990-901238 19891120  
R: BE, CH, DE, ES, FR, GB, IT, LI, NL, SE  
JP 04503802 T2 19920709 JP 1990-501551 19891120  
PRAI US 1988-275151 19881121  
WO 1989-US5248 19891120  
OS MARPAT 114:229392  
IT **131385-71-2P**  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(prepn. and reaction of, in renin inhibitor prepn. for vascular disease  
treatment)  
RN 131385-71-2 CAPLUS  
CN 1-Piperazineacetic acid, 4-[(4-methyl-1-piperazinyl)sulfonyl]-2-oxo-3-  
(phenylmethyl)-.alpha.-(4-thiazolylmethyl)-, methyl ester, [S-(R\*,R\*)]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 67 OF 82 CAPLUS COPYRIGHT 2003 ACS  
AN 1991:82497 CAPLUS  
DN 114:82497  
TI Macrocyclic peptides. 5. Chiral recognition of (R)- and  
(S)-trimethyl-1-phenethylammonium bromides by 24-, 27- and 36-membered  
ring peptides containing glycine and N,N'-ethylene-bridged  
(S)-leucyl-(S)-leucine  
AU Miyake, Hiroyuki; Shibata, Kozo; Kojima, Yoshitane; Yamashita, Tetsushi;  
Ohsuka, Akio  
CS Fac. Sci., Osaka City Univ., Osaka, 558, Japan  
SO Makromolekulare Chemie, Rapid Communications (1990), 11(12), 667-71  
CODEN: MCRCD4; ISSN: 0173-2803  
DT Journal  
LA English  
IT **131919-88-5**  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(complexation of, with trimethylphenethylammonium bromide  
stereoisomers)  
RN 131919-88-5 CAPLUS  
CN 1-Piperazineacetic acid, 4-[[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]-  
.alpha.,3-bis(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

10/039,898

V. Balasubramanian

Absolute stereochemistry.



L5 ANSWER 68 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 1991:43580 CAPLUS

DN 114:43580

TI Preparation of heterocyclic peptides as renin and retroviral protease inhibitors

IN De, Biswanath; Dellaria, Joseph F.; Baker, William R.; Zydowsky, Thomas M.; Rosenberg, Saul H.; Jae, Hwan Soo

PA Abbott Laboratories, USA

SO Eur. Pat. Appl., 150 pp.

CODEN: EPXXDW

DT Patent


LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 365992	A1	19900502	EP 1989-119329	19891018
	R: ES, GR				
	CA 2000929	AA	19900419	CA 1989-2000929	19891018
	WO 9004917	A1	19900517	WO 1989-US4649	19891018
	W: AU, DK, JP, KR, US				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	AU 9048493	A1	19900528	AU 1990-48493	19891018
	EP 439556	A1	19910807	EP 1990-901957	19891018
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL; SE				
	JP 04501566	T2	19920319	JP 1990-502077	19891018
	DK 9100704	A	19910617	DK 1991-704	19910418
	US 5164388	A	19921117	US 1991-678266	19910418
PRAI	US 1988-259959		19881019		
	US 1989-390571		19890807		
	WO 1989-US4649		19891018		
OS	MARPAT 114:43580				
IT	131288-17-0P 131288-18-1P				
	RL: SPN (Synthetic preparation); PREP (Preparation)				
	(prepn. of, as intermediate for heterocyclic peptide renin inhibitor and antiretroviral)				
RN	131288-17-0 CAPLUS				
CN	1-Piperazineacetic acid, .alpha.-butyl-4-[(1,1-dimethylethoxy)carbonyl]-2-oxo-3-(phenylmethyl)-, methyl ester, [R-(R*,S*)]- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.


V. Balasubramanian



RN 131288-18-1 CAPLUS

CN 1-Piperazineacetic acid, .alpha.-butyl-4-[(1,1-dimethylethoxy)carbonyl]-2-oxo-3-(phenylmethyl)-, [R-(R\*,S\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 131287-76-8P 131287-77-9P 131287-78-0P

131287-79-1P 131287-80-4P 131287-81-5P

131287-82-6P 131287-92-8P 131287-93-9P

131287-95-1P 131287-96-2P 131287-97-3P

131287-98-4P 131287-99-5P 131288-00-1P

131288-01-2P 131316-82-0P 131316-83-1P


131316-84-2P 131349-10-5P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of, as renin inhibitor and antiretroviral)

RN 131287-76-8 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-[[[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]amino]carbonyl]pentyl]-3-oxo-2-(phenylmethyl)-, 1,1-dimethylethyl ester, [2R-[2R\*,4[S\*(1S\*,2R\*,3S\*)]]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 131287-77-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]amino]-1-(1H-imidazol-4-ylmethyl)-2-oxoethyl]-3-oxo-2-(phenylmethyl)-, 1,1-dimethylethyl ester, [2R-[2R\*,4[R\*(1S\*,2R\*,3S\*)]]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 131287-78-0 CAPLUS

CN 1-Piperazineacetamide, .alpha.-butyl-N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)carbonyl]-2-oxo-3-(phenylmethyl)-, [3R-[1[S\*(1S\*,2R\*,3S\*)],3R\*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 131287-79-1 CAPLUS

CN 1-Piperazineacetamide, .alpha.-butyl-N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-4-[[2-(methoxymethoxy)ethyl]methylamino]carbonyl]-2-oxo-3-(phenylmethyl)-, [3R-[1[S\*(1S\*,2R\*,3S\*)],3R\*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 131287-80-4 CAPLUS

CN 1-Piperazineacetamide, N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-4-(4-morpholinylcarbonyl)-2-oxo-3-(phenylmethyl)-.alpha.-(4-thiazolylmethyl)-, [3R-[1[R\*(1S\*,2R\*,3S\*)],3R\*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 131287-81-5 CAPLUS

CN 1-Piperazineacetamide, .alpha.-butyl-N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-4-(4-morpholinylcarbonyl)-2-oxo-3-(phenylmethyl)-, [3R-[1[S\*(1S\*,2R\*,3S\*)],3R\*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 131287-82-6 CAPLUS


CN 1-Piperazineacetamide, N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-.alpha.-(1H-imidazol-4-ylmethyl)-4-(4-morpholinylcarbonyl)-2-oxo-3-(phenylmethyl)-, [3R-[1[S\*(1S\*,2R\*,3S\*)],3R\*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 131287-92-8 CAPLUS

CN 1-Piperazineacetamide, N-[5-(butylamino)-1-(cyclohexylmethyl)-2-hydroxy-4-(1-methylethyl)-5-oxopentyl]-4-(4-morpholinylcarbonyl)-2-oxo-3-(phenylmethyl)-.alpha.-(4-thiazolylmethyl)- (9CI) (CA INDEX NAME)



RN 131287-93-9 CAPLUS


CN 1-Piperazineacetamide, N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-4-[(4-methylphenyl)sulfonyl]-2-oxo-3-(phenylmethyl)-.alpha.-(4-thiazolylmethyl)- (9CI) (CA INDEX NAME)



V. Balasubramanian


RN 131287-95-1 CAPLUS

CN 1-Piperazineacetamide, N-[1-(cyclohexylmethyl)-2-hydroxy-2-(tetrahydro-4-methyl-2-furanyl)ethyl]-4-[(4-methylphenyl)sulfonyl]-2-oxo-3-(phenylmethyl)-.alpha.-(4-thiazolylmethyl)- (9CI) (CA INDEX NAME)




RN 131287-96-2 CAPLUS

CN 1-Piperazineacetamide, N-[4-[(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-methyl-1-piperazinyl)sulfonyl]-2-oxo-3-(phenylmethyl)-.alpha.-(4-thiazolylmethyl)- (9CI) (CA INDEX NAME)



RN 131287-97-3 CAPLUS


CN 1H-Imidazole-1-carboxylic acid, 2-[3-[[1-(cyclohexylmethyl)-2-(3-ethyl-2-oxo-5-oxazolidinyl)-2-hydroxyethyl]amino]-2-[4-[(4-methyl-1-piperazinyl)sulfonyl]-2-oxo-3-(phenylmethyl)-1-piperazinyl]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 131287-98-4 CAPLUS

CN 1-Piperazineacetamide, N-[1-(cyclohexylmethyl)-2-(3-ethyl-2-oxo-5-oxazolidinyl)-2-hydroxyethyl]-.alpha.-(1H-imidazol-2-ylmethyl)-4-[(4-methyl-1-piperazinyl)sulfonyl]-2-oxo-3-(phenylmethyl)- (9CI) (CA INDEX NAME)


PAGE 1-A






RN 131287-99-5 CAPLUS

CN 1H-Imidazole-1-carboxylic acid, 2-[3-[[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]amino]-2-[4-[(4-methyl-1-piperazinyl)sulfonyl]-2-oxo-3-(phenylmethyl)-1-piperazinyl]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI)  
(CA INDEX NAME)



RN 131288-00-1 CAPLUS


CN 1H-Imidazole-1-carboxylic acid, 2-[3-[[1-(cyclohexylmethyl)-2-hydroxy-2-(tetrahydro-4-methyl-2-furanyl)ethyl]amino]-2-[4-[(4-methyl-1-piperazinyl)sulfonyl]-2-oxo-3-(phenylmethyl)-1-piperazinyl]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



V. Balasubramanian


RN 131288-01-2 CAPLUS

CN 1-Piperazineacetamide, N-[1-(cyclohexylmethyl)-2-hydroxy-2-(tetrahydro-4-methyl-2-furanyl)ethyl]-.alpha.-(1H-imidazol-2-ylmethyl)-4-[(4-methyl-1-piperazinyl)sulfonyl]-2-oxo-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 131316-82-0 CAPLUS


CN 1-Piperazineacetamide, N-[4-[(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4-[(4-methylphenyl)sulfonyl]-2-oxo-3-(phenylmethyl)-.alpha.-(4-thiazolylmethyl)- (9CI) (CA INDEX NAME)



RN 131316-83-1 CAPLUS


CN 1-Piperazineacetamide, N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-.alpha.-(1H-imidazol-2-ylmethyl)-4-[(4-methyl-1-piperazinyl)sulfonyl]-2-oxo-3-(phenylmethyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 131316-84-2 CAPLUS


CN 1-Piperazineacetamide, N-[1-(cyclohexylmethyl)-2-hydroxy-4-methyl-5-[(1-methylethyl)sulfonyl]pentyl]-4-[(4-methyl-1-piperazinyl)sulfonyl]-2-oxo-3-(phenylmethyl)-.alpha.-(4-thiazolylmethyl)- (9CI) (CA INDEX NAME)



RN 131349-10-5 CAPLUS

CN 1-Piperazineacetamide, N-[1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-4-(4-morpholinylcarbonyl)-2-oxo-3-(phenylmethyl)-.alpha.-(4-thiazolylmethyl)-, [3R-[1[S\*(1S\*,2R\*,3S\*)],3R\*]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



V. Balasubramanian


LS ANSWER 69 OF 82 CAPLUS COPYRIGHT 2003 ACS  
AN 1990:7904 CAPLUS  
DN 112:7904  
TI Macrocyclic peptides. II. Synthesis and structure of a novel dipeptide, (2S,3'S)-2-(2'-oxo-3'-methylpiperazin-1'-yl)-propanoic acid, and its use as the unit of cyclic peptides  
AU Yamashita, Tetsushi; Kojima, Yoshitane; Hirotsu, Ken; Ohsuka, Akio  
CS Fac. Sci., Osaka City Univ., Osaka, 558, Japan  
SO International Journal of Peptide & Protein Research (1989), 33(2), 110-14  
CODEN: IJPPC3; ISSN: 0367-8377  
DT Journal  
LA English  
OS CASREACT 112:7904  
IT **124194-13-4P**  
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (prepn. and crystal structure of)  
RN 124194-13-4 CAPLUS  
CN 1-Piperazineacetic acid, 4-[(1,1-dimethylethoxy)carbonyl]-.alpha.,3-dimethyl-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT **124194-21-4P**  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (prepn. and cyclization of)  
RN 124194-21-4 CAPLUS  
CN 1-Piperazineacetamide, N-[2-[[2-[4-[2-[[2-[4-[2-[[2-[(2,5-dioxo-1-pyrrolidinyl)oxy]-2-oxoethyl]methylamino]-1-methyl-2-oxoethyl]-2-methyl-3-oxo-1-piperazinyl]-2-oxoethyl]methylamino]-1-methyl-2-oxoethyl]-2-methyl-3-oxo-1-piperazinyl]-2-oxoethyl]methylamino]-2-oxoethyl]-N,.alpha.,3-trimethyl-4-[[methyl[2-[3-methyl-4-[(methylamino)acetyl]-2-oxo-1-piperazinyl]-1-oxopropyl]amino]acetyl]-2-oxo-, stereoisomer, mono(trifluoroacetate) (9CI) (CA INDEX NAME)  
  
CM 1  
  
CRN 124194-20-3  
CMF C54 H83 N15 O17


PAGE 1-A



PAGE 1-B




PAGE 1-C



CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT 124194-14-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(prepn. and deblocking of, with trifluoroacetic acid)

V. Balasubramanian

RN 124194-14-5 CAPLUS

CN Glycine, N-[2-[4-[[[(1,1-dimethylethoxy)carbonyl]methylamino]acetyl]-3-methyl-2-oxo-1-piperazinyl]-1-oxopropyl]-N-methyl-, ethyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 124194-15-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and peptide coupling of, with [oxo(methyl)piperazinyl]propanoic acid dipeptide)

RN 124194-15-6 CAPLUS

CN Glycine, N-methyl-N-[2-[3-methyl-4-[(methylamino)acetyl]-2-oxo-1-piperazinyl]-1-oxopropyl]-, ethyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 124194-18-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and peptide coupling of, with pentapeptide deriv.)


RN 124194-18-9 CAPLUS

CN Glycine, N-methyl-N-[2-[3-methyl-4-[[methyl[2-[3-methyl-4-[(methylamino)acetyl]-2-oxo-1-piperazinyl]-1-oxopropyl]amino]acetyl]-2-oxo-

V. Balasubramanian

1-piperazinyl]-1-oxopropyl]-, ethyl ester, [3S-[1(R\*),3R\*,4[R\*(R\*)]]]-  
(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—NHMe

IT 124194-17-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(prepn. and peptide coupling of, with pentapeptide ester)

RN 124194-17-8 CAPLUS

CN Glycine, N-[2-[4-[[[2-[4-[[[(1,1-dimethylethoxy)carbonyl]methylamino]acetyl]-3-methyl-2-oxo-1-piperazinyl]-1-oxopropyl]methylamino]acetyl]-3-methyl-2-oxo-1-piperazinyl]-1-oxopropyl]-N-methyl-, [3S-[1(R\*),3R\*,4[R\*(R\*)]]]-  
(9CI) (CA INDEX NAME)

PAGE 1-A



—CH<sub>2</sub>—CO<sub>2</sub>H

IT **114967-01-0P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and peptide coupling of, with sarcosine Et ester)

RN 114967-01-0 CAPLUS

CN 1-Piperazineacetic acid, 4-[[[(1,1-dimethylethoxy)carbonyl]methylamino]acetyl]-.alpha.,3-dimethyl-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **114967-00-9P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and sapon. of)

RN 114967-00-9 CAPLUS

CN 1-Piperazineacetic acid, 4-[[[(1,1-dimethylethoxy)carbonyl]methylamino]acetyl]-.alpha.,3-dimethyl-2-oxo-, methyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and sapon. or deblocking of)

CN Glycine, N-[2-[4-[[[2-[4-[[[(1,1-dimethylethoxy)carbonyl]methylamino]acetyl]-3-methyl-2-oxo-1-piperazinyl]-1-oxopropyl]methylamino]acetyl]-3-methyl-2-oxo-1-piperazinyl]-1-oxopropyl]-N-methyl-, ethyl ester,  
[3S-[1(R\*),3R\*,4[R\*(R\*)]]]- (9CI) (CA INDEX NAME)


[illegible]
$$-\text{CH}_2-\overset{\text{O}}{\parallel}{\text{C}}-\text{OEt}$$

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and sequential sapon., esterification of, with  
hydroxysuccinimide, and deblocking of)


CN Glycine, N-[2-[4-[[[2-[4-[N-[N-[2-[4-[[[2-[4-[[[(1,1-dimethylethoxy)carbonyl]methylamino]acetyl]-3-methyl-2-oxo-1-piperazinyl]-

1-oxopropyl]methylamino]acetyl]-3-methyl-2-oxo-1-piperazinyl]-1-oxopropyl]-N-methylglycyl]-N-methylglycyl]-3-methyl-2-oxo-1-piperazinyl]-1-oxopropyl]methylamino]acetyl]-3-methyl-2-oxo-1-piperazinyl]-1-oxopropyl]-N-methyl-, ethyl ester, stereoisomer (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B



PAGE 1-C



L5 ANSWER 70 OF 82 CAPLUS COPYRIGHT 2003 ACS  
 AN 1989:478575 CAPLUS  
 DN 111:78575  
 TI Macrocyclic peptides. 3. Enantioface-differentiating abilities of 24-membered ring peptides containing N,N'-ethylene-bridged dipeptides, glycine and sarcosine  
 AU Kojima, Yoshitane; Yamashita, Tetsushi; Washizawa, Megumi; Ohsuka, Akio  
 CS Fac. Sci., Osaka City Univ., Sugimoto, 558, Japan  
 SO Makromolekulare Chemie, Rapid Communications (1989), 10(3), 121-5  
 CODEN: MCRCD4; ISSN: 0173-2803  
 DT Journal  
 LA English  
 OS CASREACT 111:78575  
 IT 121925-95-9P

V. Balasubramanian


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(prepn. and cyclization of)

RN 121925-95-9 CAPLUS

CN 1-Piperazineacetamide, 4-(aminoacetyl)-N-[2-[[2-[4-[1-[[[2-[(2,5-dioxo-1-  
pyrrolidinyl)oxy]-2-oxoethyl]amino]carbonyl]-3-methylbutyl]-2-(2-  
methylpropyl)-3-oxo-1-piperazinyl]-2-oxoethyl]amino]-2-oxoethyl]-.alpha.,3-  
bis(2-methylpropyl)-2-oxo-, monohydrochloride, [2S-[1(R\*(R\*)),2R\*,4(R\*)]]-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



● HCl

PAGE 1-B



10/039,898


IT 121925-91-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(prepn. and deblocking of)

RN 121925-91-5 CAPLUS

CN Glycine, N-[2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]-3-(2-methylpropyl)-2-oxo-1-piperazinyl]-4-methyl-1-oxopentyl]-, methyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 121925-92-6P 121925-93-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(prepn. and peptide coupling of)

RN 121925-92-6 CAPLUS

CN Glycine, N-[2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]-3-(2-methylpropyl)-2-oxo-1-piperazinyl]-4-methyl-1-oxopentyl]-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 121925-93-7 CAPLUS

V. Balasubramanian

CN Glycine, N-[2-[4-(aminoacetyl)-3-(2-methylpropyl)-2-oxo-1-piperazinyl]-4-methyl-1-oxopentyl]-, methyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 121925-90-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. and sapon.-peptide coupling of)

RN 121925-90-4 CAPLUS

CN 1-Piperazineacetic acid, 4-[[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]-.alpha.,3-bis(2-methylpropyl)-2-oxo-, methyl ester, [S-(R\*,R\*)]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




IT 121925-94-8P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and sequential sapon. and esterification with  
hydroxysuccinimide)


RN 121925-94-8 CAPLUS

CN Glycine, N-[2-[4-[[[2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]-3-(2-methylpropyl)-2-oxo-1-piperazinyl]-4-methyl-1-oxopentyl]amino]acetyl]amino]acetyl]-3-(2-methylpropyl)-2-oxo-1-piperazinyl]-4-methyl-1-oxopentyl]-, methyl ester, [3S-[1(R\*),3R\*,4[R\*(R\*)]]]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L5 ANSWER 71 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 1989:115348 CAPLUS

DN 110:115348

TI Preparation of tachykinin agonists and antagonists as drugs

IN Weber, Wolf Dietrich; Hoelzemann, Guenter; Jonczyk, Alfred; Wild, Albrecht; Lues, Ingeborg; Wienrich, Marion; Greiner, Hartmut

PA Merck Patent G.m.b.H., Fed. Rep. Ger.

SO Eur. Pat. Appl., 21 pp.

CODEN: EPXXDW

DT Patent


LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 284942	A2	19881005	EP 1988-104483	19880321
	EP 284942	A3	19900905		
	R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
	DE 3711335	A1	19881020	DE 1987-3711335	19870403
	AU 8814134	A1	19881006	AU 1988-14134	19880331
	ZA 8802347	A	19881130	ZA 1988-2347	19880331
	JP 63258894	A2	19881026	JP 1988-78334	19880401
	HU 49149	A2	19890828	HU 1988-1623	19880401
PRAI	DE 1987-3711335		19870403		
OS	CASREACT 110:115348; MARPAT 110:115348				
IT	119156-28-4				
	RL: RCT (Reactant); RACT (Reactant or reagent) (acylation of, in prepn. of drug)				
RN	119156-28-4 CAPLUS				
CN	L-Phenylalaninamide, L-phenylalanyl-N-[1-[[4-[1-[[[1-(aminocarbonyl)-3-				

## V. Balasubramanian

(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]carbonyl]-2-methylpropyl]-, monohydrochloride, stereoisomer (9CI) (CA INDEX NAME)




IT      119156-41-1P   119156-42-2P   119156-43-3P  
          119156-44-4P   119156-45-5P   119156-46-6P  
          119156-47-7P   119156-48-8P   119156-49-9P  
          119156-50-2P   119156-51-3P   119156-52-4P  
          119156-53-5P   119156-54-6P   119156-55-7P  
          119156-56-8P   119156-57-9P   119156-68-2P  
          119156-69-3P   119156-91-1P   119156-92-2P  
          119157-38-9P   119157-39-0P   119157-40-3P  
          119157-41-4P   119157-45-8P   119188-54-4P  
          119240-51-6P   119240-60-7P   119240-61-8P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of, as drug)


RN 119156-41-1 CAPLUS

CN D-Tryptophanamide, N2-[(1,1-dimethylethoxy)carbonyl]-L-lysyl-N-[2-[4-[1-[[[1-(aminocarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-, stereoisomer (9CI) (CA INDEX NAME)




RN 119156-42-2 CAPLUS

CN L-Phenylalaninamide, N-(3-carboxy-1-oxopropyl)-L-phenylalanyl-N-[1-[[4-[1-[[[1-(aminocarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]carbonyl]-2-methylpropyl]-, stereoisomer (9CI) (CA INDEX NAME)




RN 119156-43-3 CAPLUS

CN D-Tryptophanamide, N2-[(1,1-dimethylethoxy)carbonyl]-N6-[(phenylmethoxy)carbonyl]-L-lysyl-N-[2-[4-[1-[[[1-(methoxycarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-, stereoisomer (9CI) (CA INDEX NAME)



RN 119156-44-4 CAPLUS


CN D-Tryptophanamide, N2-[(1,1-dimethylethoxy)carbonyl]-N6-[(phenylmethoxy)carbonyl]-L-lysyl-N-[2-[4-[1-[[[1-carboxy-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-, stereoisomer (9CI) (CA INDEX NAME)



RN 119156-45-5 CAPLUS


CN D-Tryptophanamide, N2-[(1,1-dimethylethoxy)carbonyl]-N6-[(phenylmethoxy)carbonyl]-L-lysyl-N-[2-[4-[1-[[[1-(aminocarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-, stereoisomer (9CI) (CA INDEX NAME).

V. Balasubramanian




RN 119156-46-6 CAPLUS

CN Carbamic acid, [2-[[1-[[4-[1-[[[1-(aminocarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]carbonyl]-2-methylpropyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, phenylmethyl ester, stereoisomer (9CI) (CA INDEX NAME)




RN 119156-47-7 CAPLUS

CN Carbamic acid, [2-[[2-[4-[1-[[[2-amino-2-oxo-1-(phenylmethyl)ethyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]amino]-1-(1H-indol-3-ylmethyl)-2-oxoethyl]-, 1,1-dimethylethyl ester, stereoisomer (9CI) (CA INDEX NAME)




RN 119156-48-8 CAPLUS

CN D-Tryptophanamide, D-prolyl-N-[2-[4-[1-[[[2-amino-2-oxo-1-(phenylmethyl)ethyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-, stereoisomer (9CI) (CA INDEX NAME)



RN 119156-49-9 CAPLUS

CN 1H-Indole-3-propanamide, .alpha.-amino-N-[2-[4-[1-[[[1-(aminocarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-, [.alpha.R-[N[S\*(S\*)]], .alpha.R\*]]- (9CI) (CA INDEX NAME)




RN 119156-50-2 CAPLUS

CN Butanoic acid, 4-[[2-[[1-[[4-[1-[[[1-(aminocarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]carbonyl]-2-methylpropyl]amino]-2-oxo-1-


V. Balasubramanian

(phenylmethyl)ethyl]amino]-4-oxo-, stereoisomer (9CI) (CA INDEX NAME)



RN 119156-51-3 CAPLUS

CN 1-Piperazineacetamide, N-[1-(aminocarbonyl)-3-(methylthio)propyl]-.alpha.-(2-methylpropyl)-2-oxo-4-[N-[N-(phenylacetyl)-L-phenylalanyl]-L-valyl]-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)



RN 119156-52-4 CAPLUS

CN 1-Piperazineacetamide, N-[1-(aminocarbonyl)-3-(methylthio)propyl]-4-[N-(N-benzoyl-L-phenylalanyl)-L-valyl]-.alpha.-(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

CN 1-Piperazineacetamide, N-[1-(aminocarbonyl)-3-(methylthio)propyl]-4-[N-[N-  
[(4-aminophenyl)acetyl]-L-phenylalanyl]-L-valyl]-.alpha.-(2-methylpropyl)-  
2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


$$\text{MeS}-\text{CH}_2-\text{CH}_2-\underset{\text{H}_2\text{N}-\text{C}(=\text{O})}{\text{CH}}-\text{NH}-\underset{\text{O}}{\text{C}}-\underset{\text{O}}{\text{C}}(\text{i-Bu})-\text{N}(\text{CH}_2)_4\text{N}-\underset{\text{O}}{\text{C}}(\text{Pr-i})-\text{CH}_2-\text{NH}-\underset{\text{O}}{\text{C}}(\text{CH}_2\text{Ph})-\text{CH}_2-\text{NH}-\underset{\text{O}}{\text{C}}-\text{CH}_2-$$

Nc1ccc(C)cc1


CN L-Phenylalaninamide, 5-oxo-L-prolyl-N-[1-[[4-[1-[[1-(aminocarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]carbonyl]-2-methylbutyl]-, [1S-[1R\*[R\*(R\*)],2R\*]]- (9CI) (CA

INDEX NAME)



PAGE 1-A



PAGE 2-A




RN 119156-55-7 CAPLUS  
 CN L-Phenylalaninamide, 1-[(1,1-dimethylethoxy)carbonyl]-L-prolyl-N-[2-[4-[1-  
 [[[1-(aminocarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-  
 oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-N,N.alpha.-dimethyl-,  
 stereoisomer (9CI). (CA INDEX NAME)




RN 119156-56-8 CAPLUS  
 CN 1-Piperazineacetamide, 4-[N-(N-acetyl-L-phenylalanyl)-L-valyl]-N-[1-(aminocarbonyl)-3-(methylthio)propyl]-.alpha.-(2-methylpropyl)-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 119156-57-9 CAPLUS

CN Carbamic acid, [2-[[2-[4-[1-[[[1-(aminocarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, phenylmethyl ester, stereoisomer (9CI) (CA INDEX NAME)




RN 119156-68-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-[[[1-(aminocarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-, 1,1-dimethylethyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/039,898

V. Balasubramanian




RN 119156-69-3 CAPLUS

CN L-Phenylalaninamide, N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-[1-[[4-[1-[[[1-(aminocarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]carbonyl]-2-methylpropyl]-, stereoisomer (9CI) (CA INDEX NAME)




RN 119156-91-1 CAPLUS

CN D-Tryptophanamide, N6-[(phenylmethoxy)carbonyl]-L-lysyl-N-[2-[4-[1-[[[1-(aminocarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-, stereoisomer (9CI) (CA INDEX NAME)





RN 119156-92-2 CAPLUS

CN D-Tryptophanamide, N6-[(phenylmethoxy)carbonyl]-L-lysyl-N-[2-[4-[1-[[[1-(methoxycarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-, stereoisomer (9CI) (CA INDEX NAME)





RN 119157-38-9 CAPLUS

CN L-Phenylalaninamide, 5-oxo-L-prolyl-N-[2-[4-[1-[[[1-(aminocarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-, stereoisomer (9CI) (CA INDEX NAME)





RN 119157-39-0 CAPLUS

CN L-Phenylalaninamide, 5-oxo-L-prolyl-N-[2-[4-[1-[[[1-(methoxycarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-, stereoisomer (9CI) (CA INDEX NAME)





RN 119157-40-3 CAPLUS



CN L-Phenylalaninamide, N-[(phenylmethoxy)carbonyl]-L-.alpha.-aspartyl-L-phenylalanyl-N-[1-[[4-[1-[[[1-(aminocarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester, stereoisomer (9CI) (CA INDEX NAME)



RN 119157-41-4 CAPLUS  
 CN L-Phenylalaninamide, N-[(phenylmethoxy)carbonyl]-L-.alpha.-aspartyl-L-phenylalanyl-N-[1-[[4-[1-[[[1-(methoxycarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]carbonyl]-2-methylpropyl]-, 1,1-dimethylethyl ester, stereoisomer (9CI) (CA INDEX NAME)




RN 119157-45-8 CAPLUS  
 CN L-Phenylalaninamide, N-[(phenylmethoxy)carbonyl]-L-.alpha.-aspartyl-L-phenylalanyl-N-[1-[[4-[1-[[[1-(aminocarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]carbonyl]-2-methylpropyl]-, stereoisomer (9CI) (CA INDEX NAME)





RN 119188-54-4 CAPLUS  
 CN L-Phenylalaninamide, L-.alpha.-aspartyl-L-phenylalanyl-N-[1-[[4-[1-[[[1-(aminocarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]carbonyl]-2-methylpropyl]-, stereoisomer (9CI) (CA INDEX NAME)

$$\begin{array}{c}
 \text{O} \\
 \parallel \\
 \text{C} - \text{NH} - \text{CH} - \text{CH}_2 - \text{CH}_2 - \text{SMe} \\
 \parallel \qquad \qquad \parallel \\
 \text{O} \qquad \qquad \text{C} - \text{NH}_2 \\
 | \\
 \text{CH} - \text{Bu-i} \\
 | \\
 \text{N} \qquad \qquad \text{O} \\
 \diagup \quad \diagdown \\
 \text{C} - \text{CH} - \text{Pr-i} \\
 \parallel \quad | \\
 \text{O} \quad \text{NH} - \text{C} - \text{CH} - \text{CH}_2 - \text{Ph} \\
 \parallel \quad | \\
 \text{O} \quad \text{NH} - \text{C} - \text{CH} - \text{CH}_2 - \text{Ph} \\
 \parallel \quad | \\
 \text{O} \quad \text{NH} - \text{C} - \text{CH} - \text{CH}_2 - \text{CO}_2\text{H} \\
 \parallel \quad | \\
 \text{O} \quad \text{NH}_2
 \end{array}$$

CN: L-Phenylalaninamide, L-phenylalanyl-N-[1-[[4-[1-[[[1-(aminocarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]carbonyl]-2-methylpropyl]-, stereoisomer (9CI) (CA INDEX NAME)





CN L-Phenylalaninamide, 5-oxo-L-prolyl-N-[2-[4-[1-[[1-(aminocarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-, stereoisomer (9CI) (CA INDEX NAME)



RN 119240-61-8 CAPLUS

CN L-Phenylalaninamide, 5-oxo-L-prolyl-N-[2-[4-[1-[[[1-(methoxycarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-3-oxo-1-piperazinyl]-2-oxo-1-(phenylmethyl)ethyl]-, stereoisomer (9CI) (CA INDEX NAME)




IT 119156-39-7

RL: RCT (Reactant); RACT (Reactant or reagent)  
(reaction of, in prepn. of drug)

RN 119156-39-7 CAPLUS

CN L-Phenylalaninamide, N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-[1-[[4-(1-carboxy-3-methylbutyl)-3-oxo-1-piperazinyl]carbonyl]-2-methylpropyl]-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)



L5 ANSWER 72 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 1988:423356 CAPLUS

DN 109:23356

TI Interactions of organic substrates with 30- and 36-membered ring peptides containing (2S,3'S)-2-(2'-oxo-3'-methylpiperazin-1'-yl)propanoic acid and sarcosine

AU Kojima, Yoshitane; Yamashita, Tetsushi; Shibata, Kozo; Ohsuka, Akio

CS Fac. Sci., Osaka City Univ., Osaka, 558, Japan

SO Polymer Journal (Tokyo, Japan) (1987), 19(10), 1221-3

CODEN: POLJB8; ISSN: 0032-3896

DT Journal

LA English

IT 114967-10-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and cyclization of)

RN 114967-10-1 CAPLUS


CN 1-Piperazineacetamide, N-[2-[4-[2-[2-[4-[2-[(2,5-dioxo-1-pyrrolidinyl)oxy]-1-methyl-2-oxoethyl]-2-methyl-3-oxo-1-piperazinyl]-2-oxoethyl]methylamino]-1-methyl-2-oxoethyl]-2-methyl-3-oxo-1-piperazinyl]-2-oxoethyl]-N,.alpha.,3-trimethyl-4-[[methyl[2-[3-methyl-4-[(methylamino)acetyl]-2-oxo-1-piperazinyl]-1-oxopropyl]amino]acetyl]-2-oxo-, [3S-[1[R\*[R\*[R\*[R\*(R\*)]]],3R\*,4[R\*(R\*)]]]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 114967-09-8

CMF C48 H73 N13 O15

PAGE 1-A




PAGE 1-B



CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT 114967-00-9P 114967-04-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. and hydrolysis of)

RN 114967-00-9 CAPLUS

CN 1-Piperazineacetic acid, 4-[[[(1,1-dimethylethoxy)carbonyl]methylamino]acetyl]-.alpha.,3-dimethyl-2-oxo-, methyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

V. Balasubramanian



RN 114967-04-3 CAPLUS

CN 1-Piperazineacetic acid, 4-[[[2-[4-[[[(1,1-dimethylethoxy)carbonyl]methylamino]acetyl]-3-methyl-2-oxo-1-piperazinyl]-1-oxopropyl]methylamino]acetyl]-.alpha.,3-dimethyl-2-oxo-, methyl ester, [3S-[1(R\*),3R\*,4[2R\*(3R\*)]]]- (9CI) (CA INDEX NAME)



IT 114967-01-0P 114967-03-2P 114967-05-4P

114967-07-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (prepn. and peptide coupling of)

RN 114967-01-0 CAPLUS

CN 1-Piperazineacetic acid, 4-[[[[(1,1-dimethylethoxy)carbonyl]methylamino]acetyl]-.alpha.,3-dimethyl-2-oxo-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

V. Balasubramanian



RN 114967-03-2 CAPLUS


CN 1-Piperazineacetic acid, .alpha.,3-dimethyl-4-[(methylamino)acetyl]-2-oxo-  
methyl ester, [S-(R\*,R\*)]-, mono(trifluoroacetate) (9CI) (CA INDEX  
NAME)

CM 1

CRN 114967-02-1

CMF C12 H21 N3 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 114967-05-4 CAPLUS

10/039,898

V. Balasubramanian

CN 1-Piperazineacetic acid, 4-[[[2-[4-[[[(1,1-dimethylethoxy)carbonyl]methylamino]acetyl]-3-methyl-2-oxo-1-piperazinyl]-1-oxopropyl]methylamino]acetyl]-.alpha.,3-dimethyl-2-oxo-, [3S-[1(R\*),3R\*,4[R\*(R\*)]]]- (9CI) (CA INDEX NAME)




RN 114967-07-6 CAPLUS

CN 1-Piperazineacetic acid, .alpha.,3-dimethyl-4-[[methyl[2-[3-methyl-4-[(methylamino)acetyl]-2-oxo-1-piperazinyl]-1-oxopropyl]amino]acetyl]-2-oxo-, methyl ester, [3S-[1(R\*),3R\*,4[R\*(R\*)]]]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 114967-06-5


CMF C23 H38 N6 O7



CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT 114967-08-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(prepn., sapon., and esterification of, with hydroxysuccinimide)

RN 114967-08-7 CAPLUS


CN 1-Piperazineacetic acid, 4-[[[2-[4-[[[2-[4-[[[2-[4-[[[(1,1-

dimethylethoxy) carbonyl]methylamino]acetyl]-3-methyl-2-oxo-1-piperazinyl]-1-oxopropyl]methylamino]acetyl]-3-methyl-2-oxo-1-piperazinyl]-1-oxopropyl]methylamino]acetyl]-3-methyl-2-oxo-1-piperazinyl]-1-oxopropyl]methylamino]acetyl]-.alpha.,3-dimethyl-2-oxo-, methyl ester, [3S-[1(R\*),3R\*,4[R\*[R\*[R\*[R\*[R\*(R\*)]]]]]]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




L5 ANSWER 73 OF 82 CAPLUS COPYRIGHT 2003 ACS  
AN 1987:28107 CAPLUS  
DN 106:28107  
TI Analgesic activities of spinal cord substance P antagonists implicate  
substance P as a neurotransmitter of pain sensation  
AU Piercey, M. F.; Moon, M. W.; Blinn, J. R.; Dobry-Schreur, P. J. K.  
CS Upjohn Co., Kalamazoo, MI, 49001, USA  
SO Brain Research (1986), 385(1), 74-85  
CODEN: BRREAP; ISSN: 0006-8993  
DT Journal  
LA English  
IT 105655-58-1 105655-59-2 105680-08-8  
105761-69-1 106121-83-9  
RL: BIOL (Biological study)  
(as analgesic)  
RN 105655-58-1 CAPLUS  
CN L-Methioninamide, 5-oxo-L-prolyl-(.alpha.S,3R)-2-oxo-.alpha.,3-  
bis(phenylmethyl)-1-piperazineacetylglycyl-L-leucyl- (9CI) (CA INDEX  
NAME)

V. Balasubramanian





RN 105655-59-2 CAPLUS

CN L-Methioninamide, 5-oxo-L-prolyl-(.alpha.S,3R)-2-oxo-.alpha.,3-bis(phenylmethyl)-1-piperazineacetyl-D-prolyl-L-leucyl- (9CI) (CA INDEX NAME)




RN 105680-08-8 CAPLUS

CN L-Methioninamide, 5-oxo-L-prolyl-(.alpha.S,3R)-2-oxo-.alpha.,3-bis(phenylmethyl)-1-piperazineacetyl-(.alpha.S,3R)-3-amino-.alpha.-(2-methylpropyl)-2-oxo-1-pyrrolidineacetyl- (9CI) (CA INDEX NAME)





RN 105761-69-1 CAPLUS  
 CN L-Methioninamide, 5-oxo-L-prolyl-(.alpha.S,3S)-2-oxo-.alpha.,3-bis(phenylmethyl)-1-piperazineacetyl-D-prolyl-L-leucyl- (9CI) (CA INDEX NAME)



RN 106121-83-9 CAPLUS  
 CN 1-Piperazineacetamide, N-[(3R)-1-[(3R)-1-[[[(1S)-1-(aminocarbonyl)-3-(methylthio)propyl]amino]carbonyl]-3-methylbutyl]-2-oxo-3-pyrrolidinyl]-2-oxo-4-[[[(4S)-2-oxo-4-imidazolidinyl]carbonyl]-.alpha.,3-bis(phenylmethyl)-, (.alpha.S)- (9CI) (CA INDEX NAME)

PAGE 1-A





L5 ANSWER 74 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 1986:110169 CAPLUS

DN 104:110169

TI (Phenylalanyl)-2-piperazinones and -1,4-diazepin-2-ones

IN Moon, Malcolm W.

PA Upjohn Co., USA

SO U.S., 25 pp. Division of U.S. Ser. No. 153,435.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4534897	A	19850813	US 1984-598608	19840410
	US 4593098	A	19860603	US 1980-153435	19800527
PRAI	US 1980-153435		19800527		
	US 1979-48330		19790614		

OS CASREACT 104:110169

IT 78551-78-7P 78551-79-8P 78551-80-1P

78551-81-2P 78551-82-3P 78551-83-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(prepn. and reaction of)

RN 78551-78-7 CAPLUS

CN 1-Piperazineacetic acid, .alpha.-(2-methylpropyl)-2-oxo-4-  
[(phenylmethoxy)carbonyl]-3-(phenylmethyl)-, methyl ester, [S-(R\*,R\*)]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 78551-79-8 CAPLUS

CN 1-Piperazineacetic acid, .alpha.-(2-methylpropyl)-2-oxo-4-[(phenylmethoxy)carbonyl]-3-(phenylmethyl)-, methyl ester, [R-(R\*,R\*)]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 78551-80-1 CAPLUS

CN 1-Piperazineacetic acid, .alpha.-(2-methylpropyl)-2-oxo-4-[(phenylmethoxy)carbonyl]-3-(phenylmethyl)-, methyl ester, [R-(R\*,S\*)]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 78551-81-2 CAPLUS

CN 1-Piperazineacetic acid, .alpha.-(2-methylpropyl)-2-oxo-4-[(phenylmethoxy)carbonyl]-3-(phenylmethyl)-, methyl ester, [S-(R\*,S\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 78551-82-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-(aminocarbonyl)-3-methylbutyl]-3-oxo-2-(phenylmethyl)-, phenylmethyl ester, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/039,898

V. Balasubramanian

RN 78551-83-4 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-(aminocarbonyl)-3-methylbutyl]-3-oxo-2-(phenylmethyl)-, phenylmethyl ester, [R-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 100459-94-7P 100471-85-0P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)


RN 100459-94-7 CAPLUS

CN 1-Piperazineacetic acid, .alpha.-(2-methylpropyl)-2-oxo-4-[(phenylmethoxy)carbonyl]-3-(phenylmethyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 100471-85-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-(aminocarbonyl)-3-methylbutyl]-3-oxo-2-(phenylmethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 75 OF 82 CAPLUS COPYRIGHT 2003 ACS  
 AN 1985:79151 CAPLUS  
 DN 102:79151  
 TI Organic phosphorous quinoxalinones and their use  
 IN Kondo, Michitada; Sato, Ryo; Matsumoto, Hiroshi; Okabe, Takayuki  
 PA Sumitomo Chemical Co., Ltd. , Japan  
 SO Eur. Pat. Appl., 31 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 2


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 118982	A1	19840919	EP 1984-300532	19840127
	R: CH, DE, FR, GB, IT, LI				
	JP 59141592	A2	19840814	JP 1983-15838	19830201
	JP 60081195	A2	19850509	JP 1983-190545	19831012
PRAI	JP 1983-15838		19830201		
	JP 1983-190545		19831012		

IT 94562-18-2P 94562-19-3P 94562-20-6P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. and herbicidal activity of)

RN 94562-18-2 CAPLUS


CN Phosphorodithioic acid, S-[2-[3,4-dihydro-4-(1-methylethyl)-3-oxo-1(2H)-quinoxaliny]-2-oxoethyl] O,O-diethyl ester (9CI) (CA INDEX NAME)



V. Balasubramanian


RN 94562-19-3 CAPLUS

CN Phosphorothioic acid, S-[2-[3,4-dihydro-4-(1-methylethyl)-3-oxo-1(2H)-quinoxaliny]]-2-oxoethyl] O,O-diethyl ester (9CI) (CA INDEX NAME)



RN 94562-20-6 CAPLUS

CN Phosphorodithioic acid, S-[2-[3,4-dihydro-4-(1-methylethyl)-3-oxo-1(2H)-quinoxaliny]]-2-oxoethyl] O,O-dipropyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 76 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 1985:62424 CAPLUS

DN 102:62424

TI 1,2,3,4-Tetrahydro-2-quinoxalone derivatives

PA Sumitomo Chemical Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 10 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 59141592	A2	19840814	JP 1983-15838	19830201
	EP 118982	A1	19840919	EP 1984-300532	19840127

R: CH, DE, FR, GB, IT, LI

PRAI JP 1983-15838 19830201

JP 1983-190545 19831012


IT 94562-18-2P 94562-19-3P 94562-20-6P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. and herbicidal activity of)

V. Balasubramanian


RN 94562-18-2 CAPLUS

CN Phosphorodithioic acid, S-[2-[3,4-dihydro-4-(1-methylethyl)-3-oxo-1(2H)-quinoxaliny]l]-2-oxoethyl] O,O-diethyl ester (9CI) (CA INDEX NAME)




RN 94562-19-3 CAPLUS

CN Phosphorothioic acid, S-[2-[3,4-dihydro-4-(1-methylethyl)-3-oxo-1(2H)-quinoxaliny]l]-2-oxoethyl] O,O-diethyl ester (9CI) (CA INDEX NAME)



RN 94562-20-6 CAPLUS

CN Phosphorodithioic acid, S-[2-[3,4-dihydro-4-(1-methylethyl)-3-oxo-1(2H)-quinoxaliny]l]-2-oxoethyl] O,O-dipropyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 77 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 1983:71807 CAPLUS

DN 98:71807

TI Penicillins.

PA Toyama Chemical Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 36 pp.

10/039,898

V. Balasubramanian


CODEN: JKXXAF

DT Patent


LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 57118587	A2	19820723	JP 1981-188407	19811126
PRAI	JP 1981-188407		19811126		
OS	CASREACT 98:71807				
IT	59702-78-2 59702-94-2				
	RL: RCT (Reactant); RACT (Reactant or reagent)				
	(acylation by, of glycinamidopenam deriv.)				
RN	59702-78-2 CAPLUS				
CN	1-Piperazinecarbonyl chloride, 4-(1-methylethyl)-3-oxo- (9CI) (CA INDEX NAME)				




RN 59702-94-2 CAPLUS  
CN 1-Piperazinecarbonyl chloride, 4-(1-methyl-2-propenyl)-3-oxo- (9CI) (CA INDEX NAME)



IT 59703-50-3P 59703-66-1P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(prepn. and bactericidal activity of)  
RN 59703-50-3 CAPLUS  
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-[[[[[4-(1-methylethyl)-3-oxo-1-piperazinyl]carbonyl]amino]phenylacetyl]amino]-7-oxo-, monosodium salt, [2S-[2.alpha.,5.alpha.,6.beta.(S\*)]]- (9CI) (CA INDEX NAME)

V. Balasubramanian

Absolute stereochemistry.




● Na

RN 59703-66-1 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-[[[4-(1-methyl-2-propenyl)-3-oxo-1-piperazinyl]carbonyl]amino]phenylacetyl]amino]-7-oxo-, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 78 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 1982:211131 CAPLUS

DN 96:211131

TI Piperazinone enkephalin analogs

AU Moon, M. W.; Lahti, R. A.; Vonvoigtlander, P. F.; Samanen, J.

CS Upjohn Co., Kalamazoo, MI, 49001, USA

SO. Pept.: Synth., Struct., Funct., Proc. Am. Pept. Symp., 7th (1981), 641-4.  
Editor(s): Rich, Daniel H.; Gross, Erhard. Publisher: Pierce Chem. Co., Rockford, Ill.

CODEN: 47LMAO

DT Conference

LA English

IT 81851-85-6 81851-86-7 81939-19-7


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(analgesic activity of, structure in relation to)

RN 81851-85-6 CAPLUS


CN D-Alaninamide, L-tyrosyl-N-[2-[4-[1-(aminocarbonyl)-3-methylbutyl]-3-oxo-2-(phenylmethyl)-1-piperazinyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 81851-86-7 CAPLUS

CN 1-Piperazineacetamide, N-[1-(aminocarbonyl)-3-methylbutyl]-2-oxo-.alpha.-(phenylmethyl)-4-(N-L-tyrosyl-D-alanyl)-, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)



RN 81939-19-7 CAPLUS

CN 1-Piperazineacetamide, N-[1-(aminocarbonyl)-3-methylbutyl]-2-oxo-.alpha.-(phenylmethyl)-4-(N-L-tyrosyl-D-alanyl)-, [R-(R\*,S\*)]- (9CI) (CA INDEX NAME)



L5 ANSWER 79 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 1982:7084 CAPLUS

DN 96:7084

TI Piperazinone and piperazine polypeptides

IN Moog, Malcolm W.

PA Upjohn Co., USA

SO U.S., 23 pp.

CODEN: USXXAM

DT Patent

10/039,898

V. Balasubramanian

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4251438	A	19810217	US 1979-48330	19790614
	US 4593098	A	19860603	US 1980-153435	19800527
PRAI	US 1979-48330		19790614		

IT 78551-78-7P 78551-79-8P 78551-80-1P


78551-81-2P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and amidation)

RN 78551-78-7 CAPLUS

CN 1-Piperazineacetic acid, .alpha.-(2-methylpropyl)-2-oxo-4-  
[(phenylmethoxy)carbonyl]-3-(phenylmethyl)-, methyl ester, [S-(R\*,R\*)]-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 78551-79-8 CAPLUS

CN 1-Piperazineacetic acid, .alpha.-(2-methylpropyl)-2-oxo-4-  
[(phenylmethoxy)carbonyl]-3-(phenylmethyl)-, methyl ester, [R-(R\*,R\*)]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 78551-80-1 CAPLUS

CN 1-Piperazineacetic acid, .alpha.-(2-methylpropyl)-2-oxo-4-  
[(phenylmethoxy)carbonyl]-3-(phenylmethyl)-, methyl ester, [R-(R\*,S\*)]-

10/039,898


Absolute stereochemistry.



RN 78551-81-2 CAPLUS

CN 1-Piperazineacetic acid, .alpha.-(2-methylpropyl)-2-oxo-4-  
[(phenylmethoxy)carbonyl]-3-(phenylmethyl)-, methyl ester, [S-(R\*,S\*)]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 78551-82-3P 78551-83-4P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)

RN 78551-82-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-(aminocarbonyl)-3-methylbutyl]-3-oxo-2-(phenylmethyl)-, phenylmethyl ester, [S-(R\*,R\*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 78551-83-4 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[1-(aminocarbonyl)-3-methylbutyl]-3-oxo-2-(phenylmethyl)-, phenylmethyl ester, [R-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 80 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 1978:62362 CAPLUS

DN 88:62362

TI Studies on .beta.-lactam antibiotics for medicinal purposes. I. Synthesis of D(-)-.alpha.-[(monooxo)-1-piperazinecarboxamido]benzylpenicillins and structure-antibacterial activity

AU Saikawa, Isamu; Takano, Shuntaro; Yoshida, Chosaku; Takashima, Okuta; Momonoi, Kaishu; Yasuda, Takashi; Kasuya, Kyoko

CS Res. Lab., Toyama Chem. Co., Ltd., Toyama, Japan

SO Yakugaku Zasshi (1977), 97(8), 883-9

CODEN: YKKZAJ; ISSN: 0031-6903

DT Journal

LA Japanese

IT 60122-99-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. and bactericidal activity of)


RN 60122-99-8 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-[[[[[4-

V. Balasubramanian

(1-methylethyl)-3-oxo-1-piperazinyl]carbonyl]amino]phenylacetyl]amino]-7-oxo-, [2S-[2.alpha.,5.alpha.,6.beta.(S\*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 59702-78-2

RL: RCT (Reactant); RACT (Reactant or reagent)  
(reaction of, with aminobenzylpenicillin)

RN 59702-78-2 CAPLUS

CN 1-Piperazinecarbonyl chloride, 4-(1-methylethyl)-3-oxo- (9CI) (CA INDEX NAME)



L5 ANSWER 81 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 1976:494355 CAPLUS

DN 85:94355

TI Penicillins

IN Saikawa, Isamu; Takano, Shuntaro; Yoshida, Chosaku; Takashima, Okuta;  
Kuroda, Seietsu; Komatsu, Miwako; Momonoi, Kaishu; Yasuda, Takashi;  
Kodama, Yutaka

PA Toyama Chemical Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 45 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 50148380	A2	19751127	JP 1974-52254	19740513
	AU 7580431	A1	19761028	AU 1975-80431	19750423
	US 4087424	A	19780502	US 1975-571479	19750424
	IL 47168	A1	19790725	IL 1975-47168	19750424
	IL 53485	A1	19790930	IL 1975-53485	19750424
	IN 141981	A	19770514	IN 1975-CA852	19750428
	GB 1508062	A	19780419	GB 1975-17557	19750428
	GB 1508064	A	19780419	GB 1977-15360	19750428

V. Balasubramanian

GB 1508063	A	19780419	GB 1977-15363	19750428
DE 2519400	A1	19760304	DE 1975-2519400	19750430
DE 2519400	B2	19810521		
DE 2519400	C3	19820211		
DE 2559932	C2	19830421	DE 1975-2559932	19750430
DE 2560239	C2	19841011	DE 1975-2560239	19750430
CA 1061331	A1	19790828	CA 1975-226043	19750501
FR 2269937	A1	19751205	FR 1975-14159	19750506
FR 2269937	B1	19790615		
CH 605995	A	19781013	CH 1975-5847	19750506
FI 7501340	A	19751110	FI 1975-1340	19750507
FI 63760	B	19830429		
FI 63760	C	19830810		
DK 7502019	A	19751110	DK 1975-2019	19750507
DK 151338	B	19871123		
DK 151338	C	19880718		
NL 7505375	A	19751111	NL 1975-5375	19750507
NL 162386	B	19791217		
NL 162386	C	19800516		
AT 7503511	A	19770315	AT 1975-3511	19750507
AT 340046	B	19771125		
DD 117882	C	19760205	DD 1975-185922	19750508
HU 169633	P	19761228	HU 1975-TO1002	19750508
SE 7505392	A	19751223	SE 1975-5392	19750509
SE 431457	B	19840206		
SE 431457	C	19840517		
GB 1508071	A	19780419	GB 1976-2002	19760119
US 4112090	A	19780905	US 1976-654060	19760130
US 4110327	A	19780829	US 1976-732860	19761015
FR 2320295	A1	19770304	FR 1976-31895	19761022
FR 2320295	B1	19801107		
IN 145443	A	19781014	IN 1976-CA2121	19761127
IN 145444	A	19781014	IN 1976-CA2122	19761127
US 4410522	A	19831018	US 1977-841608	19771012
CH 616939	A	19800430	CH 1977-16075	19771227
FI 62833	B	19821130	FI 1978-330	19780201
FI 62833	C	19830310		
US 4219554	A	19800826	US 1978-915873	19780615
CA 1078384	A1	19800527	CA 1978-308161	19780726
SE 7808204	A	19780727	SE 1978-8204	19780727
SE 435062	B	19840903		
SE 435062	C	19841213		
DK 7901049	A	19790314	DK 1979-1049	19790314
DK 149950	B	19861103		
DK 149950	C	19870928		
US 4379152	A	19830405	US 1979-39904	19790517
US 4327097	A	19820427	US 1979-47818	19790612
DK 8000958	A	19800306	DK 1980-958	19800306
DK 151958	B	19880118		
DK 151958	C	19880718		
FI 8100165	A	19810121	FI 1981-165	19810121
FI 65780	B	19840330		
FI 65780	C	19840710		
FI 8100468	A	19810216	FI 1981-468	19810216
FI 62834	B	19821130		
FI 62834	C	19830310		
PRAI JP 1974-50663		19740509		
JP 1974-52254		19740513		

V. Balasubramanian

JP 1974-60787	19740531
JP 1974-91996	19740813
JP 1974-109954	19740926
JP 1974-142499	19741213
JP 1975-142499	19750327
JP 1975-37027	19750327
JP 1975-37207	19750327
IL 1975-47168	19750424
US 1975-571479	19750424
GB 1975-17557	19750428
IN 1975-CA852	19750428
CH 1975-5847	19750506
DK 1975-2019	19750507
FI 1975-1340	19750507
US 1976-654060	19760130
FI 1978-330	19780201
US 1978-915873	19780615


IT 59703-66-1P 60122-99-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(prepn. and bactericidal activity of)

RN 59703-66-1 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-[[[[[4-(1-methyl-2-propenyl)-3-oxo-1-piperazinyl]carbonyl]amino]phenylacetyl]amino]-7-oxo-, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 60122-99-8 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-[[[[[4-(1-methylethyl)-3-oxo-1-piperazinyl]carbonyl]amino]phenylacetyl]amino]-7-oxo-, [2S-[2.alpha.,5.alpha.,6.beta.(S\*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 82 OF 82 CAPLUS COPYRIGHT 2003 ACS

10/039,898

V. Balasubramanian

AN 1976:433052 CAPLUS  
DN 85:33052  
TI Penicillin and cephalosporin derivatives  
IN Saikawa, Isamu; Takano, Shuntaro; Yoshida, Chosaku; Takashima, Okuta;  
Momonoi, Kaishu; Kuroda, Seietsu; Komatsu, Miwako; Yasuda, Takashi;  
Kodama, Yutaka  
PA Toyama Chemical Co., Ltd., Japan  
SO Ger. Offen., 237 pp.  
CODEN: GWXXBX

DT Patent

LA German

FAN.CNT.5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2519400	A1	19760304	DE 1975-2519400	19750430
	DE 2519400	B2	19810521		
	DE 2519400	C3	19820211		
	JP 50148378	A2	19751127	JP 1974-50663	19740509
	JP 50148380	A2	19751127	JP 1974-52254	19740513
	JP 50151891	A2	19751206	JP 1974-60787	19740531
	JP 51023284	A2	19760224	JP 1974-91996	19740813
	JP 51039687	A2	19760402	JP 1974-109954	19740926
	JP 51070788	A2	19760618	JP 1974-142499	19741213
	JP 51113890	A2	19761007	JP 1975-37207	19750327
	AT 7608289	A	19771215	AT 1976-8289	19761108
	ES 454266	A1	19771216	ES 1976-454266	19761215
	ES 454267	A1	19771216	ES 1976-454267	19761215
	US 4379152	A	19830405	US 1979-39904	19790517
PRAI	JP 1974-50663		19740509		
	JP 1974-52254		19740513		
	JP 1974-60787		19740531		
	JP 1974-91996		19740813		
	JP 1974-109954		19740926		
	JP 1974-142499		19741213		
	JP 1975-37207		19750327		
	AT 1975-3511		19750507		
	US 1976-654060		19760130		
	US 1978-915873		19780615		


IT 59702-78-2P 59702-94-2P

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. and acylation of aminobenzylpenams and aminobenzylcephems by)

RN 59702-78-2 CAPLUS


CN 1-Piperazinecarbonyl chloride, 4-(1-methylethyl)-3-oxo- (9CI) (CA INDEX NAME)



V. Balasubramanian

RN 59702-94-2 CAPLUS

CN 1-Piperazinecarbonyl chloride, 4-(1-methyl-2-propenyl)-3-oxo- (9CI) (CA INDEX NAME)



IT 59703-50-3P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. and bactericidal activity of)

RN 59703-50-3 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-[[[[[4-(1-methylethyl)-3-oxo-1-piperazinyl]carbonyl]amino]phenylacetyl]amino]-7-oxo-, monosodium salt, [2S-[2.alpha.,5.alpha.,6.beta.(S\*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

IT 59703-66-1P


RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and bactericidal of)

RN 59703-66-1 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-[[[[[4-(1-methyl-2-propenyl)-3-oxo-1-piperazinyl]carbonyl]amino]phenylacetyl]amin o]-7-oxo-, [2S-(2.alpha.,5.alpha.,6.beta.)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

V. Balasubramanian



=> log y

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE

ENTRY

257.41

TOTAL

SESSION

406.17

STN INTERNATIONAL LOGOFF AT 11:09:28 ON 14 JUN 2003

10/039,898

X

CC(=O)N(C)CC(=O)N1CCN(C1)C(=O)N(C)CC(=O)N(C)CC(=O)N2CCN(C2)C(=O)N(C)CC(=O)OC

```
=> s ll sss ful
FULL SEARCH INITIATED 11:07:53 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 5089 TO ITERATE
```

L4 445 SEA SSS FUL L1

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
148.55	148.76

FILE 'CAPLUS' ENTERED AT 11:07:59 ON 14 JUN 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Jun 2003 VOL 138 ISS 25  
FILE LAST UPDATED: 13 Jun 2003 (20030613/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s 14
L5      82 L4
```

10/039,898

V. Balasubramanian

=> d 15 1-82 bib hitstr

L5 ANSWER 1 OF 82 CAPLUS COPYRIGHT 2003 ACS  
AN 2003:173381 CAPLUS  
DN 138:221847  
TI Preparation of piperazinone compounds as antitumor and anticancer agents  
IN Hamilton, Andrew D.; Sebti, Said; Peng, Hairuo  
PA Yale University, USA  
SO PCT Int. Appl., 90 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003017939	A2	20030306	WO 2002-US26881	20020823
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,				
	RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,				
	UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,				
	CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,				
	PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,				
	NE, SN, TD, TG				

PRAI US 2001-314795P P 20010824

OS MARPAT 138:221847


IT **501009-95-6P**, GGTI 2376

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(prepn. of piperazinone compds. as antitumor and anticancer agents)

RN 501009-95-6 CAPLUS

CN 1-Piperazineacetic acid, 4-[3-(1H-imidazol-4-yl)-1-oxopropyl]-2-oxo-.alpha.,3-bis(phenylmethyl)-, ethyl ester, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **501009-96-7P**, GGTI 2377

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of piperazinone compds. as antitumor and anticancer agents)


RN 501009-96-7 CAPLUS

10/039,898

V. Balasubramanian

CN 1-Piperazineacetic acid, 4-[3-(1H-imidazol-4-yl)-1-oxopropyl]-2-oxo-.alpha.,3-bis(phenylmethyl)-, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 500783-09-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. of piperazinone compds. as antitumor and anticancer agents)

RN 500783-09-5 CAPLUS

CN 1-Piperazineacetic acid, 2-oxo-4-[1-oxo-3-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-.alpha.,3-bis(phenylmethyl)-, ethyl ester, (.alpha.S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 2 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 2002:869496 CAPLUS

DN 137:363033

TI Peptidomimetic modulators of cell adhesion

IN Gour, Barbara J.; Blaschuk, Orest W.; Ali, Anmar; Ni, Feng; Chen, Zhigang; Michaud, Stephanie D.; Wang, Shoameng; Hu, Zenjian

PA Can.

SO U.S. Pat. Appl. Publ., 309 pp., Cont.-in-part of U.S. Ser. No. 491,078.  
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002168761	A1	20021114	US 2001-769145	20010124
PRAI	US 2000-491078	A2	20000124		
OS	MARPAT 137:363033				
IT	351857-32-4				

1-Piperazineacetamide, 4-[(2S)-2-(acetylamino)-3-(1H-

V. Balasubramanian


imidazol-4-yl)-1-oxopropyl]-3-methyl-.alpha.-(1-methylethyl)-2-oxo-,  
(.alpha.S,3S)- **351857-33-5**, 1-Piperazineacetamide,  
4-[(2S)-2-(acetylamino)-3-(1H-imidazol-4-yl)-1-oxopropyl]-.alpha.-[(4-  
hydroxyphenyl)methyl]-3-methyl-2-oxo-, (.alpha.S,3S)- **351857-34-6**  
, L-Tyrosinamide, N-acetyl-L-histidyl-(.alpha.S,3S)-3-methyl-.alpha.-(1-  
methylethyl)-2-oxo-1-piperazineacetyl-  
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);  
PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES  
(Uses)

(peptidomimetic modulators of cadherin-mediated cell adhesion for  
therapeutic use in relation to three-dimensional structure)

RN 351857-32-4 CAPLUS

CN 1-Piperazineacetamide, 4-[(2S)-2-(acetylamino)-3-(1H-imidazol-4-yl)-1-  
oxopropyl]-3-methyl-.alpha.-(1-methylethyl)-2-oxo-, (.alpha.S,3S)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 351857-33-5 CAPLUS

CN 1-Piperazineacetamide, 4-[(2S)-2-(acetylamino)-3-(1H-imidazol-4-yl)-1-  
oxopropyl]-.alpha.-[(4-hydroxyphenyl)methyl]-3-methyl-2-oxo-,  
(.alpha.S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 351857-34-6 CAPLUS

CN L-Tyrosinamide, N-acetyl-L-histidyl-(.alpha.S,3S)-3-methyl-.alpha.-(1-  
methylethyl)-2-oxo-1-piperazineacetyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 3 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 2002:868740 CAPLUS

DN 137:370075

TI Preparation of diazabicyclo[3.3.1]nonane derivatives as FKBP-ligands

IN Guo, Chuangxing; Augelli-Szafran, Corinne E.; Barta, Nancy Sue; Bender, Steven Lee; Bigge, Christopher Franklin; Caprathe, Bradley William; Chatterjee, Arindam; Deal, Judith; Dong, Liming; Fay, Lorraine Kathleen; Hou, Xinjun; Hudack, Raymond Andrew, Jr.

PA Agouron Pharmaceuticals, Inc., USA; Warner-Lambert Company

SO PCT Int. Appl., 177 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002089806	A1	20021114	WO 2002-US14966	20020510
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2001-289828P P 20010510

OS MARPAT 137:370075

IT 475301-55-4P 475301-58-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(prepn. of diazabicyclo[3.3.1]nonane derivs. as inhibitors of rotamase)

RN 475301-55-4 CAPLUS

CN 3,9-Diazabicyclo[3.3.1]nonane-9-carboxylic acid, 3-[(1S)-1-methyl-2-phenylethyl]-2,4-dioxo-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 475301-58-7 CAPLUS

CN 3,9-Diazabicyclo[3.3.1]nonane-9-carboxylic acid, 3-[(1R)-1-methyl-2-phenylethyl]-2,4-dioxo-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 2002:849621 CAPLUS

DN 137:353056

TI Preparation of benzenesulfonylpiperazines as matrix metalloproteinase inhibitors.

IN Chung, Yong-Jun; Lee, Keyong-Ho; Kim, Youn-Chul; Park, Ho-Jin

PA Kolon Ind. Inc., S. Korea

SO PCT Int. Appl., 71 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002088115	A1	20021107	WO 2002-KR759	20020424
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	KR 2001-22767	A	20010426		
	KR 2001-77522	A	20011207		
	KR 2002-14481	A	20020318		
OS	MARPAT 137:353056				
IT	474410-58-7P				

V. Balasubramanian

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(prepn. of benzenesulfonylpiperazines as matrix metalloproteinase  
inhibitors)

RN 474410-58-7 CAPLUS

CN 2-Piperazinecarboxylic acid, 1-[(4'-bromo[1,1'-biphenyl]-4-yl)sulfonyl]-4-  
(1-octyldecyl)-5-oxo-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 82 CAPLUS COPYRIGHT 2003 ACS

AN 2002:832817 CAPLUS

DN 137:338139

TI Preparation of pyrrolidine, piperidine, or piperazine amino acid  
derivatives as melanocortin receptor ligands

IN Mazur, Adam Wieslaw; Tian, Xinrong; Hu, Xiufeng Eric; Ebetino, Frank  
Hallock

PA The Procter & Gamble Company, USA

SO PCT Int. Appl., 143 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002085925	A2	20021031	WO 2002-US13340	20020424
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2003109556	A1	20030612	US 2002-121874	20020412
PRAI	US 2001-286610P	P	20010425		
	US 2002-386620P	P	20020605		

OS MARPAT 137:338139

IT 474094-72-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic  
preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
(Preparation); RACT (Reactant or reagent); USES (Uses)


V. Balasubramanian

(prepn. of pyrrolidine, piperidine, or piperazine amino acid derivs. as melanocortin receptor ligands)

RN 474094-72-9 CAPLUS

CN 1-Piperazineacetic acid, 4-(N-acetyl-L-tyrosyl-4-fluorophenylalanyl)-3-(3-aminopropyl)-.alpha.-(2-naphthalenylmethyl)-2-oxo-, methyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



IT 474094-74-1P 474094-76-3P 474094-78-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn. of pyrrolidine, piperidine, or piperazine amino acid derivs. as melanocortin receptor ligands)

RN 474094-74-1 CAPLUS

CN 1-Piperazineacetic acid, 4-(N-acetyl-L-tyrosyl-4-fluorophenylalanyl)-3-[3-[(aminoiminomethyl)amino]propyl]-.alpha.-(2-naphthalenylmethyl)-2-oxo-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


V. Balasubramanian



RN 474094-76-3 CAPLUS

CN 1-Piperazineacetamide, 4-(N-acetyl-L-tyrosyl-4-fluorophenylalanyl)-3-(3-aminopropyl)-N-methyl-.alpha.-(2-naphthalenylmethyl)-2-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474094-78-5 CAPLUS

CN 1-Piperazineacetamide, 4-(N-acetyl-L-tyrosyl-4-fluorophenylalanyl)-3-(2-hydroxyethyl)-N-methyl-.alpha.-(2-naphthalenylmethyl)-2-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 474024-25-4

RL: RCT (Reactant); RACT (Reactant or reagent)  
(prepn. of pyrrolidine, piperidine, or piperazine amino acid derivs. as melanocortin receptor ligands)

RN 474024-25-4 CAPLUS

CN 1-Piperazineacetic acid, 4-[2-[[ (1,1-dimethylethoxy) carbonyl] amino]-3-(4-fluorophenyl)-1-oxopropyl]-.alpha.-(2-naphthalenylmethyl)-2-oxo-3-[3-[[ (phenylmethoxy) carbonyl] amino]propyl]-, methyl ester (9CI) (CA INDEX NAME)



IT 474023-92-2P 474023-94-4P 474023-95-5P

474023-96-6P 474024-00-5P 474024-01-6P

474024-02-7P 474024-04-9P 474024-05-0P

474024-06-1P 474024-08-3P 474024-09-4P

474094-71-8P 474094-73-0P 474094-75-2P


474094-77-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of pyrrolidine, piperidine, or piperazine amino acid derivs. as melanocortin receptor ligands)


RN 474023-92-2 CAPLUS

CN 1-Piperazineacetic acid, .alpha.-(2-naphthalenylmethyl)-4-[(2-nitrophenyl)sulfonyl]-2-oxo-3-[3-[[ (phenylmethoxy) carbonyl] amino]propyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 474023-94-4 CAPLUS

CN 1-Piperazineacetic acid, 4-[2-[[ (1,1-dimethylethoxy) carbonyl] amino]-3-(4-fluorophenyl)-1-oxopropyl]-.alpha.-(2-naphthalenylmethyl)-2-oxo-3-[3-[(phenylmethoxy) carbonyl]amino]propyl- (9CI) (CA INDEX NAME)



RN 474023-95-5 CAPLUS


CN Carbamic acid, [3-[1-[2-[[ (1,1-dimethylethoxy) carbonyl] amino]-3-(4-fluorophenyl)-1-oxopropyl]-4-[2-(methylamino)-1-(2-naphthalenylmethyl)-2-oxoethyl]-3-oxo-2-piperazinyl]propyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 474023-96-6 CAPLUS


+ CN Carbamic acid, [3-[1-[2-amino-3-(4-fluorophenyl)-1-oxopropyl]-4-[2-(methylamino)-1-(2-naphthalenylmethyl)-2-oxoethyl]-3-oxo-2-piperazinyl]propyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 474024-00-5 CAPLUS

CN 1-Piperazineacetic acid, 3-[2-[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-.alpha.-(2-naphthalenylmethyl)-4-[(2-nitrophenyl)sulfonyl]-2-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 474024-01-6 CAPLUS


CN 1-Piperazineacetic acid, 3-[2-[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-.alpha.-(2-naphthalenylmethyl)-4-[(2-nitrophenyl)sulfonyl]-2-oxo- (9CI) (CA INDEX NAME)



RN 474024-02-7 CAPLUS


CN 1-Piperazineacetamide, 3-[2-[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-N-methyl-.alpha.-(2-naphthalenylmethyl)-4-[(2-nitrophenyl)sulfonyl]-2-oxo- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 474024-04-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 2-[2-[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-4-[2-(methylamino)-1-(2-naphthalenylmethyl)-2-oxoethyl]-3-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 474024-05-0 CAPLUS


CN 1-Piperazinecarboxylic acid, 2-(2-hydroxyethyl)-4-[2-(methylamino)-1-(2-naphthalenylmethyl)-2-oxoethyl]-3-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 474024-06-1 CAPLUS


CN 1-Piperazinecarboxylic acid, 2-[2-(acetyloxy)ethyl]-4-[2-(methylamino)-1-(2-naphthalenylmethyl)-2-oxoethyl]-3-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 474024-08-3 CAPLUS

CN Carbamic acid, [2-[2-[2-(acetyloxy)ethyl]-4-[2-(methylamino)-1-(2-naphthalenylmethyl)-2-oxoethyl]-3-oxo-1-piperazinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 474024-09-4 CAPLUS


CN 1-Piperazineacetamide, 3-[2-(acetyloxy)ethyl]-4-[2-amino-3-(4-fluorophenyl)-1-oxopropyl]-N-methyl-.alpha.-(2-naphthalenylmethyl)-2-oxo- (9CI) (CA INDEX NAME)



RN 474094-71-8 CAPLUS

CN 1-Piperazineacetic acid, 4-(N-acetyl-L-tyrosyl-4-fluorophenylalanyl)-.alpha.-(2-naphthalenylmethyl)-2-oxo-3-[3-[(phenylmethoxy)carbonyl]amino]propyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 474094-73-0 CAPLUS

CN 1-Piperazineacetic acid, 4-(N-acetyl-L-tyrosyl-4-fluorophenylalanyl)-3-[3-[[bis[(1,1-dimethylethoxy)carbonyl]amino]methylene]amino]propyl]-.alpha.-(2-naphthalenylmethyl)-2-oxo-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 474094-75-2 CAPLUS

CN Carbamic acid, [3-[1-(N-acetyl-L-tyrosyl-4-fluorophenylalanyl)-4-[2-(methylamino)-1-(2-naphthalenylmethyl)-2-oxoethyl]-3-oxo-2-piperazinyl]propyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)